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ABSTRACT
Inflammatory Bowel Disease (IBD) [Ulcerative colitis (UC) and Crohn’s Disease
(CD)] is a group of chronic disorders of unknown etiology characterized by inflammation
in the gastrointestinal tract associated with a high colon cancer risk. UC is characterized
by periods of active disease (“flare-ups”), followed by periods when the disease is
inactive (“remission”). The end result is an abnormal immune response with repeated
episodes of colonic inflammation. Conventional treatment of UC by aminosalicylates,
TNFα inhibitors, and steroids have modest effects, and come with a high risk of side
effects including dyspeptic symptoms, gastric ulceration and sometimes hospitalization
and deaths. Because of higher acceptance, efficacy, minimal side effects and relatively
low cost, patients (up to 50%) are using complementary and alternative medicines
(CAMs). In this light, because of the anti-inflammatory and anti-oxidant properties of
American Ginseng (AG), we tested the hypothesis that AG suppresses colitis and
prevents colon cancer in mice.
AG (Panax quinquefolius), an obligate shade perennial native of North America
has previously been shown by our lab to treat and prevent colitis and associated colon
cancer. Here, to further delineate the putative active components of AG against colitis
and colon cancer, we performed a bioassay-guided fractionation of AG using several
polar (Water, Butanol, Dicholoromethane, Ethylacetate) and non-polar (Hexane) solvent
extraction methods. Only the Hexane fraction of AG (HAG) was found to be potent anti-
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oxidant and can drive inflammatory cell apoptosis and ameliorate colitis and associated
colon cancer in an experimental mouse model (Chapter 2).
Inflammation induced Reactive Oxygen Species (ROS) and Nitric Oxide (NO)
leads to p53 activation to eliminate damaged cells by apoptosis during colitis. HAG
showed increased anti-inflammatory and pro-apoptotic properties in a mouse model of
colitis (Chapter 2). From these observations, we tested the hypothesis that HAG might
prevent colitis through p53-mediated apoptosis of inflammatory cells.

Results are

consistent with this hypothesis (Chapter 3).
MicroRNAs (miRNAs) have recently been shown to play a key role in
inflammation and cancer. Alternatively, inflammation can modulate miRNA expression,
which in turn regulates carcinogenesis. Because HAG suppresses colon inflammation
and prevents colon cancer, we examined the effects of HAG in miRNA expression.
miRNAs are the small non-coding RNA of approximately 22 nucleotides long that posttranscriptionally regulates the gene expression in plants and animals. Dysregulated
microRNA (miR) expression has been observed in several disease conditions including
colon cancer. Using global miR expression profiling, we observed increased miR-29b in
colon cancer cells following exposure to HAG. Since miR-29b plays a role in regulating
the migration of cancer cells, we hypothesized that HAG induces miR-29b expression to
target matrix metalloproteinase-2 (MMP-2) thereby suppressing the migration and
invasion of colon cancer cells. Results are consistent with this hypothesis. Our study
supports the understanding that targeting MMP-2 by miR-29b is a mechanism by which
HAG suppresses the migration and invasion of colon cancer cells (Chapter 4).
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Finally to initiate further studies to identify the bioactive component/s present in
HAG, preparative reverse-phase HPLC subfractionation was performed (Chapter 5).
Subfractions F2 and F3 [both with a major polyacetylene content (Panaxynol, Panaxydol
and Panaxydiol)] exhibited anti-inflammatory property, thereby supporting the notion
that Polyacetylenes could be the bioactive compounds responsible for the antiinflammatory and anti-cancer property of HAG. Future studies will confirm
Polyacetylenes as bioactive compound of HAG in the suppression of colitis and
prevention of colon cancer.

In conclusion, data presented here have identified key

components of AG and some mechanisms by which HAG suppresses colitis and prevents
colon cancer in mice.
components

of

These results support the possibility of testing individual
AG

in

treating
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IBD

in

humans.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 GENERAL OVERVIEW
Inflammation is the body’s first line of defense against injury and infection that could
lead to pain, heat, swelling and redness (due to the increased blood flow to the area) in
order to seal off the injured tissue, destroy damaged tissue and kill the invading bacteria.
Inflammation in general is an important mechanism that safeguards the body against
infection or injury by launching a well-coordinated immune response involving both
innate and adaptive immune systems [Reviewed in (1)]. Inflammation is both beneficial
and detrimental. When the body’s inflammatory response is normal, the body benefits
from the response. However if the response goes awry, the over-activation of an
inflammatory response could cause harm to the body by destroying the normal tissues in
addition to damaged tissues. Hence a balanced inflammatory response is necessary which
is maintained by the body’s immune system. An overactive immune system is associated
with autoimmune disorders.
The study of association between inflammation and cancer is long standing. In 1863,
Rudolf Virchow first suggested the connection between inflammation and cancer. Since
then, a tremendous amount of information has been obtained linking inflammation and
cancer. Chronic inflammation involves the generation of free radicals including Nitric
Oxide (NO) and an increased number of p53 mutations in the cells of inflamed areas of
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colon. Interesting, there is a correlation between NOS2 activity and p53 status in UC (1,
2).
Infection and chronic inflammation are implicated in about 25% of all human cancers
worldwide [Reviewed in (1)]. Several key molecules that are involved in inflammationdriven carcinogenesis are nuclear factor κβ (NF-κβ); toll-like receptors; reactive oxygen
and nitrogen species (RONS); cyclooxygenases (COXs); nitric oxide synthases (NOSs);
pro and anti-inflammatory cytokines; metals; antioxidant enzymes; peroxisome
proliferator-activated receptor ligands; kinases; growth factors; and the tumor suppressor
proteins, p53 and retinoblastoma (pRb) proteins [Reviewed in (3)]. For the most part, in
IBD, neoplastic lesions arise within areas of the mucosa that have been involved with
colonic inflammation (4). This might explain that during inflammation, the healing of UC
by re-epithelization of colonic mucosa leads to abnormal cell growth resulting in
neoplastic lesions (4). Therefore targeting the key players that are involved in this
inflammation to cancer cascade has shown significant improvement in the therapeutics.
In the 1930s exploration of the role of diet in human cancers began and even at that
stage evidence emerged of the capacity of a higher intake of plant foods to reduce the risk
of cancer (5). Several classes of anti-inflammatory drugs, such as corticosteroids,
NSAIDs, and biologics possess several adverse effects and biologics are expensive (6).
Patients who received biologic therapies are also at higher risk for the development of
cardiac complications (7). Natural products or natural product derived compounds
represent great structural diversity, commonly not seen in synthetic compounds and plays
a dominant role in the discovery of leads for the development of drugs for the treatment
of human diseases (8). American ginseng (AG) is a herbal plant that has been widely
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used for stress, to boost the immune system, and as a general tonic and stimulant. We
have recently reported the anti-inflammatory and anti-cancer properties of AG (9-11). To
further delineate the bioactive components of AG against colitis and colon cancer, we
performed a bioassay-guided fractionation of AG using various polar (water, butanol,
dicholoromethane, ethylacetate) and non-polar (hexane) solvent extraction methods. Of
these Hexane fraction of AG (HAG) possessed particularly potent anti-inflammatory and
anti-cancer properties. This thesis is aimed at further exploring the mechanisms of colitis
and colitis-associated colon cancer inhibition by HAG and identifying the bioactive
components present in HAG.
1.1.1

INFLAMMATORY BOWEL DISEASE

Ulcerative colitis (UC), Crohn’s disease (CD) and indeterminate colitis are defined by
a common term of inflammatory bowel disease (IBD) (12). Patients with UC and CD are
at an increased risk of developing the colorectal cancer (CRC). The risk of CRC in
patients with UC increases with the duration of the disease with a cumulative risk of 18%
after 30 years (1). A number of genetic alterations, including microsatellite instability and
mutation in TP53 tumor suppressor gene, are early events in UC-associated CRC (13,
14). The risk of CRC in UC patients is 2% after 10 years and 8% after 20 years and 18%
after 30 years of active disease (15). Current opinion regarding the pathogenesis of IBD
is that in genetically susceptible individuals, there is an overreaction of the immune
systems towards antigens of gut microbiota leading to chronic inflammation (16). The
pathogenesis of UC and CD is of multifactorial nature as genetic and immunologic
factors, alterations in the colonic barrier function, bacterial and viral infection, altered
colonic microflora and furthermore, nutrition and psychosocial factor are involved (17).
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UC is caused by an atypical T helper (Th)2-mediated immune response characterized by
high levels of IL-5 (but not IL-4) and IL-13: in CD there is a prevalent activation of Th1
cells with high expression of TNF-α and IFN-γ (18-21).
1.1.1.1 CD4 T CELLS AND IMMUNE RESPONSE IN IBD
T helper (Th) cells have important roles in combating infections and cancers;
however, dysregulation of their function can lead to chronic inflammatory diseases (22).
T cells are further divided into 2 types: i) CD4 T cells, which express the CD4 surface
glycoprotein and are termed T helper (Th) cells as they provide help to B and other T
cells in directing B- and T-cell responses; and ii) CD8 T cells, which express the CD8
surface glycoprotein and which are termed cytotoxic T cells owing to their high
expression of macrophage-activating interferon-γ (IFNγ) and granzymes. Dysfunctional
and aberrant immune responses in which the adaptive immune response attacks the host
tissues as if they were foreign is one of the main cause of chronic inflammatory disease
like IBD, Multiple Sclerosis, Systemic Lupus Erythematosus and Rheumatoid Arthritis
[Reviewed in (22)].
Animal studies have established that dysregulated effector T cell responses to the
commensal flora can be causative in IBD and likely represent a final, common
immunopathogenetic mechanism in most, if not all, forms of IBD, irrespective of the
inciting events that promote them (23). Th1, Th2 and Th17 are CD4+ effector T cell
lineages that are involved in some form of IBD. Adaptive transfer of CD4+CD45RBhigh T
cells from healthy wild-type (WT) mice into syngeneic recipients that lack T and B cells
induces colitis at 5–8 wk following T cell transfer (24, 25). Although breakdowns in
intrinsic barrier and innate immune system functions may initiate IBD, it is evident that
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effector T cells of the adaptive immune system figure prominently in sustaining disease
and are probably essential to disease chronicity (23). IL-10-expressing CD4+ T cells
plays a dominant role in suppressing intestinal effector T cell development and function
and is consistent with the spontaneous development of colitis under conditions of genetic
deficiency of IL-10 production by CD4+ T cells (26), explain IL-10 as an antiinflammatory cytokine.
1.1.2

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), STEROIDS

AND

BIOLOGICS
NSAIDs are a group of drugs that are prescribed to reduce the pain and inflammation.
Some of these drugs require prescription, while some over the counter drugs do not
require prescription. Most commonly used NSAIDs are aspirin, sulindac, ibuprofen etc.
Acetaminophen and codeine are pure pain relievers that are not NSAIDs. NSAIDs
interfere with the cyclo-oxygenase (COX) pathways which lead to the production of
prostanoids (prostaglandins, prostacycline, and thromboxane) (27). Main problem with
NSAIDs is that there are two isoforms of COX enzymes (COX-1 and COX-2). COX-1
plays an important housekeeping role as it is constitutively expressed in most tissues,
including the stomach, duodenum, platelets, and kidneys; and involved in production of
prostaglandins which regulate important physiological processes such as gastrointestinal
cytoprotection (27). COX-2, on the other hand, is normally undetectable in most tissues,
but it can be induced rapidly, and in large quantities to 200–300-fold during inflammation
and other pathological processes (27). Most conventional NSAIDs are non-selective in
their COX inhibition, exerting their anti-inflammatory effects through the inhibition of
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COX-2, but exert adverse effects (such as gastrointestinal mucosal damage and
nephrotoxicity) primarily due to inhibition of COX-1 (27).
Steroids are effective short term but fail long term in most patients and are associated
with numerous side effects and low rates of mucosal healing (28, 29). Another strategy is
the use of biologics, which are genetically engineered medications made from living
organisms and their products. The ideal biologic agent for treating IBD should target a
specific event of the inflammatory cascade, induce and maintain a sustained remission, be
well tolerated and induce no immunogenicity (30). Common biologics used against
inflammation that targets TNFα are adalimumab (Humira), certolizumab (Cimzia),
infliximab (Remicade); while natalizumab (Tysabri) targets cell adhesion molecule α4integrin. Because biologics are given either by intravenous infusions or subcutaneous
injections, it may produce redness, itching, bruising, pain, or swelling on the injection
site. Additionally, anti-TNFα (as biologics) are	
   closely linked with mycobacterial
infections leading an incidence of tuberculosis (TB) (31) and sepsis, a life-threatening
blood infection is reported with biologics (32).
1.1.3

ROLE OF BIOASSAY-GUIDED FRACTIONATION OF HAG

American Ginseng (AG, Panax quinquefolius) is an obligate shade perennial native of
North America and its root is the commonly used part. AG has antioxidant properties,
and targets many key players involved in inflammation, including iNOS, COX-2 and NFκB (33). In a series of studies, we have recently shown that AG can treat colitis and
prevent colon cancer associated with colitis (9, 11, 33). In general, active or inactive
chemical entities obtained from ginseng species can be classified into five categories:
saponins, polysaccharides, polyynes/polyacetylenes, flavonoids, and oils (fatty-acids)

6	
  

(34). Ginseng’s saponins (generally called ginsenosides, mostly Rb1, Rg1, Rg3, Re and
Rd), and acidic polysaccharides of AG have been the main focus of its pharmacological
activities (35-40) such as vasorelaxation, anti-inflammatory, and anti-cancer properties
(41). Other putative active components of AG, include polyacetylenes such as panaxynol
and panaxydol, which are non-polar compounds (42). In contrast to ginsenosides and
polysaccharides; polyynes, flavonoids, and volatile oils have been less studied, and
therefore less is known about their medicinal properties.
Many studies have also reported pro-apoptotic properties of some of the ingredients
we have determined to be in the Hexane Fraction of AG (HAG) (43-49). Mostly
polyacetylenes (panaxynol, panaxydol and panaxydiol) and fatty acids are present in the
HAG (50). Interestingly, others have found an n-Hexane extract of red ginseng is
particularly potent in inhibiting the growth of human lung tumor xenografts in nude mice
(51). However, many fatty acids detected in our HAG, can induce apoptosis in various
cell types (43-49), and conjugated linoleic acid and oleic acid has been shown to suppress
colitis in other studies (52-55). Thus the study of bioassay-guided fractionation of HAG
will provide a significant insight in the bioactive components present in AG against
colitis and colon cancer.
1.1.4

OXIDATIVE STRESS AND FREE RADICALS

As a result of photosynthesis, our earth’s atmosphere consists of 21% oxygen level.
Oxygen is toxic to biological organisms as it generates free radicals. Hence the aerobic
organism has developed antioxidant defense system to tolerate oxygen and protect from
oxidative damage caused by the oxygen-free radicals. It is estimated that in the aerobic
metabolism 1-2% of total O2 consumption results in the production of ROS (56). This is
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the reason why in aerobic organisms, certain amounts of ROS, including hydroxyl
radicals (OH), superoxide anions (O2) and hydrogen peroxide (H2O2) are constantly
generated (56). For every 1012 Oxygen molecules that enter a cell per day, it is estimated
that 1 in 100 of these molecules damages DNA and protein (57, 58). Oxidative stress is
defined as an imbalance between generation of ROS and decreased antioxidant defense
system (56). Oxidative stress develops particularly in inflammatory reactions because the
inflammatory cells, neutrophils, and macrophages produce large amounts of ROS (56).
Increased ROS lead to protein damage, lipid peroxidation, and DNA damage which
results in genetic and epigenetic alterations that accounts for increasing grades of
dysplasia and carcinoma [Modified (56)].
Oxidation of DNA by ROS can result in damage to all four bases and to the deoxyribose-molecule. One of the most abundant molecules which is a product of this oxidation
is 8-oxo-7,8-dihydro-2,-deoxyguanosine (8-OH-dG), and has been established as a useful
biomarker of oxidative stress (59, 60). 8-OH-dG has a mutagenic effect in mammalian
cells, and can therefore be considered carcinogenic. Defense enzymes such as Superoxide
Dismutase (SOD) form a mutually supportive group of enzymes with peroxydases and
catalases to provide a defense against different ROS (61-64). Another enzyme
Glutathione-S-transferases (GSTs) protects macromolecules from attack of reactive
electrophiles and plays an important role in cellular detoxification (56). Nitric oxide, an
anorganic substance is an antioxidant defense factor that acts as a potent scavenger of
other free radicals and is a good inhibitor of lipid peroxidation (65, 66). However during
chronic inflammation, sustained production of larger concentration (usually micro-molar
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range) of NO by iNOS has been suggested to be cytotoxic and may contribute to cell
injury and is associated with pathogenesis of mucosal damage (67).
1.1.5

COLITIS ASSOCIATED COLON CANCER

Cancers in the setting of IBD are believed to occur by a progression from no
dysplasia to indefinite dysplasia to low-grade dysplasia (LGD) to high-grade dysplasia
(HGD) to carcinoma (4). Colitis-associated colorectal cancer (CAC) accounts for up to
5% of all colorectal cancers (68), and the incidence of CAC in the UC patients increases
with age.	
   The frequency of CIN (85%) and MSI (15%) in CAC is roughly the same as in
SCC (13). For the most part, in IBD, neoplastic lesions arise within areas of the mucosa
that have been involved with colonic inflammation (4). This might explain that during
inflammation, the healing of UC by re-epithelization of colonic mucosa leads to
abnormal cell growth resulting in neoplastic lesions (4). Colorectal cancer is one of the
two major cancers, the risk of which is commonly agreed to be modified mainly by food
and nutrition (69).
1.1.6

MOLECULAR PLAYERS IN COLITIS ASSOCIATED COLON CANCER

Several key molecules that are involved in inflammation-driven carcinogenesis are
nuclear factor κβ (NF-κβ); toll-like receptors; reactive oxygen and nitrogen species
(RONS); cyclooxygenases (COXs); nitric oxide synthases (NOSs); pro and antiinflammatory cytokines; metals; antioxidant enzymes; peroxisome proliferator-activated
receptor ligands; kinases; growth factors; and the tumor suppressor proteins, p53 and
retinoblastoma (pRb) proteins [Reviewed in (3)].
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1.1.6.1 NUCLEAR FACTOR-ΚΒ (NF- ΚΒ)
NF-κβ is a pleiotropic transcription factor with a key role in innate and adaptive
immunity and is required for the expression of various proinflammatory factors (70).
Activation of NF-κβ also supports carcinogenesis by increasing cell proliferation, and
angiogenesis, inhibiting cell death, promoting cell invasion and metastasis (71). NF-κβ is
a transcription factor consisting of closely related proteins that generally exist as dimers
and bind to a common DNA sequence within the promoter/enhancer of target genes
called the κβ site to promote transcription of target genes (such as COX-2, iNOS, Bcl-2,
Bcl-x(L), cyclin D1, MMP and VEGF) through the recruitment of coactivators and
corepressors (72). Inhibition of NF-κβ pathways by blocking one of the five members of
NF-κβ (p50, p52, p65(Rel A), c-Rel and Rel B) and upstream activators such as TNF-α
receptors and finally the target genes by nutraceuticals is one of the chemopreventive
aspects.
1.1.6.2 P53 FAMILY MEMBERS
The tumor suppressor, p53, plays a pivotal role in controlling cell cycle, apoptosis,
genomic integrity and DNA repair in response to various genotoxic stresses (72). After
activation, p53 can bind to regulatory DNA sequences and activate the expression of
target genes which can be grouped into four categories: cell cycle inhibition (p21,
reprimo, cyclin G1, GADD45, 14-3-3), apoptosis (PERP, NOXA, PUMA, p53AIP1,
ASPP1/2, Fas, BAX, PIDD), genetic stability (p21, DDB2, MSH2, XPC) and inhibition
of angiogenesis (TSP1, Maspin, BAI1, GD-AIF) [Reviewed in (72)]. Briefly, following
DNA damage, p53 levels rise and proliferating cells are arrested at G1-phase, allowing
time for DNA repair prior to the next round of replication. This arrest is mediated by
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stimulation of expression of p21CIP1, the cyclin kinase inhibitor (73). Increased p53 level
transactivates Bax (proapoptotic) for induction of apoptosis through caspase cascade
(74).
1.1.6.3 P53 AND TUMOR FORMATION
The TP53 (Tumor Protein p53) gene provides instructions for making a protein called
tumor protein p53 which acts as a tumor suppressor by regulating cell division by
keeping the cells from growing and dividing too fast or in an uncontrolled way [Adapted
from NCBI]. The TP53 gene is located on chromosome 17p13.1. It directly binds to
DNA and if DNA is damaged (by toxic chemicals, radiation, UV light), p53 protein
determines whether DNA be repaired or the damaged cell be self destructed (undergo
apoptosis). p53 is regulated by MDM2 (Mouse Double Minute 2, a p53 specific ubiquitin
ligase) (75-77). Mdm2 inhibits p53 cell-cycle arrest and apoptotic functions (78, 79)
during a normal cell growth by binding and masking p53 transcriptional activation
domain leading to ubiquitlyation and degradation of p53 (76, 77). During cellular stress
or DNA damage, p53 gets activated (phosphorylated/ acetylated), which inhibits Mdm2
activity thereby facilitating the damaged cells to undergo apoptosis or cell cycle arrest.	
  
Somatic mutation in TP53 gene is observed in about 50% of all human cancer (80, 81).
Many of these mutations change a single protein building block (Amino acid) in tumor
protein p53 leading to a production of non functional protein, that can’t regulate cell
growth and division, ultimately resulting in the unregulated growth and division of the
damaged cells forming a cancerous tumors [Adapted from NCBI]. When activated by
phosphorylation or acetylation, p53 negatively regulates cell proliferation and contribute
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to the maintenance of the genomic stability by regulating cell cycle checkpoints, DNA
repair, apoptosis and senescence (82, 83).
1.1.6.4 NITRIC OXIDE SYNTHASE
NOSs are the family of enzymes that catalyses the biosynthesis of NO. NOS are
dimeric enzymes with each monomer composed of two distinct catalytic domains: NH2terminal oxygenase domain and COOH-terminal reductase domain. N-terminal is the
binding site for heme 5,6,7,8-tetrahydrobiopterin (BH4), oxygen and l-arginine, whereas
NADPH, FMN and FAD bind on C-terminal (84). The catalytic mechanisms of NOS
involve flavin-mediated electron transport from NADPH to the heme centre, where
oxygen is reduced and incorporated into the guanidine nitrogen of l-arginine producing
NO and L-citrulline (85). There are 3 distinct isoforms of NOSs with 50% sequence
homology and can be divided into 2 broader classes:
1.1.6.4.1

CONSTITUTIVE NOSS: eNOS and nNOS isoforms are constitutive and
Calcium/Calmodulin dependent and generate NO in picomolar to nanomolar
range for short period of time [Reviewed in (86)]. cNOS is responsible for
physiological production of NO that has multiple beneficial effects including
modulation of platelet aggregation, inhibition of leukocyte adhesion and
control of vascular smooth muscle cell proliferation (87).

1.1.6.4.2

INDUCIBLE NOS: iNOS isoform is induced by cytokines and is independent
upon Calcium/Calmodulin for its enzymatic action [Reviewed in (86)]. iNOS
is expressed essentially in every cell type and can locally generate high output
quantities of NO at micromolar range for prolonged period of time [Reviewed
in (86)]. Type II or iNOS is not expressed under normal conditions and can be
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induced by exposure to cytokines and LPS in many cells (macrophages,
neurtrophils and the endothelium) (67) and is associated with NO production
in pathophysiological condition.
Thus NO serves as a dual role to mediate both physiological and
pathophysiological processes. In the Gastrointestinal tract, NO is important in protection
of mucosal damage and this is especially true in case of acute injury. NO produced in
such ways by cNOS influences virtually every component of mucosal defense by
reducing mast cell degranulation and release of pro-inflammatory substances from
macrophages, platelets and neutrophils (67). NO has been reported to be a free radical
scavanger (88) and its ability to scavange superoxide anion (O2-), has been well reported
both in vitro (89) and in vivo (90).
During chronic inflammatory conditions, sustained production of larger
concentration of NO (micromolar range) by iNOS has been suggested to be cytotoxic and
may contribute to cell injury (67). Increased level of NO has been associated with
experimental model of colonic inflammation induced by DSS (91) and increased activity
of iNOS has been measured in UC (92-95). This suggests that inhibition of iNOS may
have therapeutic implications against UC.
It is reported that NO induces p53 phosphorylation via ATM and ATR, which
leads to cell cycle checkpoint arrest at G2/M (96) during inflammation. NO also increases
cancer risk in chronically inflamed tissues. It has been shown that NO could target p53
tumor suppressor causing an increased p53 mutation load in inflamed colon tissue from
patients with UC, Wilson’s disease, hemochromatosis (96). It is evident that NO serve a
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dual role of p53 stabilization and p53 mutation depending upon the condition of
inflammation.
1.1.6.5 CYCLOOXYGENASES
COX-2 is an inducible prostaglandin G/H synthase, that is involved in prostaglandin
(PG) synthesis. Overproduction of COX-2 and PG production from free arachidonic acid
have been implicated in colon carcinogenesis (97). COX-2 mediated increased PGE2
levels have been believed to enhance tumor promotion by promoting cell proliferation,
angiogenesis and apoptotic evasion, stimulating tumor metastasis and decreasing immune
surveillance (98).
Cyclooxygenase-2 is a cytoplasmic protein that catalyzes the synthesis of lipid
inflammatory mediators (prostaglandins and prostacyclins) from arachidonic acid. COX2 expression is increased at the site of inflammation (99) and also in 80% of CRC and
40% of colorectal adenocarcinoma (100). Indeed, the COX-2 protein is found in the
cytoplasm of neoplastic colonic epithelial cells and to a lesser extent in stromal cells,
whereas normal epithelium is negative for COX-2 (101). COX-2 may contribute to tumor
development by modulating apoptosis, angiogenesis and tumor invasiveness, as overexpression of COX-2 in rat intestinal epithelial cells had increased adherence to the
extracellular matrix, resistance to apoptosis-inducing agents and up-regulation of the antiapoptotic protein B-cell lymphoma-2 (Bcl-2) (102).
1.1.6.6 WNT/Β-CATENIN PATHWAY
Abnormal activation of the Wnt/β-catenin pathway has been implicated in the
development of human colon cancer (97). In normal cells, Wild Type Adenomatous
Polyposis Coli (WT APC) protein controls the steady state levels β-catenin by targeting it
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for routine degradation (103, 104). Loss of WT APC function results in the translocation
of β-catenin to the nucleus, where it interacts with TCF-family transcription factors and
activates the transcription of several genes including those encoding cyclin D1, c-Myc
and anti-apoptotic protein survivin which is over-expressed by colorectal tumors (105).
1.1.6.7 MATRIX METALLOPROTEINASES (MMPS)
MMPs are secreted by inactive zymogens and are activated extracellularly, and once
activated, they are able to degrade most of the extracellular matrix components (such as
Collagen, laminin, fibronectin, vitonectin, enactin and proteoglycans), thus enhancing the
metastatic potential of cancer cells (106). Degradation of Type IV-Collagen by MMP-2
and -9 often occurs in cancer (106).
1.1.6.8 CDK/CYCLINS
Loss of the cell cycle regulation is a hallmark of cancer. The eukaryotic cell cycle is
regulated by the sequential activation and inactivation of cyclin-dependent kinases
(Cdks), that drive cell cyle progression by forming Cdk/Cyclin complex (assisted by Cdk
activating kinase, CAKs), and alternatively Cdk inhibitory subunits (CKIs, such as p21,
p27, p16INK4) inactivates the active Cdk/cylin complex [Reviewed in (107)]. Thus the
induction of cell cycle arrest and/or apoptosis is considered to be a promising
chemopreventive strategy.
1.1.7

MICRORNA

MicroRNAs (MiRs) are a group of small non-coding endogenous single stranded
RNAs of 18-25 nucleotide (approx. 22nts) length that negatively regulate gene expression
by translational inhibition or exonucleolytic messenger RNA (mRNA) decay (108).
Deregulated miR expressions have been found in several autoimmune disorders and
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inflammatory conditions (109-111). MiR-155 and miR-146a have been identified as
inflammatory response miRs, that are upregulated by NF-κβ (112-114). Additionally,
apoptosis of unwanted T cell clones is an important mechanism in resolution of
inflammation and miRs are clearly linked with regulation of apoptosis; indicates the
association of miR’s with inflammatory conditions. Several miRs have been found to be
either upregulated or downregulated in tumors (115-118). Besides the global microRNA
expression and signature identification in cancer, several individual microRNAs have
evolved as a key player in certain malignancies. The miRBase Version 16.0 has 1048
miRNA sequences annotated in the human genome, and miRNAs are believed to target
about one-third of human mRNAs; a single miR can target approximately 200 transcripts
simultaneously (119). There are different mechanisms to inhibit mutagenesis and
carcinogenesis and the modulation of miR as an epigenetic response to dietary agents is
one such mechanism that has recently evolved as an efficient tool in the cancer
chemoprevention study.
1.2 IN VITRO STUDY MODELS
For the in vitro study of inflammation, several oncogene immortalized mouse
macrophage and lymphoblastoid cell lines are generated that emulate normal tissue
macrophage and lymphoblasts which avoid difficulties associated with the isolation of
large homogenous population of macrophage or lymphoblasts (120-123). Cell lines used
for the inflammatory studies are ANA-1 mouse macrophage, TK6, NH32 and Jurkat T
cells.
In vitro cellular models permit isolation of specific aspects of tumor biology such that
functional analysis of relevant genes or the assessment of effects of endogenous
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mediators and pharmacological compounds are faster and simpler than in the intact
organism (124). Various cell lines are used for the in vitro models such as HCT116,
LOVO, HT29, and DLD1 etc. The limitation of in vitro models of colon cancer is that it
reflects only a specific stage of tumor development depending on the stage, the cells
originated from and it also lacks the tissue context study of tumor growth and metastasis
in vivo (124). To address this issue, in vivo animal models similar to human CRC have
emerged to provide the opportunity to study tumor stages and metastatic processes due to
the reliability to induce and establish colon tumors and study chemopreventive features
1.3 ANIMAL MODELS
Carcinogen induced CRC models are a highly reliable way to recapitulate the phases
of tumor growth and progression, that occurs in human and is frequently used to study the
chemopreventive compounds efficacy or their associated risk factors (124). An important
benefit of this model is that it is highly reproducible and can be readily tested on animals
with different genetic backgrounds.
1.3.1

DSS MOUSE MODEL OF COLITIS
DSS model of colitis is widely used model of experimental colitis because it has

similarities to human IBD in aetiology, pathology, pathogenesis and therapeutic response
(125). DSS is administered through the drinking water in cycles. For our experiments we
followed a protocol of each cycle of DSS as 7-days of DSS in drinking water followed by
7 days of normal drinking water. Acute colitis can be induced by single cycle of DSS
exposure (high concentration) to the mice whereas multiple cycles of DSS administration
(low concentration) will lead to chronic colitis (126). Exact mechanism of DSS induced
colitis is unknown, however a possible mechanism could be a direct alteration of gut
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permeability where tight junction protein (Zona occludens-1) were directly reduced by
DSS leading to an increase permeability; changes that precede colonic inflammation
[Reviewed in (125)]. Another possible mechanism could be direct cytotoxicity of DSS on
the colonic mucosa which leads to alteration of integrin-α4 and M290 subunit level of
epithelial cells disrupting their interaction with γδ-intraepithelial T cells (127) thought to
be involved in mucosal protection and healing (128). The exact mechanism of how DSS
initiates colitis is unknown but the fact that crypt loss and increased permeability usually
precede inflammation is suggestive that DSS causes initial insult at the epithelial cell
level with inflammation developing secondarily (129).
1.3.2

AOM/DSS MOUSE MODEL OF COLITIS ASSOCIATED COLON CANCER
Single to double dose of AOM injections induce colon tumors with pathological

features similar to that seen in sporadic human diseases (130-132).Currently studies with
AOM are preferred because of its practical advantage such as reproducibility, high
potency, simple mode of application, excellent stability in solution and low price (131).
AOM-induced tumors share many of the histopathological characteristics of human CRC
and they carry frequent mutations in K-Ras and β-catenin and some show MSI indicative
of defective MMR system (124). APC and p53 mutations are rare and tendency to
metastasize is also low (133). The intraperitoneal (I.P.) injection of AOM (Tumor
initiating agent) with DSS (Dextran Sulfate Sodium: Tumor promoting agent) in drinking
water (periodic cycle-alternate week between water and DSS) (AOM/DSS-model) is
applicable for the study of tumor progression driven by colitis (131) which causes rapid
growth of multiple colon tumors within 10 weeks compared to 30 weeks (for AOM I.P.
injection alone); hence it also shorten the latency time (131).
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AOM requires several metabolic activation steps (including N-oxidation and
hydroxylation) to induce DNA reactive adducts. Hydroxylation of AOM results in the
formation of reactive metabolite MAM which alkylate macromolecule in liver and colon
and operate the addition of methyl group at O6 and N7 positions of guanine (O6-methyldeoxyguanosine and N-7-methyl-deoxyguanosine) in the DNA molecule. Methylation at
the O6-position of guanine has been shown to be the primary promutagenic lesions
produced by AOM. MAM is activated by (mouse) colon alcoholdehydrogenase (134) and
alcohol inducible CYP2E1 (135).
1.4 OBJECTIVES OF THE RESEARCH
UC is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which
starts in the rectum and generally extends proximally in a continuous manner through
part of, or the entire colon (136). North American and Northern Europe have the highest
incidence rate (Varying from 9-20 cases/100000 person-years) and highest prevalence
rate (From 156-291 cases/100000 people) of UC (136). Incidence pattern of UC is
bimodal with main onset peak at 15-30 years (137) and second smaller peak at 50-70
years (136). The clinical features of UC are rectal bleeding, diarrhea, urgency, abdominal
pain, fever (severe cases); endoscopic features are loss of vascular pattern, erythema,
granularity, erosion and ulceration; and pathological features are distortion of crypt
architechture, crypt abscesses, Lamina propria cellular infiltrate, shortening of crypts,
lymphoid aggregates, erosion and ulceration [Reviewed in (136)]. Conventional NSAIDs
used for the treatment of UC have adverse side effects of gastrointestinal mucosal
damage (27). Anti-TNFα treatment have shown increased incidence of tuberculosis (31)
and sepsis (32). The use of complementary medicine among patients with IBD,
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particularly in the form of herbal therapies, is widespread in the Western world as well as
in many Asian countries including China and India (138). The use of herbal medicines by
natives is dated for centuries because of its efficiency and lesser known side effects.
Ginseng has been used for centuries in eastern Asia as an immune suppressant. We have
reported the anti-inflammatory and anti-cancer effects of AG (9-11). To identify the
bioactive compound/s present in AG extract, we performed a bioassay guided
fractionation of AG using different solvents for extraction of AG components.
Increased iNOS activity and expression has been widely reported in active UC
(92, 94, 139-141). Increased COX-2 expression has also been widely reported in IBD
(142, 143). Stabilization of p53 leads to transactivation of series of proteins responsible
for cell cycle arrest, apoptosis and senescence (144). Thus, we tested the antiinflammatory property of the fractions of AG in vitro and in vivo for these end points of
inflammation. Since stabilization p53 is responsible for apoptosis and AG whole extract
has been reported to induce apoptosis of inflammatory cells through p53 pathway (9), in
Chapter 3 we assessed the ability of HAG to induce apoptosis in inflammatory cells and
tested if this HAG mediated apoptosis is p53 dependent. To further elucidate the
mechanism of action of HAG, we explored the approach of miR mechanism (Chapter 4).
To identify the differentially regulated miR after HAG treatment on colon cancer cells,
global miR microarray approach was utilized and significantly regulated miR (miR-29b)
was further studied. Functional assay was studied by performing a loss of miR-29b
functional analysis experiments (Chapter 4). Having explored the anti-inflammatory and
anti-cancer effects and mechanisms of HAG, we performed a next step of bioassayguided fractionation by preparative reverse phase HPLC technique to further delineate
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the bioactive compound/s (Chapter 5). Suppression of iNOS expression in activated
mouse macrophages was assessed for each subfraction of HAG to initiate the
identification of bioactive compound/s.
Chapter 5 also includes the overall conclusion and summary of the project
followed by the future directions of this project.
1.5 SPECIFIC AIMS
A proposed scheme summarizing this research project is shown in Figure 1.1. The
specific aims of this dissertation are addressed below:
Specific Aim One: To detect if HAG suppresses colitis and associate colon cancer in the
experimental mouse model. (Chapter 2)
Specific Aim Two: To determine if p53 is a key mediator of the protective effects of AG
against the experimental mouse model of colitis. (Chapter 3)
Specific Aim Three: To explore HAG mediated regulation of miR in colon cancer cells.
(Chapter 4)
Specific Aim Four: To perform a next step bioassay-guided fractionations to further
delineate the bioactive compound/s present in HAG (Chapter 5).
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Figure 1.1 Schematic Overview of the Project. Specific Aims (I-IV) of the project is also
outlined.

22	
  

REFERENCES FOR CHAPTER 1
1.
Hussain SP. Inflammation and cancer: is AID aiding? Gastroenterology.
2008;135:736-737.
2.
Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al.
Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a
cancer-prone chronic inflammatory disease. Cancer Res. 2000;60:3333-3337.
3.
Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr.
2007;137:183S-185S.
4.
Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in
inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver
Physiol. 2004;287:G7-17.
5.
Stocks P, Karn MN. A co-operative study of the habits, home life, dietary and
family histories of 450 cancer patients and of an equal number of control patients. Ann
Eugen Human Genet. 1933;5:30-33.
6.
Gautam R, Jachak SM. Recent developments in anti-inflammatory natural
products. Med Res Rev. 2009;29:767-820.
7.
Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons
learned, future directions. Nat Rev Drug Discov. 2007;6:75-92.
8.
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30
years from 1981 to 2010. J Nat Prod. 2012;75:311-335.
9.
Jin Y, Hofseth AB, Cui X, Windust AJ, Poudyal D, Chumanevich AA, et al.
American ginseng suppresses colitis through p53-mediated apoptosis of inflammatory
cells. Cancer Prev Res (Phila). 2010;3:339-347.
10.
Jin Y, Kotakadi VS, Ying L, Hofseth AB, Cui X, Wood PA, et al. American
ginseng suppresses inflammation and DNA damage associated with mouse colitis.
Carcinogenesis. 2008;29:2351-2359.
11.
Cui X, Jin Y, Poudyal D, Chumanevich AA, Davis T, Windust A, et al.
Mechanistic insight into the ability of American ginseng to suppress colon cancer
associated with colitis. Carcinogenesis. 2010;31:1734-1741.
12.
Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and
colorectal cancer: a double-edged sword? World J Gastroenterol. 2011;17:3092-3100.

23	
  

13.
Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH, 2nd,
et al. Genomic instability is an early event during the progression pathway of ulcerativecolitis-related neoplasia. Am J Pathol. 1999;154:1825-1830.
14.
Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC,
et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative
colitis. Gastroenterology. 1994;107:369-378.
15.
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative
colitis: a meta-analysis. Gut. 2001;48:526-535.
16.
Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of
inflammation. Annu Rev Immunol. 2002;20:495-549. Epub 2001 Oct 2004.
17.
Head KA, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev.
2003;8:247-283.
18.
Fais S, Capobianchi MR, Pallone F, Dimarco P, Boirivant M, Dianzani F, et al.
Spontaneous Release of Interferon-Gamma by Intestinal Lamina Propria Lymphocytes in
Crohns-Disease - Kinetics of Invitro Response to Interferon-Gamma Inducers. Gut.
1991;32:403-407.
19.
Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al.
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2
response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.
20.
Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al.
Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory
bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma,
whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol.
1996;157:1261-1270.
21.
Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, et al.
Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina
propria mononuclear cells. Gastroenterology. 1997;112:1169-1178.
22.
Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory
bowel disease. Trends Mol Med. 2009;15:199-207.
23.
Maynard CL, Weaver CT. Intestinal effector T cells in health and disease.
Immunity. 2009;31:389-400.
24.
Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of
Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with
CD45RBhi CD4+ T cells. Immunity. 1994;1:553-562.

24	
  

25.
Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles.
Immunity. 1995;3:171-174.
26.
Roers A, Siewe L, Strittmatter E, Deckert M, Schluter D, Stenzel W, et al. T cellspecific inactivation of the interleukin 10 gene in mice results in enhanced T cell
responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med.
2004;200:1289-1297.
27.
Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damageproblems and solutions. Postgrad Med J. 2001;77:82-88.
28.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al.
Early combined immunosuppression or conventional management in patients with newly
diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
29.
Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ.
The natural history of corticosteroid therapy for inflammatory bowel disease: a
population-based study. Gastroenterology. 2001;121:255-260.
30.
Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in
inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106.
31.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman
WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med. 2001;345:1098-1104.
32.
Goode S, Tierney G, Deighton C. Life threatening intra-abdominal sepsis in
patients on anti-TNF-alpha therapy. Gut. 2006;55:590-591.
33.
Jin Y, Kotakadi VS, Ying L, Hofseth AB, Cui X, Wood PA, et al. American
ginseng suppresses inflammation and DNA damage associated with mouse colitis.
Carcinogenesis. 2008;29:2351-2359. Epub 2008 Sep 2318.
34.
Jia L, Zhao Y. Current evaluation of the millennium phytomedicine--ginseng (I):
etymology, pharmacognosy, phytochemistry, market and regulations. Curr Med Chem.
2009;16:2475-2484.
35.
Kim KH, Lee YS, Jung IS, Park SY, Chung HY, Lee IR, et al. Acidic
polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines
and generates LAK cells in synergy with rIL-2. Planta Med. 1998;64:110-115.
36.
Lee J-H, Shim JS, Lee JS, Kim M-K, Chung M-S, Kim KH. Pectin-like acidic
polysaccharide from Panax ginseng with selective antiadhesive activity against
pathogenic bacteria. Carbohydrate Research. [doi: DOI: 10.1016/j.carres.2006.03.032].
2006;341:1154-1163.

25	
  

37.
Wang J, Li S, Fan Y, Chen Y, Liu D, Cheng H, et al. Anti-fatigue activity of the
water-soluble polysaccharides isolated from Panax ginseng C. A. Meyer. J
Ethnopharmacol. 2010;130:421-423.
38.
Park E, Hwang I, Song JY, Jee Y. Acidic polysaccharide of Panax ginseng as a
defense against small intestinal damage by whole-body gamma irradiation of mice. Acta
Histochem. 2009.
39.
Choi HS, Kim KH, Sohn E, Park JD, Kim BO, Moon EY, et al. Red ginseng
acidic polysaccharide (RGAP) in combination with IFN-gamma results in enhanced
macrophage function through activation of the NF-kappaB pathway. Biosci Biotechnol
Biochem. 2008;72:1817-1825.
40.
Sasaki T, Oh KB, Matsuoka H, Saito M. [Effect of Panax ginseng components on
the differentiation of mouse embryonic stem cells into cardiac-like cells]. Yakugaku
Zasshi. 2008;128:461-467.
41.
Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular
mechanisms and medical applications. Curr Vasc Pharmacol. 2009;7:293-302.
42.
Liu JH, Lee CS, Leung KM, Yan ZK, Shen BH, Zhao ZZ, et al. Quantification of
two polyacetylenes in Radix Ginseng and roots of related Panax species using a gas
chromatography-mass spectrometric method. J Agric Food Chem. 2007;55:8830-8835.
43.
Pan Z, Wang J, Tang H, Li L, Lv J, Xia L, et al. Effects of palmitic acid on lipid
metabolism homeostasis and apoptosis in goose primary hepatocytes. Mol Cell Biochem.
2010.
44.
Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, et al. Docetaxel loaded oleic
acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis
through activation of caspase-2 in androgen independent prostate cancer cells. J Control
Release. 2010;147:278-288.
45.
Hsu YC, Meng X, Ou L, Ip MM. Activation of the AMP-activated protein kinasep38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53mutant mouse mammary tumor cells. Cell Signal. 2010;22:590-599.
46.
Cho HJ, Kwon GT, Park JH. trans-10,cis-12 Conjugated linoleic acid induces
depolarization of mitochondrial membranes in HT-29 human colon cancer cells: a
possible mechanism for induction of apoptosis. J Med Food. 2009;12:952-958.
47.
Cvjeticanin T, Stojanovic I, Timotijevic G, Stosic-Grujicic S, Miljkovic D. T cells
cooperate with palmitic acid in induction of beta cell apoptosis. BMC Immunol.
2009;10:29.
48.
Lu ZH, Mu YM, Wang BA, Li XL, Lu JM, Li JY, et al. Saturated free fatty acids,
palmitic acid and stearic acid, induce apoptosis by stimulation of ceramide generation in
rat testicular Leydig cell. Biochem Biophys Res Commun. 2003;303:1002-1007.
26	
  

49.
Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, Hirano K. Myristoleic acid, a
cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis
in human prostatic LNCaP cells. Prostate. 2001;47:59-65.
50.
Poudyal D, Le PM, Davis T, Hofseth AB, Chumanevich AP, Chumanevich AA,
et al. A hexane fraction of american ginseng suppresses mouse colitis and associated
colon cancer: anti-inflammatory and pro-apoptotic mechanisms. Cancer Prev Res (Phila).
2012.
51.
Lee SD, Park SK, Lee ES, Kim HM, Lee CW, Lee K, et al. A lipid-soluble red
ginseng extract inhibits the growth of human lung tumor xenografts in nude mice. J Med
Food. 2010;13:1-5.
52.
Evans NP, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J.
Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice
through activation of PPARgamma. J Nutr. 2010;140:515-521.
53.
Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate
clinical activity and colonic PPAR-responsive gene expression in a pig model of
experimental IBD. Clin Nutr. 2006;25:454-465.
54.
Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L,
Gonzalez F, et al. Activation of PPAR gamma and delta by conjugated linoleic acid
mediates protection from experimental inflammatory bowel disease. Gastroenterology.
2004;127:777-791.
55.
Borniquel S, Jansson EA, Cole MP, Freeman BA, Lundberg JO. Nitrated oleic
acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease.
Free Radic Biol Med. 2010;48:499-505.
56.
Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R. Oxidative stress in
ulcerative colitis-associated carcinogenesis. Pathol Res Pract. 2008;204:511-524.
57.
I.N. A, B. B. The Handbook of Oxidative Metabolism. Chelmsford, MA: ESA
Inc; 1996.
58.
Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and
aging. Mol Cell Biochem. 1997;174:305-319.
59.
Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, Dogliotti E. 8Oxoguanine DNA damage: at the crossroad of alternative repair pathways. Mutat Res.
2003;531:127-139.
60.
Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2'deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat
Res. 1997;387:147-163.

27	
  

61.
Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related
matters. J Biol Chem. 1997;272:18515-18517.
62.
Ho YS, Gargano M, Cao J, Bronson RT, Heimler I, Hutz RJ. Reduced fertility in
female mice lacking copper-zinc superoxide dismutase. J Biol Chem. 1998;273:77657769.
63.
Lebovitz RM, Zhang H, Vogel H, Cartwright J, Jr., Dionne L, Lu N, et al.
Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide
dismutase-deficient mice. Proc Natl Acad Sci U S A. 1996;93:9782-9787.
64.
Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, et al. Dilated
cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide
dismutase. Nat Genet. 1995;11:376-381.
65.
O'Donnell VB, Chumley PH, Hogg N, Bloodsworth A, Darley-Usmar VM,
Freeman BA. Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid
peroxyl radicals and comparison with alpha-tocopherol. Biochemistry. 1997;36:1521615223.
66.
Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, et al. Nitric
oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation
of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem. 1994;269:2606626075.
67.
Elliott SN, Wallace JL. Nitric oxide: a regulator of mucosal defense and injury. J
Gastroenterol. 1998;33:792-803.
68.
Ishikawa TO, Herschman HR. Tumor formation in a mouse model of colitisassociated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis.
2010;31:729-736.
69.
Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global
Perspective. Washington DC: WCRF/AICR; 2007.
70.
Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci
STKE. 2006;2006:re13.
71.
Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and
mechanisms. Curr Opin Genet Dev. 2008;18:19-26.
72.
Amin AR, Kucuk O, Khuri FR, Shin DM. Perspectives for cancer prevention with
natural compounds. J Clin Oncol. 2009;27:2712-2725.
73.
Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated
G1 arrest in human cancer cells. Cancer Res. 1995;55:5187-5190.

28	
  

74.
Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator
of the human bax gene. Cell. 1995;80:293-299.
75.
Barak Y, Oren M. Enhanced binding of a 95 kDa protein to p53 in cells
undergoing p53-mediated growth arrest. Embo J. 1992;11:2115-2121.
76.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene
product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
Cell. 1992;69:1237-1245.
77.
Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction
domains. Mol Cell Biol. 1993;13:4107-4114.
78.
Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated
apoptosis by mdm2. Embo J. 1996;15:1596-1606.
79.
Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis
functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996;16:2445-2452.
80.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human
cancers. Science. 1991;253:49-53.
81.
Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature.
1991;351:453-456.
82.
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature.
2000;408:307-310.
83.
Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis.
Oncogene. 2002;21:6898-6907.
84.
Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J.
1994;298 ( Pt 2):249-258.
85.
Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem.
1994;269:13725-13728.
86.
Singh S, Gupta AK. Nitric oxide: role in tumour biology and iNOS/NO-based
anticancer therapies. Cancer Chemother Pharmacol. 2011;67:1211-1224.
87.
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology,
and pharmacology. Pharmacol Rev. 1991;43:109-142.
88.
Kanner J, Harel S, Granit R. Nitric oxide as an antioxidant. Archives of
Biochemistry and Biophysics. 1991;289:130-136.

29	
  

89.
Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Botelho LH. Cytoprotective
function of nitric oxide: inactivation of superoxide radicals produced by human
leukocytes. Biochem Biophys Res Commun. 1991;181:1392-1397.
90.
Gaboury J, Woodman RC, Granger DN, Reinhardt P, Kubes P. Nitric oxide
prevents leukocyte adherence: role of superoxide. Am J Physiol. 1993;265:H862-867.
91.
Rajora N, Boccoli G, Catania A, Lipton JM. alpha-MSH modulates experimental
inflammatory bowel disease. Peptides. 1997;18:381-385.
92.
Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in
ulcerative colitis. Lancet. 1993;341:465-466.
93.
Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky
DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in
ulcerative colitis and Crohn's disease. Gut. 1995;36:718-723.
94.
Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, et
al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet.
1993;342:338-340.
95.
McLaughlan JM, Seth R, Vautier G, Robins RA, Scott BB, Hawkey CJ, et al.
Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel
disease at first presentation. Journal of Pathology. 1997;181:87-92.
96.
Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al. Nitric
oxide-induced cellular stress and p53 activation in chronic inflammation. Proceedings of
the National Academy of Sciences of the United States of America. 2003;100:143-148.
97.
Spychalski M, Dziki L, Dziki A. Chemoprevention of colorectal cancer - a new
target needed? Colorectal Dis. 2007;9:397-401.
98.
Eisinger AL, Prescott SM, Jones DA, Stafforini DM. The role of cyclooxygenase2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 2007;82:147154.
99.
Herschman HR, Xie W, Reddy S. Inflammation, reproduction, cancer and all
that.... The regulation and role of the inducible prostaglandin synthase. Bioessays.
1995;17:1031-1037.
100. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN.
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
101. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer
Metastasis Rev. 2004;23:63-75.

30	
  

102. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial
cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
103. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst.
1999;91:916-932.
104. Vogelstein B, Kinzler KW. The Genetic Basis of Human Cancer. New York:
McGraw-Hill; 2001.
105. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, et al. Expression of
survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol.
2001;32:119-125.
106. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal
cancer. Cancer Metastasis Rev. 2004;23:101-117.
107. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP
transcription factors. J Cell Sci. 2005;118:2545-2555.
108.

Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165-173.

109. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, et al.
MicroRNAs are differentially expressed in ulcerative colitis and alter expression of
macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135:1624-1635
e1624.
110. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, et al. MicroRNA-146A contributes
to abnormal activation of the type I interferon pathway in human lupus by targeting the
key signaling proteins. Arthritis Rheum. 2009;60:1065-1075.
111. Jones SW, Watkins G, Le Good N, Roberts S, Murphy CL, Brockbank SM, et al.
The identification of differentially expressed microRNA in osteoarthritic tissue that
modulate the production of TNF-alpha and MMP13. Osteoarthritis Cartilage.
2009;17:464-472.
112. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent
induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate
immune responses. Proc Natl Acad Sci U S A. 2006;103:12481-12486.
113. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of
the germinal center response by microRNA-155. Science. 2007;316:604-608.
114. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155
is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A.
2007;104:1604-1609.

31	
  

115. Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y, et al. MicroRNA-192 and
-215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in
vitro. Oncogene. 2011;30:1577-1585.
116. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, et al.
MicroRNA expression and identification of putative miRNA targets in ovarian cancer.
PLoS One. 2008;3:e2436.
117. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression
signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011;6:e18286.
118. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al.
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.
Cell. 2009;138:592-603.
119. Izzotti A, Cartiglia C, Steele VE, De Flora S. MicroRNAs as targets for dietary
and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res. 2012.
120. Blasi E, Mathieson BJ, Varesio L, Cleveland JL, Borchert PA, Rapp UR.
Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc
recombinant murine retrovirus. Nature. 1985;318:667-670.
121. Blasi E, Radzioch D, Durum SK, Varesio L. A murine macrophage cell line,
immortalized by v-raf and v-myc oncogenes, exhibits normal macrophage functions. Eur
J Immunol. 1987;17:1491-1498.
122. Cox GW, Mathieson BJ, Gandino L, Blasi E, Radzioch D, Varesio L.
Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus
infection of bone marrow or fetal liver. J Natl Cancer Inst. 1989;81:1492-1496.
123. Levy JA, Virolainen M, Defendi V. Human lymphoblastoid lines from lymph
node and spleen. Cancer. 1968;22:517-524.
124. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, et al. The
AOM/DSS murine model for the study of colon carcinogenesis: From pathways to
diagnosis and therapy studies. J Carcinog. 2011;10:9.
125. Solomon L, Mansor S, Mallon P, Donnelly E, Hoper M, Loughrey M, et al. The
dextran sulphate sodium (DSS) model of colitis: an overview. Comp Clin Pathol.
2010;19:235-239.
126. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel
method in the induction of reliable experimental acute and chronic ulcerative colitis in
mice. Gastroenterology. 1990;98:694-702.
127. Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal
epithelial cells and intestinal lymphocytes. Gut. 1996;39:234-241.

32	
  

128. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal
mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A.
2002;99:14338-14343.
129. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of
dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238-249.
130. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel
inflammation-related mouse colon carcinogenesis model induced by azoxymethane and
dextran sodium sulfate. Cancer Sci. 2003;94:965-973.
131. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon
carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression.
Nat Protoc. 2007;2:1998-2004.
132. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the
susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis
in mice. Carcinogenesis. 2006;27:162-169.
133. Kobaek-Larsen M, Thorup I, Diederichsen A, Fenger C, Hoitinga MR. Review of
colorectal cancer and its metastases in rodent models: comparative aspects with those in
humans. Comp Med. 2000;50:16-26.
134. Delker DA, McKnight SJ, 3rd, Rosenberg DW. The role of alcohol
dehydrogenase in the metabolism of the colon carcinogen methylazoxymethanol. Toxicol
Sci. 1998;45:66-71.
135. Sohn OS, Fiala ES, Requeijo SP, Weisburger JH, Gonzalez FJ. Differential
effects of CYP2E1 status on the metabolic activation of the colon carcinogens
azoxymethane and methylazoxymethanol. Cancer Res. 2001;61:8435-8440.
136. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis.
Lancet. 2012;380:1606-1619.
137. Loftus EV, Jr., Sandborn WJ. Epidemiology of inflammatory bowel disease.
Gastroenterol Clin North Am. 2002;31:1-20.
138. D'Inca R, Garribba AT, Vettorato MG, Martin A, Martines D, Di Leo V, et al.
Use of alternative and complementary therapies by inflammatory bowel disease patients
in an Italian tertiary referral centre. Dig Liver Dis. 2007;39:524-529.
139. Singer, II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, et al.
Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in
inflammatory bowel disease. Gastroenterology. 1996;111:871-885.
140. Godkin AJ, De Belder AJ, Villa L, Wong A, Beesley JE, Kane SP, et al.
Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest. 1996;26:867872.

33	
  

141. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al.
Increased expression of an inducible isoform of nitric oxide synthase and the formation
of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut.
1998;42:180-187.
142. Singer, II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF.
Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.
Gastroenterology. 1998;115:297-306.
143. Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active
inflammatory bowel disease. Am J Gastroenterol. 1997;92:1170-1173.
144. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell
Death Differ. 2006;13:941-950.

34	
  

FW:	
  Poudyal	
  (Thesis)	
  /	
  CaPR	
  -‐	
  Journal	
  Article:	
  Cancer	
  Prev	
  Re...	
  
https://mail.sccp.sc.edu/owa/?ae=Item&t=IPM.Note&id=Rg...	
  

FW: Poudyal (Thesis) / CaPR -Journal Article: Cancer
Prev Res CAPR-11-0421 for Phd Thesis Dissertation
Chapter
permissions [Permissions@aacr.org]
Sent:Sunday, March 03,
2013 12:58 PM
To: Poudyl, Deepak

Dear Deepak,
RE: Cancer Prevention Research, 2012; 5 #4; 685-696; Poudyal et al thesis
Authors of articles published in AACR journals are permitted to use
their article or parts of their article in the following ways without
requesting permission fromthe AACR. All such uses must include without
modification appropriate attribution to the original AACR publication:
Adapted (or reprinted) by permission from the American Association for
Cancer Research: author, article title, journal name, year, vol. issue,
pages.
Authors may:
1. reproduce parts of their article, including figures and tables, in
books,reviews, or subsequent research articles they write;
2. use parts of their article in presentations, including figures
downloadedinto PowerPoint, which can be done directly from the
journal's website;
3. post the accepted version of their article (after revisions
resulting frompeer review but before editing and formatting) on
their institutional website, ifthis is required by their
institution. The version on the institutional repositorymust contain
a link to the final, published version of the article on the
AACRjournal website. The posted version may be released publicly
(made open to anyone)12 months after its publication in the journal;
4. submit a copy of their article to his or her university in support
of adoctoral thesis.
Hope this is helpful,
Kind regards,
Karola
(Ms) Karola Rac,Assistant Director,
Circulation & Fulfillment American
Association for Cancer Research 615
Chestnut Street - 17th Floor
Philadelphia, PA 19106
www.permissions@aacr.org
Tel: 215.440.9300
1 of 2 3/9/13 5:21 PM FW: Poudyal (Thesis) / CaPR - Journal Article: Cancer Prev Re...
https://mail.sccp.sc.edu/owa/?ae=Item&t=IPM.Note&id=Rg...

CHAPTER 2
A HEXANE FRACTION OF AMERICAN GINSENG SUPPRESSES MOUSE COLITIS
AND ASSOCIATED COLON CANCER: ANTI-INFLAMMATORY AND
PROAPOPTOTIC MECHANISMS
∗

ABSTRACT: Ulcerative colitis (UC) is a chronic inflammatory condition associated with a
high colon cancer risk. We have previously reported that American Ginseng (AG) extract
significantly reduced the inflammatory parameters of chemically induced colitis. The aim
of this study was to further delineate the components of AG that suppress colitis and
prevent colon cancer.

Among five different fractions of AG (Butanol, Hexane,

Ethylacetate, Dicholoromethane and Water), a Hexane Fraction has particularly potent
anti-oxidant and pro-apoptotic properties. The effects of this fraction were shown in a
mouse macrophage cell line (ANA-1 cells), in a human lymphoblastoid cell line (TK6),
and in an ex-vivo model (CD4+/CD25- primary effector T cells). A key in vivo finding
was that compared with the whole AG extract, the Hexane Fraction of AG was more
potent in treating colitis in a dextran sulfate sodium (DSS) mouse model, as well as
suppressing azoxymethane (AOM)/DSS-induced colon cancer. Furthermore, TUNEL
labeling of inflammatory cells within the colonic mesenteric lymph nodes (MLN) was
elevated in mice consuming DSS + the Hexane Fraction of AG. Results are consistent
with our in vitro data, and with the hypothesis that the Hexane Fraction of AG has anti	
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inflammatory properties, and drives inflammatory cell apoptosis in vivo, providing a
mechanism by which this fraction protects from colitis in this DSS mouse model. This
study moves us closer to understanding the molecular components of AG that suppress
colitis, and prevent colon cancer associated with colitis.
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2.1 INTRODUCTION
Inflammatory Bowel Disease (IBD) [Ulcerative colitis (UC) and Crohn’s Disease
(CD)] is a group of chronic disorders of unknown etiology characterized by inflammation
in the gastrointestinal tract (1) and associated with an increased risk of colon cancer (2).
The histopathogenesis of UC-associated colorectal cancer involves a stepwise
progression from inflamed and hyperplastic epithelia, to flat dysplasia, to
adenocarcinoma (3). Colitis-associated colorectal cancer (CAC) accounts for up to 5% of
all colorectal cancers (4), and the incidence of CAC in the UC patients increases with
age. The azoxymethane (AOM)-tumor model has been used extensively to identify
molecular mechanisms involved in the multistage progression of sporadic colorectal
cancers (5). The addition of DSS to AOM has been used frequently because of its
reproducibility, and the cyclical and dynamic nature of colitis replicates the flare ups
characteristic of human UC (6-8).
American Ginseng (AG, Panax quinquefolius) is a perennial native of North
America, and ginseng is one of the most popular medicinal herbs used in the world (9).
AG has antioxidant properties, and targets many key players involved in inflammation,
including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (Cox-2) and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) (10). In a series of
studies, we have recently reported that AG suppresses the expression of inflammatory
markers of colitis and prevents colon cancer associated with colitis (10-12). In general,
active or inactive chemical entities obtained from ginseng species can be classified into
five categories: saponins, polysaccharides, polyynes, flavonoids, and volatile oils (13).
Ginseng’s saponins (generally called ginsenosides), and acidic polysaccharides of AG
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have been the main focus of its pharmacological activities (14-19). Water soluble
polysaccharides also have medicinal properties, including immune-modulating and antiproliferative effects (13). Other putative active components of AG, include
polyacetylenes such as panaxynol and panaxydol, which are non-polar compounds (20).
In contrast to ginsenosides and polysaccharides; polyynes, flavonoids, and volatile oils
have been less studied, and therefore less is known about their medicinal properties. To
further delineate the putative active components of AG against colitis, we have used
Bioassay-Guided Fractionation. In doing so, we show here that a Hexane Fraction of AG
is a potent anti-oxidant, can drive inflammatory cell apoptosis, and is more effective in its
ability to ameliorate colitis and prevent colon cancer in mice compared with the whole
AG extract.
2.2 MATERIAL AND METHODS
2.2.1

BIOASSAY-GUIDED FRACTIONATION OF AMERICAN GINSENG EXTRACT
The P. quinquefolius extract has been described previously in detail by our

laboratory (10). For bioassay-guided fractionation, 10 gm of AG extract was dissolved in
150 ml of water and sequentially partitioned against 3 x 50 ml aliquots of: hexane,
dichloromethane, ethyl acetate, water, and butanol. The fractions were reduced to near
dryness on a vacuum centrifuge, freeze dried, and their respective dry weights
determined: water fraction, 7.320 g (i.e., 73% of the original material); butanol fraction,
1.544 g; ethyl acetate fraction, 0.064 g; dichloromethane fraction, 0.062 g and hexane
fraction, 0.044 g. Each fraction was then re-dissolved in a small volume of solvent to
facilitate blending with the appropriate amount of maltodextrin to give a final weight of
10 g after a second round of evaporation by vacuum centrifuge and freeze drying. Thus,
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the original extract was subdivided based on polarity and reconstituted with maltodextrin
to give an equivalent weight as the starting material for bioassay. All fractions were
thoroughly vortex mixed to give a free flowing powder and split into two: one set was
retained at NRC Canada as a reference, the other used for bioassay. Neat maltodextrin
was used as a negative control.
2.2.2

CHEMICALS AND REAGENTS
Dextran sulfate sodium (DSS) was purchased from MP Biomedicals (molecular

weight, 36,000-50,000). Concanavalin A (diluted to a final concentration of 2.5 µg/mL)
was purchased from Sigma-Aldrich.
2.2.3

ANALYSIS OF THE HEXANE FRACTION OF AMERICAN GINSENG
With further long-term Bioassay-Guided Fractionation studies ongoing and given

our current findings, we thought it was prudent to provide a preliminary analysis of the
Hexane Fraction of AG for potential bioactive compounds. To provide additional hexane
fraction of AG for chemical analysis by gas and liquid chromatography and ultimately
further sub-fractionation and bioassay, 100 g of the AG extract was dissolved in 1 L of
water and partitioned against 8 x 400 mL of hexane using a 2 L separatory funnel. The
combined hexane fractions were filtered through glass fiber to remove particulates and
evaporated down using a vacuum centrifuge to yield 0.54 g of a free flowing, light yellow
colored oil.
2.2.4

FATTY ACID ANALYSIS BY GAS CHROMATOGRAPHY – MASS SPECTROMETRY AND
FLAME IONIZATION DETECTOR
For fatty acid analysis, two aliquots, nominally 50 mg, of the Hexane Fraction of

AG were transferred to 10 mL reaction vials, and exact weights recorded. An accurately
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weighed spike of 23:0 methyl ester solution was added to each vial as an internal
standard prior to the reaction and the contents thoroughly mixed by brief sonication. The
spiked hexane extracts were directly transesterified using 3 mL of 2% H2SO4 in methanol
for 30 min at 90oC in a thermostated heating block (Pierce, Rockford, IL). After cooling
and addition of 1 mL water, the fatty acid methyl esters were recovered by partitioning
into hexane (2 x 2 mL) and brought to a final volume of 5 mL in a volumetric flask.
Fatty acid methyl esters were analyzed on a Varian Saturn 2200 GC-MS system
(Varian Inc., Palo Alto. CA). The GC was a model CP3800 equipped with both a CTC
Analytics CombiPal autosampler (Zwingen, CH) and a flame ionization detector (FID).
Samples (1 uL) were injected at a temperature of 250oC with split ratios of 1/25 (FID) or
1/100 (MS) on a 30 m x 0.25 mm ID x 0.25µm film thickness Famewax column (Restek
Corp., Bellefonte, PA). The temperature program was as follows: initial temperature
195oC, ramped at 5oC/min to 240oC and held for 9 min for a total run time of 18 min.
Ultra high purity helium was used as a carrier gas at a flow rate of 1.1 mL/min.
2.2.5

LIQUID CHROMATOGRAPHY – UV ANALYSIS
The Hexane Fraction of AG was also quantitatively analyzed by LC-MS

specifically to look for the presence of ginsenosides and their aglycones (protopanaxdiol
and protopanaxtriol) using single ion monitoring in negative ion mode using authentic inhouse materials as standards. Two replicate samples of the hexane extract, accurately
weighed, were prepared in MeOH at a nominal concentration of 0.5 mg/mL. Ginsenoside
analysis was done on a 2.1 x 100 mm Waters Symmetry Shield C-18 column using
gradient elution from 20 to 40% ACN in water in 40 min at a flow rate of 0.3 mL/min
and an injection volume of 2 µL and aglycone analysis was done on a 2.1 x 50 mm
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Waters Symmetry Shield C-8 column using gradient elution from 40 to 75% ACN in
water in 15 min at a flow rate of 0.4 mL/min and an injection volume of 2 µL.
2.2.6

CELL CULTURE AND TREATMENT
ANA-1 murine macrophage cells were received as a kind gift from Michael Espey

(National Cancer Institute, Bethesda, MD) and maintained in Dulbecco's modified
Eagle's media (Hyclone, Logan, UT) supplemented with 10% New Born Calf serum
(NBCS) (Biofluids, Rockville, MD), 2 mM glutamine (Biofluids), penicillin (10 U/ml)
and streptomycin (10 µg/ml, Biofluids) in growing suspension culture at 37°C in a
humidified 5% CO2 atmosphere. Experiments with AG extract/fractions were carried out
by pre-incubating cells with indicated concentrations of AG extract/fractions for
indicated times. All AG extracts/fractions were dissolved in DMEM medium (0.1%
NBCS). Following a wash, cells were activated by exposure to 100 U/ml interferon
(IFN)-γ (R&D Systems, Minneapolis, MN).
TK6 lymphoblastoid cells were a kind gift from Curtis C. Harris (National Cancer
Institute, Bethesda, MD), originally derived from Dr. William Thilly's and Howard
Liber's labs. TK6 cells are a lymphoblastoid cell line derived from the spleen more than
30 y ago (21). TK6 cells were maintained in exponentially growing suspension culture at
37°C in a humidified 5% CO2 atmosphere in RPMI 1640 supplemented with 10% heatinactivated calf serum, 100 units/mL penicillin, 100 µg/mL streptomycin, and 2 mmol/L
l-glutamine. No authentication of the ANA-1 or TK6 cell lines was done by the authors.
CD4+/CD25− cells from C57BL/6 mice were purified from the spleens using
nylon wool columns (Polysciences) followed by depletion of B cells and macrophages.
The purity of T cells was 90% as determined by flow cytometry (Cytomics FC 500,
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Beckman Coulter). CD4+/CD25−T cells were then isolated using a MACS mini separator
and CD4 and CD25 microbeads according to the manufacturer's instructions (Miltenyi
Biotec) by depletion of CD4−CD25+ T cells (negative selection). CD4+/CD25− effector
T cells (1 X 106) were cultured in six-well plates overnight followed by experimentation
as indicated. All cells were maintained in exponentially growing suspension culture at
37°C in a humidified, 5% CO2 atmosphere in RPMI 1640 supplemented with 10% heatinactivated calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM Lglutamine.
2.2.7

DSS MOUSE MODEL OF COLITIS
We followed our previous protocol for our DSS (MP Biomedicals, Solon, OH: 36

000-50 000 mw) mouse model of colitis (10). 11.9 mg/kg of whole AG extract or the
Hexane Fraction of AG were dissolved in 100 µl 1x PBS per mouse and administered
daily by oral gavage (per os: p.o.). 11.9 mg/kg daily, which is the human equivalent dose
of 58 mg daily (22). Of note, currently the use of ginseng in human clinical trials can
range anywhere from 200 mg to 9 g daily (23, 24). The control group of mice was given
100 µl of maltodextrin dissolved in 1x PBS by oral gavage. All procedures performed
were in accordance with the Guide for care and Use of laboratory animals (National
Research Council, Washington, DC) and approved by the Animal Resource Facility,
University of South Carolina, Institutional Animal Care and Use Committee. To
determine whether the Hexane Fraction of AG can reverse/treat colitis, mice were fed 1%
DSS for 1.5 cycles (7 days DSS, 7 days water and 7 days DSS) and then given control,
the whole AG extract, or the Hexane Fraction of AG daily by oral gavage throughout the
course of the experiment. Mice were euthanized at 0 cycles, 1.5 cycles, 3.5 cycles
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(another 2 cycles of DSS and water) and 5.5 cycles (another 4 cycles of DSS and water)
(Supplementary Figure 1). For pathology and immunohistochemistry, colon tissue
samples were washed with phosphate-buffered saline (PBS; Mediatech, Herndon, VA),
cut longitudinally, swiss-rolled, then formalin fixed overnight, and paraffin embedded.
2.2.8

DISEASE ACTIVITY INDEX
The DAI, which monitors weight loss, stool consistency, and blood in the stool as

a measure of disease severity, was scored for each animal every third day throughout the
experiment. The DAI was calculated for each animal as done previously (12). With this
scoring system, the DAI is calculated by scoring each animal for weight loss, stool
consistency, and blood in the stool and then dividing the total score by 3. For example, an
animal that lost 12% of its body weight (score of 3) with evidence of loose stool (score of
2) plus gross rectal bleeding (score of 4) would have a calculated DAI of 3.
2.2.9

QUANTIFICATION OF INFLAMMATION TO EXAMINE EFFECTS OF COLITIS
Paraffin embedded tissues were serially sectioned, and one section from each

mouse was stained with H&E. Sections were microscopically examined for
histopathologic changes using the following scoring system. Histology score was
determined by multiplying the percent involvement for each of the three following
histologic features by the percent area of involvement (12) : inflammation severity (0,
none; 1, minimal; 2, moderate; 3, severe), inflammation extent (0, none; 1, mucosa; 2,
mucosa and submucosa; 3, transmural), and crypt damage (0, none; 1, one third of crypt
damaged; 2, two thirds of crypt damaged; 3, crypts lost, surface epithelium intact; 4,
crypts lost, surface epithelium lost). Percent area involvement was defined as: 0, 0%; 1,
1-25%; 2, 26-50%; 3, 51-75%; 4, 76-100%. Therefore, the minimal score is 0 and the
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maximal score is 40. The intensity of the staining was evaluated independently by two
blinded investigators (D.P and A.C).
2.2.10 AOM/DSS-INDUCED COLON CANCER MODEL
We carried out experiments with the AOM/DSS model of colitis-driven colon
cancer as we have described previously (25). A total of 11.9 mg/kg of the Hexane
fraction of AG, whole AG extract and vehicle groups (1x PBS), were given to the mice at
day 14 (after AOM and first week of DSS) by oral gavage and continued daily
throughout the course of the experiment. The mice were euthanized at day 35 (1 ½
cycles), and day 50 (2 cycles). Figure 2.11 outlines the time line of the protocol. We
followed a modified protocol outlined recently by the Wirtz et al (8) to chemically induce
colon cancer in the C57BL/6 mice. Briefly 8- to 12- week-old male C57BL/6 mice were
weighed and given a single intraperitoneal (IP) injection of AOM (10 mg/kg) or vehicle
(1x PBS) on experimental day 0. One week later, animals received 1% DSS in their
drinking water. Throughout the course of the experiment the animals were fed the AIN
93M chow. Colitis associated colon cancer was induced with cyclical DSS treatment
(following the initial single IP injection of AOM), which consisted of 7 days of 1% DSS
and 14 days of normal drinking water (a total of 21 days). The cycle here consisted of 14
days normal drinking water for recovery, because in our experience, mice were too
distressed with a shorter recovery when given both AOM and 1% DSS for the colon
cancer model. 11.9 mg/kg of the Hexane fraction of AG, whole AG extract and vehicle
groups (1x PBS), were given to the mice at day 14 (after AOM and first week of DSS) by
oral gavage and continued daily throughout the course of the experiment. The mice were
euthanized at day 35 (1 1/2 cycles), and day 50 (2 cycles. For pathology and
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immunohistochemistry, colon tissue samples were washed with 1x PBS (Mediatech,
Herndon, VA), cut longitudinally, swissrolled, then formalin fixed overnight, and
paraffin embedded.
2.2.11 DEFINITION OF TERMS TO QUANTIFY THE EFFECTS OF TREATMENT ON
PRECANCEROUS AND CANCEROUS LESIONS IN AOM/DSS MOUSE MODEL
All lesions were examined blindly by a trained pathologist, specializing in mouse
tissues. Inflammatory lesions were characterized by increased intensity of lamina propria
cellular infiltrate with alterations of the composition and changes in distribution. Based
on the area of the inflammatory stretch and its extension into the submucosa, the
inflammatory lesions were categorized into severe and mild. For ulceration, the infiltrate
was identified as extensive and extends diffusely towards deeper areas (transmucosal).
The presence of neutrophils, indicating a change in the composition of inflammatory
infiltrate was a feature of Ulcerative colitis (UC) and this activity could be recognized by
the presence of neutrophils infiltrating the walls of some crypts. Polyps were defined as
well demarcated circumscribed lumps of epithelial dysplasia, with uncontrolled crypt cell
division.

Dysplasia in non-invasive adenomas was identified where

part of the

epithelium was replaced by cells showing varying degree of atypia, with changes in
architecture and aberrant differentiation. Nuclear changes include hyperchromatism and
enlargement with nuclear crowding and frequent overlapping with nuclei typically
stratified near the base of the crypts and cytoplasm shows increased basophilia. Low
Grade Dysplasia was defined as mild and moderate dysplasia in which architectural
changes are modest and nuclear stratification was confined to the lower half of the cell.
High Grade Dysplasia was defined by more profound architectural alterations and
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stratification of nuclei into the upper half of the cells. Invasive Adenocarcinoma is
recognized by neoplastic cells that invades or infiltrates through the muscularis mucosa,
into or beyond the submucosa.
2.2.12 IMMUNOHISTOCHEMICAL STAINING
For immunohistochemical staining, serial sections of mouse colon tissues
(processed as described above) were incubated with antibodies against p53 (Rabbit
polyclonal, cat# 31333, diluted 1 in 1000; Abcam, Cambridge, MA), cyclooxygenase-2
(Cox-2) (Rabbit polyclonal, cat# 160126; diluted 1 in 5000; Cayman Chemical, Ann
Arbor, MI) or iNOS (Rabbit Polyclonal, Cat# 160862, diluted 1 in 3500; Cayman
Chemical, Ann Arbor, MI). To ensure even staining and reproducible results, sections
were incubated by slow rocking overnight in primary antibodies (4°C) using the
Antibody Amplifier™ (ProHisto, LLC, Columbia, SC).

Following incubation with

primary antibody, sections were processed with EnVision+ System-HRP kits
(DakoCytomation, Carpinteria, CA) according to the kit protocol. The chromogen was
diaminobenzidene and sections were counter stained with 1% methyl green. The positive
control tissue was colon cancer sections.

The negative control was devoid of primary

antibody incubation. Immunohistochemistry was quantified as we described previously
(25), with a slight modification. The intensity of the staining was evaluated independently
by two blinded investigators (D.P and A.C). For each tissue section, the percentage of
positive cells was scored on a scale of 0 to 5 for the percentage of tissue stained: 0 (0%
positive cells), 1 (<10%), 2 (11% to 25%), 3 (26% to 50%), 4 (51% to 80%), or 5 (>
80%). Staining intensity was scored on a scale of 0 to 3: 0-negative staining, 1-weak
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staining, 2-moderate staining, or 3-strong staining. The two scores were multiplied
resulting in an immunoreactivity score (IRS) value ranging from 0 to 15.
2.2.13 WESTERN BLOT ANALYSIS AND ANTIBODIES
Western blots were carried out as described previously (26). Antibodies used
include: iNOS (Rabbit polyclonal, diluted 1 in 500, cat#160862; Caymen Chemicals, Ann
Arbor, MI), Cox-2 (Rabbit polyclonal, diluted 1 in 500, cat#160106; Caymen Chemicals,
Ann Arbor, MI), PARP (Full length) (Rabbit polyclonal, diluted 1 in 500, cat#9542; Cell
Signaling Technology, Danvers, MA), Cleaved PARP (Rabbit polyclonal, diluted 1 in
500, cat# 9544; Cell Signaling Technology, Danvers, MA), p53 (Mouse monoclonal,
DO-1, diluted 1 in 500, cat# OP43T; Calbiochem, Gibbstown, NJ), Phospho-p53-Serine
15 (Rabbit polyclonal, diluted 1 in 500, cat#9284; Cell Signaling Technology, Danvers,
MA), PUMA (Rabbit polyclonal, diluted 1 in 500, cat#4976; Cell Signaling Technology,
Danvers, MA), Wip1 (Rabbit polyclonal, diluted 1 in 500, cat#AP8437b, Abgent, Inc.,
San Diego, CA), and Actin (Mouse monoclonal, diluted 1 in 1000, cat#A5316m
Calbiochem, St. Louis, MO). For all the blots, a standard protein (BenchMark Prestained
Protein Ladder; Invitrogen, Carlsbad CA) was run to ensure the correct molecular weight
of each bands observed. Where possible, purified protein was also run as a positive
control. For iNOS, Cox-2, WIP1, p53, phosphor-p53-serine 15, and Actin there was only
one clear band shown at 140 kDa, 72 kDa, 61 kDa, 53 kDa, 53 kDa, and 42 kDa,
respectively. For PARP, the cleaved and full length antibodies incubated concurrently,
and 3 bands were observed [116 kDA (Full Length), 89 kDa (Cleaved PARP), and 50
kDa (presumabely non-specific binding)]. For PUMA, 3 bands were observed, and the
band at 23 kDa was chosen because this band corresponds to the molecular weight of
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PUMA. Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary
antibodies were purchased from Amersham Biosciences (Piscataway, NJ).

Both

secondary antibodies were diluted at 1:2000. All antibodies were diluted in 5%
milk/PBST (1% Tween 20 in 1× PBS). Western blot signal was detected by Pierce ECL
Western Blotting Substrate (Thermo Scientific, Rockford, IL) and developed onto
Hyperfilm.
2.2.14 REAL TIME – PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen, CA). One
µg of total RNA served as template for single strand cDNA synthesis in a reaction using
oligo(dT) primers and AMV reverse transcriptase (Promega Corp, WI) under conditions
indicated by the manufacturer. PCR of cDNA samples was performed with samples
amplified for 30 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 sec, and
extension at 72°C for 30 sec with final extension at 72°C for 10 min. The sequences for
PCR primers used were: COX-2 Forward 5’-CCC CCA CAG TCA AAG ACA CT-3’,
COX-2 Reverse 5’-CTC ATC ACC CCA CTC AGG AT-3’; iNOS Forward 5’-CAC
CTT GGA GTT CAC CCA GT-3’, iNOS Reverse 5’-ACC ACT CGT ACT TGG GAT
GC-3’; GAPDH Forward 5’-ACC CAG AAG ACT GTG GAT GG-3’, GAPDH Reverse
5’-CAC ATT GGG GGT AGG AAC AC-3’ (Integrated DNA Technologies, Inc). Realtime PCR (qPCR) was performed using the 7300 Real-Time PCR Assay System (Applied
Biosystems, CA) with Power SYBR green PCR master mix (Applied Biosystems, CA)
and primers for iNOS, COX-2 and GAPDH according to the vendor's protocol. Both
iNOS and COX-2 gene expression was normalized by GAPDH gene expression.
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2.2.15 ANNEXIN V ASSAY
CD4+/CD25- effector T cells were seeded at 1 × 106 per well into six-well dishes
for 24 h. Following this, fresh medium or medium containing concanavalin A (Con-A,
2.5 µg/mL) was added to cells and cultured for 12 h. Con-A was then washed off, and
fresh medium or fresh medium containing freshly dissolved indicated concentrations of
AG or the Hexane Fraction of AG (0 - 300 µg/mL) was added for 24 h, as indicated. TK6
cells were seeded at 1 × 106 per well into six-well dishes for 24 h and treated with AG or
the Hexane Fraction of AG (0 - 1000 µg/mL). Cells were then harvested for Annexin V
according to instructions provided by the kit manufacturer (BD Biosciences). Annexin
V/propidium iodide (PI) staining was examined using a Beckman Coulter Cytomics
FC500 flow cytometer.
2.2.16 TUNEL ASSAYS
A TUNEL assay was carried out to assess apoptosis in vivo, according to the
manufacturer’s directions (DeadEnd™ Colorimetric TUNEL System; Promega, Madison,
WI). Briefly, this is a modified TUNEL Assay designed to provide simple, accurate and
rapid detection of apoptotic cells in situ at the single-cell level. The system measures
nuclear DNA fragmentation, an important biochemical indicator of apoptosis.

It end-

labels the fragmented DNA of apoptotic cells using a modified TUNEL (TdT-mediated
dUTP Nick-End Labeling) assay. Biotinylated nucleotide is incorporated at the 3´-OH
DNA ends using the enzyme Terminal Deoxynucleotidyl Transferase (TdT).
Horseradish-peroxidase-labeled streptavidin (Streptavidin HRP) is then bound to these
biotinylated nucleotides, which are detected using the peroxidase substrate, hydrogen
peroxide, and the stable chromogen, diaminobenzidine (DAB). Using this procedure,
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apoptotic nuclei are stained dark brown.

The counterstain was CAT Hematoxylin

(Biocare Medical, Concord, CA). Labeling was carried out on serial sections to that we
used to score inflammatory index. TUNEL labeling in 10 separate sections from 10
individual mice was quantified in both the epithelial areas, and the mesenteric lymph
nodes (MLNs). For the epithelial areas, 10 random fields were evaluated per slide.
Because there are relatively fewer MLNs, we evaluated each MLN for TUNEL labeling.
Labeled tissues were examined for intensity of staining using a method similar to that
previously described (27). Briefly, intensity of staining was evaluated independently by
blinded investigators. For each tissue section, the percentage of positive cells in either the
epithelium, or in the MLNs, was scored as described for immunohistochemical staining.
To measure apoptosis in cell culture, we used the TUNEL assay involving endlabeling of DNA with fluorescein-dUTP, followed by analysis using flow cytometry. For
exposure to the Hexane Fraction of AG, cells were incubated in 1% New-Born Calf
Serum (NBCS)-supplemented DMEM media for 24 hrs. The media was changed and the
cells were either treated with Hexane Fraction of AG (260 µg/ml) or non-treated (1%
NBCS supplemented media) for 0, 6, and 8 hrs. Cells were harvested and TUNEL assay
was performed as described by vendor (Roche Diagnostics, IN). Briefly, 1 X 106 cells
were fixed using a 100 µl of fixation solution (2% paraformaldehyde) and permeabilized
using a permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate). Cells were
washed and incubated with TUNEL reaction mixture (Label Solution and Enzyme
Solution) (Roche Diagnostics, IN). Apoptosis in the samples was analyzed by flowcytometry (Beckman Coulter, CA). The fluorescence was evaluated using the excitation
wavelength of 488nm and detected in the range of 515 -565 nm (green, FL-1 channel).
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The dot plot of FS Vs FL-1 and histogram plot of (Number of Event) Vs (FL-1 Channel)
were plotted to obtain a percentage increase in the apoptosis of the Hexane fraction of
AG treated cells. The positive control for apoptosis was fixed and permeabilized cells
with DNase I recombinant (3 U/ml in 50 mM Tris-HCL, pH 7.5, 1 mg/ml Bovine Serum
Albumin) (Invitrogen, CA) to induce DNA strand breaks prior to labeling. The negative
control for apoptosis was non-treated, healthy cells. Isogenic enzyme control is the fixed
and permeabilized cells with the labeling solution but without the terminal transferase
enzyme.
2.2.17 STATISTICAL ANALYSIS
Statistical analysis was done using one-way ANOVA with Scheffe's post hoc test
for TUNEL scores or the Kruskal-Wallis test when comparing histology inflammatory
scores. A two-way ANOVA for repeated measures was used to test for group and time
effects on clinical data (e.g., DAI) over successive days of observation. For flow
cytometry data, differences between groups were compared using a two-tailed paired
Student's t test or an unpaired Mann-Whitney U test. The results were analyzed using the
Stat- View II statistical program (Abacus Concepts, Inc.) and Microsoft Excel
(Microsoft) for Macintosh computers. Single-factor variance ANOVA analyses were
used to evaluate groups. A Fisher’s exact test was used to test the significance of
association between treatments and classifications (inflammation, ulceration, polyps, low
grade dysplasia, high grade dysplasia and adenocarcinomas). The P value chosen for
significance in this study was 0.05.
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2.3 RESULTS
2.3.1

THE HEXANE FRACTION OF AG SUPPRESSES INOS AND COX-2 EXPRESSION
We have previously shown that whole AG extract suppresses the expression of

inflammatory markers in ANA-1 mouse macrophages (10). To better delineate the active
ingredients in AG, we first screened ANA-1 mouse macrophage cells for suppression of
interferon gamma (IFN-γ)-induced iNOS expression by various AG fractions obtained
through Bioassay-Guided Fractionation. Interestingly only the Hexane Fraction of AG
(260 µg/ml) was able to suppress the induction of iNOS protein to an extent similar to
that of the whole AG extract (Figures 2.1 and 2.2). To confirm these anti-inflammatory
properties, we also examined Lipopolysaccharide (LPS)-induced expression of Cox-2
protein in the same cell line. Figures 2.1 indicate Cox-2 protein expression was also
suppressed by the Hexane Fraction of AG. To determine whether the Hexane Fraction of
AG regulates iNOS and Cox-2 expression at the transcriptional level, we carried out
Real-Time PCR analysis of these two genes. Figures 2.1 indicate the Hexane Fraction of
AG (260 µg/ml) suppresses the induced transcription of both iNOS and Cox-2,
respectively.
2.3.2

THE HEXANE FRACTION OF AG INDUCES APOPTOSIS IN INFLAMMATORY CELLS
We have previously shown that AG drives apoptosis of inflammatory cells (12),

providing a mechanism by which AG suppresses inflammation associated with colitis.
To further delineate the active ingredient responsible for apoptosis, and complement our
screen of AG fractions (Figures 2.1 and 2.2), we treated TK6 cells with the increasing
concentrations (0 - 1000 µg/ml) of whole AG extract and the Hexane Fraction of AG for
24 hrs. Results are shown in Supplementary Table 2.1, and Supplementary Figure 2.3.
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Interestingly, although the whole AG fraction had a modest effect on apoptosis of these
cells [3.4-fold increase in number of cells undergoing early apoptosis when exposed to
1000 µg/ml; consistent with our previous findings (12)], there was extensive apoptosis
(10.4-fold increase in number of cells undergoing early apoptosis when exposed to 1000
µg/ml) induced by the Hexane Fraction of AG. Notably, although there was also a
modest induction of apoptosis (6.1-fold increase in number of cells undergoing early
apoptosis when exposed to 1000 µg/ml) by the Butanol Fraction of AG, there was little to
no apoptosis caused by all other AG fractions (Table 2.2).
To complement results with Annexin V, we carried out another dose-response
experiment with the Hexane Fraction of AG, and processed cells for western analysis.
Results suggest apoptotic markers, including p53, phospho-serine-15, PUMA, and
cleaved PARP are induced by the Hexane Fraction of AG in TK6 lymphoblastoid cells
(Figures 2.4 and 2.5). Interestingly, the oncogenic phosphatase, wild-type p53-induced
phosphatase (Wip1), is decreased by the Hexane Fraction of AG, correlating with
induction of p53 phosphorylation (Figure 2.5), consistent with its’ (Wip1) capacity to
dephosphorylated and deactivate p53 (28).
2.3.3

THE HEXANE FRACTION OF AG INDUCES APOPTOSIS IN CD4+/CD25- EFFECTOR T
CELLS
Overly aggressive CD4+/CD25- T cells are thought to contribute to colitis, and

defects in mucosal T-cell apoptosis are likely to be critical in the pathogenesis of colitis
(12, 29, 30). We therefore isolated CD4+/CD25- effector T cells from the spleens of
C57BL/6 mice, then exposed unactivated or activated (pre-incubated for 12 hr with 2.5
µg/ml Concanavalin A) cells to either whole AG extract or the Hexane Fraction of AG (0
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- 300 µg/ml). Table 2.3 and Figure 2.3 show the Hexane Fraction of AG induces
apoptosis of CD4+/CD25- effector T cells to a similar extent to that of the whole AG
extract (6.2-fold by AG and 6.5-fold by the Hexane Fraction of AG in unactivated cells).
Apoptosis was induced to a greater extent in the activated effector T cells (10.2-fold by
AG and 13.6-fold by the Hexane Fraction of AG).
2.3.4

THE HEXANE FRACTION OF AG SUPPRESSES INFLAMMATION IN THE DSS MODEL
OF COLITIS
We have previously shown that the whole AG extract can be used to prevent and

treat mouse colitis (10-12), and the mechanism is at least in part due to the induction of
inflammatory cell apoptosis (12). Given our in vitro results indicating substantial antiinflammatory and pro-apoptotic properties of the Hexane Fraction of AG (Figure 2.2;
Figures 2.3 – 2.5; and Tables 2.1 - 2.3), we hypothesized that this fraction can be used to
treat DSS-induced mouse colitis.
To examine whether the Hexane Fraction of AG can be used to treat colitis, mice
were given 1% DSS for 1.5 cycles (7 days DSS, 7 days water and 7 days DSS) and then
fed vehicle control (1x PBS by oral gavage), the whole AG extract (11.9 mg/kg/day by
oral gavage) or the Hexane Fraction of AG (11.9 mg/kg/day by oral gavage) for the
duration of the experiment (outlined in Figure 2.6). Figure 2.7 shows results. The colons
were graded for their histology score as described in Methods. 1% DSS stimulates colitis.
When mice were fed the Hexane Fraction of AG, there was a significant reduction in
colon inflammation (“histology score”) at 3.5 cycles. Although there was also significant
suppression of colitis at 5.5 cycles, the reduction was less than that at 3.5 cycles, but
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more than that of the whole AG extract at 5.5 cycles. Representative hematoxylin and
eosin sections are shown.
Mouse colon length shrinks with stress, inflammation and ulceration (10).
Therefore, as an additional indicator of inflammation and inflammatory stress, mouse
colon lengths were measured upon euthanasia. The control group had an average colon
length of 8.5 ± 0.5 cm. There was a significant decrease in the length of the colon from
1.5 cycle DSS group (7.3 ± 0.2 cm) and 3.5 Cycles DSS group (7.3 ± 0.3 cm). In
contrast, there was no significant decrease in colon length in the 3.5 cycles DSS + the
Hexane Fraction of AG group (8.1 ± 0.2 cm). Similarly, in the 5.5 cycle groups, there
was a significant decrease in colon length in the DSS only group (7.3 ± 0.4 cm) compared
with the DSS + whole AG extract group (8.4 ± 0.3 cm) and the DSS + the Hexane extract
of AG group (8.6 ± 0.2 cm). This is consistent with the hypothesis that the Hexane
Fraction of AG is a potent anti-inflammatory agent in the DSS mouse model of colitis.
The DAI, which monitors weight loss, stool consistency, and blood in the stool as
a measure of disease severity, was also scored for each animal at 0, 1.5 cycles, 3.5 cycles,
and 5.5 cycles. As shown in Figure 2.8, the DAI increased with 1% DSS exposure, but
this was suppressed by both the whole AG extract and the Hexane Fraction of AG.
Significance (p < 0.05) was reached at Day 21, and continued until the end of the
experiment.
2.3.5

MARKERS OF INFLAMMATION AND INFLAMMATORY STRESS ARE REDUCED IN DSS
+ HEXANE FRACTION OF AG- TREATED MICE
To further assess the impact of the Hexane Fraction of AG on inflammatory

markers in vivo, we examined iNOS, Cox-2 and p53 expression. Immunohistochemical

55	
  

staining was accomplished by rocking slides using the Antibody AmplifierTM (ProHisto,
LLC) to ensure even, consistent, sensitive and reproducible staining. Figure 2.9 shows
representative sections of each endpoint as indicated. Figure 2.9 shows quantification of
each endpoint. Overall, iNOS, Cox-2, and p53 levels were elevated in the DSS-treated
mice, with most staining appearing in the inflammatory cells. iNOS and Cox-2 staining
were statistically significantly reduced in the DSS + Hexane Fraction of AG-treated mice;
there was also a trend to decreasing p53 levels. Such results reflect a reduction in the
number of inflammatory cells (that otherwise are expressing these inflammatory
markers), and complement our H&E pathology results.
2.3.6

THE HEXANE FRACTION OF AG STIMULATES APOPTOSIS OF LYMPHOCYTES IN VIVO
To examine the effects of the Hexane Fraction of AG on apoptosis in vivo, we

carried out a TUNEL assay on serial sections used for quantifying inflammation (Figure
2, 3.5 cycles). As shown in Figure 2.10, there is a significantly higher IRS (i.e. TUNEL
label) in both epithelium and the MLN of mice treated with DSS, compared with watertreated mice. The IRS in the epithelial cells decreased when they were treated with both
DSS + Hexane Fraction of AG. This observation is consistent with data from the
inflammatory index (Figure 2.7), indicating that the Hexane Fraction of AG protects
epithelial cells from DNA damage in vivo. Alternatively, in the MLNs, there was an
increase in IRS in the MLNs in mice when treated with DSS + Hexane Fraction of AG.
Such results are consistent with our in vitro data, and with the hypothesis that the Hexane
Fraction of AG drives apoptosis in inflammatory cells in vivo, providing a mechanism by
which the Hexane Fraction of AG protects from colitis in this DSS mouse model.
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2.3.7

THE HEXANE FRACTION

OF

AG SUPPRESSES COLON CANCER ASSOCIATED WITH

COLITIS
We have shown that the Hexane Fraction of AG suppresses DSS-induced colitis
(Figure 2.7). Mechanistically, this appears to be at least in part by the ability of this
fraction to induce apoptosis of lymphocytes (Figure 2.10; Tables 2.1 and 2.3). Because
both mice and humans with chronic colitis are at a high risk for colon cancer, we next
tested the hypothesis that the Hexane Fraction of AG prevents the onset of colon cancer
in a mouse model of colitis-driven colon cancer. Tables 2.4 and 2.5 show results that are
consistent with this hypothesis. We first examined the levels of inflammation, ulceration,
pre-cancerous and cancerous lesions at an intermediate point during the experiment (day
35). As shown in Table 2.4, both the Hexane Fraction of AG and the whole AG extract
reduced the severity of microscopic lesions. There was a significant reduction in the total
number of inflammatory/ulcerative lesions from 44 in the control group (AOM + DSS +
1x PBS, p.o.) to 24 and 28 in the AG (AOM + DSS + AG, p.o.) and the Hexane Fraction
of AG (AOM + DSS + Hex AG, p.o.), respectively. There was also a shift in the severity
of lesions, with more lesions being classified as mild inflammatory lesions in the AG and
Hexane Fraction of AG groups. There was also a drop in the number of ulcerative
lesions compared with the control group; with a greater drop in the Hexane Fraction of
AG (36.4% vs. 7.2%) than the AG (36.4% vs. 16.7%) group (Table 2.4). Similarly, there
was a significant reduction in the total number of pre-cancerous/cancerous lesions from
11 in the control group (AOM + DSS + 1x PBS, p.o.) to 1 and 0 in the AG (AOM + DSS
+ AG, p.o.) and the Hexane Fraction of AG (AOM + DSS + Hex AG, p.o.), respectively.
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Interestingly, most lesions (91%) in the AOM + DSS + PBS (control) group were of high
grade dysplasia or invasive adenocarcinoma (Table 2.4).
We next examined the levels of inflammation, ulceration, pre-cancerous and
cancerous lesions at a later time point during the experiment (day 50). As shown in
Table 2.5, both the Hexane Fraction of AG and the whole AG extract reduced the
severity of microscopic lesions. There was a significant reduction in the total number of
inflammatory/ulcerative lesions from 22 in the control group (AOM + DSS + 1x PBS,
p.o.) to 14 and 17 in the AG (AOM + DSS + AG, p.o.) and the Hexane Fraction of AG
(AOM + DSS + Hex AG, p.o.), respectively. There was again a shift in the severity of
lesions, with 2.7 and 4.2 fold lesions being classified as mild inflammatory lesions in the
AG group vs. the control (PBS) group and Hex AG group vs. the control (PBS) group,
respectively.

There was also a dramatic drop in the number of ulcerative lesions

compared with the control group compared with the Hexane Fraction of AG (27.3% vs.
5.8%) than the AG (27.3% vs. 0%) group (Table 2.5). At the 50 day period, there was
not as dramatic of a drop in the total number of pre-cancerous or cancerous lesions.
However, similar to the 35 day time-point, the severity of lesions was reduced at 50 days.
More lesions (33%) in the AOM + DSS + PBS (control) group were of high grade
dysplasia or invasive adenocarcinoma. Almost half (17%) of the AG fed group, and only
4% of the Hexane Fraction of AG group were in this classification (Table 2.5).
2.3.8

PRELIMINARY CHEMICAL ANALYSIS OF THE HEXANE FRACTION OF AG
Given the potency of the Hexane Fraction of AG, we initiated experiments to

better understand the components of this fraction. The amounts of fatty acids determined
from the analysis of the Hexane Fraction of AG are given in Table 2.6, and account for
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greater than 40% w/w of the total extract. Strikingly, linoleic acid (18:2n6) was the
major fatty acid, accounting for approximately 50% of the total fatty acids detected,
followed by palmitic (16:0) and palmitoleic (16:1) acids. LC-MS analysis did not detect
either protopanaxdiol or protopanaxtriol; however, low levels of ginsenosides Re, F11,
Rb1 and Rd were found, but amounted to less than 0.1% w/w of the Hexane Fraction of
AG.
Descriptive LC-UV Diode Array Detector analysis of the Hexane Fraction of AG
gave 3 major UV active peaks, one eluting at 22.7 min with UV maxima at 220, 230, 243
and 257 nm and another eluting at 26.7 min with UV maxima at 230, 243 and 257 nm
which match the UV maxima reported for the polyacetylenes, panaxydol and falcarinol
respectively (31). The third peak eluting at 20.7 min also exhibited multiple UV maxima
at 215, 242, 255, 269 and 284 nm may be a related compound. Confirmation of identity
and precise quantification of these compounds awaits individual isolation and structural
elucidation, which is currently underway and will be reported in detail separately.
2.4 DISCUSSION
We have previously shown that whole AG root extract suppresses colitis, and
prevents colon cancer associated with colitis in mice (10-12). In order to better delineate
the ingredients responsible for these findings, we carried out Bioassay-Guided
Fractionation, using multiple solvents. Interestingly, it appears one fraction (the Hexane
Fraction of AG) is particularly potent in its anti-inflammatory and pro-apoptotic
properties. As well, this Hexane Fraction of AG appears to be more effective than the
whole AG extract in treating DSS-induced mouse colitis, and modestly more effective at
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reducing the number and severity of pre-cancerous and cancerous lesions of the colon in
the AOM/DSS mouse model.
Specifically, from our in vitro results, the Hexane Fraction of AG was most
effective in suppressing IFNγ-induced expression of iNOS in ANA-1 mourse
macrophages (Figures 2.1 and 2.2). iNOS, which is responsible for the high-output
production of NO, is up-regulated within the inflammatory infiltrate of the lamina propria
and in the cytoplasm of the epithelial cells in patients with IBD (32). Large amounts of
Cox-2 have also been found in inflamed areas, producing most of the prostaglandins (PG)
(33) and it has been reported that the increased PG production during acute colitis is
dependent upon the activity of Cox-2	
   (27, 34, 35). Therefore, suppression of the
inflammatory response may be reached through the inhibition of prostaglandin E2
(PGE2) production and Cox-2 activation (33). Compared to untreated cells, Cox-2
expression was also suppressed by the Hexane Fraction of AG in ANA-1 cells (Figure
2.1). However Cox-2 protein expression was affected minimally by the whole AG
extract (Figure 2.1). Interestingly, Ichikiwa et al. have reported that AG extract has
minimal effects on Cox-2 protein expression in Raw 246.7 murine macrophages (36).
Jeong et al. have also reported ginsenoside Rd induces Cox-2 expression in Raw 264.7
cells and other ginsenosides (Rg1, Rg3, Rb1, and Re) did not induce Cox-2 (37).	
   	
   Our
original AG extract supplied to us by the Canadian Phytopharmaceutical Corporation
contains 23.5 mg/g of Rd. This is consistent with the hypothesis that Rd may be one of
the ingredients that prevents the whole AG extract from suppressing Cox-2 expression, as
the Hexane Fraction of AG has a minimal ginsenoside content, including very little of the
ginsenoside, Rd (Table 2.6). Also, at this time, we can only speculate on the specific
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molecules targeted by the Hexane Fraction of AG.

Because Cox-2 and iNOS

transcription is regulated by Signal Transducers and Activators of Transcription-1
(STAT-1), Hypoxia Inducible Factor-1α (HIF1α), NF-ĸB and Interferon Regulatory
Factor-1 (IRF-1) (38-43), such molecules remain candidates. There also may be indirect
mechanisms, such as targeting growth factors, including tumor necrosis factor alpha
(TNFα) and IFN-γ, both of which regulate iNOS and Cox-2 levels (44).

Another

hypothesis takes into account the Fatty Acid content of the Hexane Fraction of AG (Table
2.6). Fatty acids are known to readily react with nitric oxide species to form nitro-fatty
acid derivatives (NO2-FA) (45). NO2-FA signal through anti-inflammatory mechanisms
that inhibit neutrophil activation, platelet aggregation, and macrophage activation (46). It
is therefore possible that the formation of NO2-FA plays a key role in the antiinflammatory properties of the Hexane Fraction of AG. We are currently trying to better
understand these mechanisms and will report results in future studies. Nevertheless, the
finding that the Hexane Fraction of AG is effective in suppressing both iNOS and Cox-2
expression in vitro led us to hypothesize that this fraction could be potent in suppressing
colitis in mice. Results are consistent with this hypothesis (Figure 2.7).
In IBD, lymphocytes (both B and T cells) infiltrate the mucosa to eradicate the
foreign antigen (47, 48). Once the antigen has been eliminated, T lymphocytes of
intestinal mucosa require a mechanism to attenuate the local immune response (12), and
the failure to do so results in chronic immunogenic reactions. A key mechanism of
immune suppression is the apoptosis of overly aggressive effector T cells and we have
shown that the whole AG extract induces apoptosis of such cells (12). In this study, we
show that the Hexane Fraction of AG and to a lesser extent, the Butanol Fraction of AG
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also have pro-apoptotic properties. The whole AG extract has only a modest impact on
TK6 apoptosis (Table 2.1) but is as potent as the Hexane Fraction of AG in CD4+/CD25effector T cells (Table 2.3). Due to the potential impact of differential cellular sensitivity
to apoptosis, one of several hypotheses’ being explored is that this may be a result of the
heterogeneity of the potency of AG based on the cell type. This is consistent with other
studies that have reported pro-apoptotic properties of some of the ingredients we have
determined to be in the Hexane Fraction of AG (49-55).
Another finding that deserves further attention is that AG (whole AG extract and
the Hexane Fraction of AG) both suppresses iNOS and induces apoptosis. This is
especially apparent in ANA-1 mouse macrophages, where we measured both iNOS
expression (Figure 2.1) and apoptosis by TUNEL labeling (Figure 2.12 and Table 2.7).
Although this is consistent with studies finding suppression of iNOS induces apoptosis
(56), other groups have found an induction of apoptosis by nitric oxide from iNOS in T
cells (57). These findings may again be explained by cell type selectivity, as well as
many other factors. Although our findings here indicate both an anti-inflammatory and
pro-apoptotic effect of AG, it is likely that there are mechanisms of apoptosis by AG
other than through iNOS in T cells, which we are exploring.
It is currently unclear which component(s) in the Hexane Fraction of AG
suppresses colitis and drives apoptosis of inflammatory cells.

While we are sub-

fractionating the Hexane Fraction of AG to address this question, at this time we can only
speculate. Full details of the chemical analysis and spectroscopic identification of the
major components of the hexane fraction will be reported in a separate manuscript.
However, from our initial analysis (Table 2.6), it is unlikely that the ginsenosides are
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responsible, since these comprise a very minor portion of this fraction. More likely are
either the fatty acids or the polyacetylenes which, combined, comprise approximately
70% of the total hexane fraction by weight (Table 2.6). Conjugated linoleic acid, for
example, has been shown by others to attenuate colitis in animals (58-60). However, in
humans, linoleic acid (18:2n6), the fatty acid found in greatest abundance in the Hexane
Fraction of AG, may exacerbate colitis (61). Others have shown fatty acids such as oleic
acid have no effect in suppressing colitis (62). The effects of the other fatty acids we
detected in the Hexane Fraction of AG on colitis are, to our knowledge, unknown, but
worth exploring. Interestingly, trilinolein, a triglyceride isolated from P. notoginseng
where glycerol is esterified at all three positions with linoleic acid (18:2n6) has been
shown to have antioxidant and cardioprotective effects in animal models (63). The high
relative levels of 18:2n6 found in the Hexane Fraction of AG after transesterification
suggest that trilinolein may be present in AG also. Eight polyacetylenes have now been
reported from AG (64) a class of compound with potent anti-inflammatory activities (65).
Based on LC-UV, 1H-NMR and high resolution mass spectra, three C17 polyacetylenes:
panaxydiol, panaxydol and panaxynol were identified and comprised over 25% of the
Hexane Fraction of AG (Table 2.6).

Therefore this class of compound is another

candidate responsible for the observed activity against colitis.
In the DSS model of colitis, the Hexane Fraction of AG was found to be very
effective in suppressing colon inflammation (Figure 2.7). At 3.5 Cycles, the DSS +
Hexane Fraction of AG group was able to reverse the inflammation to almost basal
levels. At 5.5 cycles, the Hexane Fraction of AG was less potent against colitis than it
was at 3.5 cycles. One reason for this observation is that the increased cycles of DSS (2
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more cycles) was able to cause much more damage to the colon to the point where
complete recovery was unattainable. Regardless, at 5.5 cycles, the Hexane Fractiontreated mice had significantly less colon inflammation than the DSS only treated groups
of mice. It therefore appears that the Hexane Fraction of AG is more effective during the
short-term inflammation (acute colitis) than the long-term inflammation (chronic colitis).
It also appears to be more potent than the whole AG extract (Figure 2.7). Interestingly,
others have found an n-Hexane extract of red ginseng is particularly potent in inhibiting
the growth of human lung tumor xenografts in nude mice (66).
Many studies have shown anti-cancer effects of AG in vitro and in vivo, which we
have described in detail previously (11). As an extension of that study, it appears that
although the Hexane Fraction of AG has a similar potent effect of suppressing colon
cancer associated with colitis in the AOM/DSS model, the severity of pre-cancerous and
cancerous lesions is modestly reduced with the Hexane Fraction of AG compared with
the whole AG extract (Tables 2.4 and 2.5). Similar to the colitis data (Figure 2.7), the
reduction in severity of such lesions is greater at the earlier time period (35 days) than at
50 days. Again, one reason for this observation is that the increased time was able to
cause much more damage to the colon to the point where complete recovery was
unattainable.
In summary, we have identified through various endpoints that the Hexane
Fraction of AG is at least one component of AG extract responsible for the suppression of
DSS-induced colitis, and apoptosis of inflammatory cells is a mechanism by which it
acts. This Hexane Fraction of AG is also modestly more potent than the whole AG
extract in suppressing the severity of AOM/DSS-induced colon cancer. This finding
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represents a significant advancement in the field, since it has previously been thought that
ginsenosides, extremely minor elements of this fraction, are key anti-inflammatory and
anti-cancer agents in AG (67). To this end, it is currently unclear what component within
the Hexane Fraction of AG suppresses colitis and colon cancer associated with colitis.
However, many of the fatty acids detected in our Hexane Fraction of AG, can induce
apoptosis in various cell types (49-55), and conjugated linoleic acid and oleic acid has
been shown to suppress colitis in other studies (58-60, 62). This is consistent with the
hypothesis that at least one of these ingredients may be responsible for the activity of AG
root extract against colitis and associated colon cancer.

Further Bioassay-Guided

Fractionation of the Hexane extract of AG is ongoing to extend these current results to
further pinpoint this active ingredient(s).
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Table 2.1 Percentage of cells from a representative experiment staining positive for
Annexin V and negative for PI (early apoptotic cells) in TK6 lymphoblastoid cells.
Dose (µg/ml, 24 hr)

Whole AG Extract

Hexane Fraction of AG

0

2.2%

2.2%

100

4.4%

6.0%

500

6.6%

6.1%

800

7.1%

14.1%

1000

7.5%

22.9%

Table 2.2 Percentage of cells from a representative experiment staining positive for
Annexin V and negative for PI (early apoptotic cells) in TK6 lymphoblastoid cells.
Dose
(µg/ml),
24hr

Butanol
fraction of
AG

0
100
500
800
1000

2.2%
2.3%
7.7%
9.7%
13.4%

Dicholoromethane
fraction of
AG
4.7%
3.9%
3.9%
3.7%
3.7%

Ethylacetate
fraction of
AG
4.7%
3.6%
3.6%
3.7%
3.7%
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Water
fraction of
AG

Maltodextrin

4.5%
4.8%
4.1%
5.2%
6.1%

4.5%
5.6%
5.5%
5.7%
6.1%

Table 2.3 Percentage of cells staining positive for Annexin V cells and negative for PI
(early apoptotic cells) in CD4+/CD25− effector T cells isolated from the spleens of
C57BL/6 mice. Values represent the mean ± S.E (n=3). *indicates, significant difference
from 0 µg/ml for each treatment group.
Dose (µg/ml, 24 hr)
0
100
200
300

Whole AG Extract
No Con A
Con A
3.6 ± 0.1%
2.8 ± 0.3%
5.5 ± 0.5%*
4.9 ± 0.6%
10.0 ± 1.4%*
18.5 ± 6.9%
22.4 ± 5.7%*
28.8 ± 7.5%*

Hexane fraction of AG
No Con A
Con A
3.9 ± 0.4%
2.5 ± 0.3%
6.9 ± 1.2%
4.6 ± 0.6%*
12.5 ± 1.5%*
15.8 ± 2.9%*
25.3 ± 7.5%*
34.1 ± 5.9%*

Table 2.4 Percentage of inflammatory and ulcerative lesions (A) and of pre-cancerous
and cancerous lesions (B) in mice treated with AOM/DSS ± AG ± Hexane fraction of AG
(Hex AG) at days 35.
Day 35: analysis of inflammatory and ulcerative lesions
Group
No. of
Total no. of inflammatory/ Inflammatory lesions
animals ulcerative lesions
Mild
Severe
PBS
4
44
45.4%
18.2%
a
c
AG
4
24
62.5%
20.8%
Hex-AGb 4
28c
71.4%
21.4%
Day 35: analysis of precancerous and cancerous lesions
Group
No. of
Total no. of
Polyps
Noninvasive adenomas
animals precancerous/
LowHighcancerous
grade
grade
lesions
dysplasia
dysplasia
PBS
4
11
0%
9%
82%
AG
4
1d
0%
100%
0%
d
Hex-AG
4
0
0%
0%
0%
Abbreviation: AG, American ginseng
a
Whole American ginseng extract.
b
Hexane fraction of American ginseng.
c
Significant decrease compared with the control (PBS) treated group (P<0.05)
d
Significant decrease compared with the control (PBS) treated group (P<0.05)
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Ulcerative
mucosa
36.4%
16.7%
7.2%
Invasive
adenocarcinoma
9%
0%
0%

Table 2.5 Percentage of inflammatory and ulcerative lesions (A) and of pre-cancerous
and cancerous lesions (B) in mice treated with AOM/DSS ± AG ± Hexane fraction of AG
(Hex AG) at days 50.
Day 50: analysis of inflammatory and ulcerative lesions
Group
No. of
Total no. of inflammatory/ Inflammatory lesions
animals ulcerative lesions
Mild
Severe
PBS
10
22
18.2%
54.5%
AGa
9
14c
50%
50%
b
c
Hex-AG
10
17
76.6%
17.6%
Day 50: analysis of precancerous and cancerous lesions
Group
No. of
Total no. of
Polyps
Noninvasive adenomas
animals precancerous/
LowHighcancerous
grade
grade
lesions
dysplasia
dysplasia
PBS
10
27
0%
67%
26%
d
AG
9
18
0%
83%
11.5%
Hex-AG
10
25
8%
88%
4%
Abbreviation: AG, American ginseng
a
Whole American ginseng extract.
b
Hexane fraction of American ginseng.
c
Significant decrease compared with the control (PBS) treated group (P<0.05)
d
Significant decrease compared with the control (PBS) treated group (P<0.05)

Ulcerative
mucosa
27.3%
0%
5.8%
Invasive
adenocarcinoma
7%
5.5%
0%

Table 2.6 Fatty acid, ginsenoside and polyacetylene content of Hexane fraction of AG
A.
Fatty Acid
myristic (14:0)
myristoleic (14:1n5)
palmitic (16:0)
palmitoleic (16:1n7)
stearic (18:0)
oleic (18:1n9)
vaccenic (18:1n7cis)
linoleic (18:2n6)
linolenic (18:3n3)
arachidic (20:0)
gondoic (20:1n9)
(20:2n9)
behenic (22:0)
erucic (22:1n9)
lignoceric (24:0)
nervonic (24:1n9)
Total Fatty Acids

Composition percent w/w (±1 sd)
0.89 (0.06)
0.07 (0.02)
8.95 (0.72)
4.85 (0.46)
0.79 (0.07)
2.20 (0.05)
1.97 (0.49)
19.18 (2.06)
1.42 (0.08)
1.02 (0.08)
0.41 (0.32)
0.13 (0.15)
0.52 (0.11)
0.26 (0.07)
0.20 (0.04)
0.15 (0.12)
43.00 (4.13)
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B. Ginsenoside
Re
F11
Rb1
Rd
protopanaxdiol
protopanaxtriol
Total ginsenosides
C. Polyacetylenes
Panaxydiol
Panaxydol
Panaxynol
Total Polyacetylenes
Total (A+B+C)

Composition percent w/w (±1 sd)
0.008 (0.001)
0.059 (0.004)
0.003 (0.001)
0.004 (0.001)
ND*
ND*
0.074 (0.005)
Composition percent w/w (±1 sd)
7.39 (0.30)
8.92 (0.35)
10.21 (0.39)
26.52
69.59 (2.40)

Table 2.7 Apoptosis of ANA-1 cells treated with 260 µg/mL of Hexane fraction of AG
(12hr), followed by 100U/ml of IFNγ (0, 6 and 8 hr).
Treatment, 100U/ml
IFNγ (hrs.)
0
6
8

Non-Treated

Hexane fraction of AG (260 µg/mL)

2.09%
5.45%
2.24%

2.54%
19.62%
18.94%
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Figures

Figure 2.1 The hexane fraction of American ginseng (AG) suppresses the induced
expression of iNOS and COX-2 at the protein and mRNA level in ANA-1 mouse
macrophages. A, effect of whole American ginseng extract and the hexane fraction of
American ginseng on IFN-γ–induced iNOS protein expression. The murine macrophage
cell line (ANA-1 cells) was incubated for 12 hours with no American ginseng (media
only), the whole American ginseng extract (260 µg/mL), or the indicated American
ginseng fraction (260 µg/mL), washed, then exposed to IFN-γ (100 U/mL) for 0, 2, 4, and
8 hours. Cell lysates were analyzed by Western blot analysis. C+, the positive control,
which was an archived ANA-1 cell lysate previously induced by IFN-γ and known to
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have iNOS induction. B, effect of whole American ginseng extract and the hexane
fraction of American ginseng on lipopolysaccharide (LPS)-induced COX-2 protein
expression. Cells were treated as described in (A). Numbers under the bands indicate
densitometry values as a ratio relative to control (time, 0 hours) for each treatment. C,
densitometric quantification of iNOS and COX-2 bands shown in (A) and (B),
respectively, and adjusted for actin levels. D, effect of the hexane fraction of American
ginseng on IFN-γ–induced iNOS mRNA expression. Cells were treated as described in
(A). E, effect of whole American ginseng extract and the hexane fraction of American
ginseng on LPS-induced COX-2 mRNA expression. All treatments were repeated 3 times
to ensure consistency. *, significant (P < 0.05) reduction in mRNA expression, relative to
the untreated sample (no American ginseng).
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Figure 2.2 Effect of whole AG extract and different fractions of AG on IFN-γ-induced
iNOS expression. The murine macrophage cell line (ANA-1 cells) was incubated for 12
hr with No AG (media only), the whole AG extract (260 µg/ml), or the indicated AG
Fraction (260 µg/ml), washed, then exposed to IFN-γ (100 U/ml) for 0, 2, 4 and 8 hrs.
Cell lysates were analyzed by Western blot analysis. C+, indicates the positive control,
which was an archived ANA-1 cell lysate previously induced by IFN-γ, and known to
have iNOS induction. The treatment was repeated 3 times to ensure consistency.
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Figure 2.3 Inflammatory cells exposed to the whole AG extract and the Hexane Fraction
of AG undergo apoptosis in vitro. A. TK6 cells were exposed to indicated doses of AG or
the Hexane Fraction of AG dissolved in media for 24 hours. The Annexin V assay was
performed to determine apoptosis post-treatment and analyzed using flow cytometry.
Percentage of apoptotic cells are depicted in each histogram. A minimum of 10,000 cells
were counted from three separate plates for each time and dose indicated. B. Primary
CD4+/CD25- T-lymphocytes from untreated C57BL/6 mice exposed to indicated doses
of AG or the Hexane Fraction of AG dissolved in media for 24 hours undergo apoptosis
(assessed by Annexin V staining). CD4+/CD25- T-lymphocytes were isolated from the
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spleens of four different mice. Purified (>90% T-cell purity) non-activated or Con Aactivated T lymphocytes (1 x 106) were exposed to indicated doses of AG or the Hexane
Fraction of AG dissolved in media for 24 hours. The Annexin V assay was performed to
determine apoptosis post-treatment and analyzed using flow cytometry. Percentage of
apoptotic cells are depicted in each histogram. A minimum of 10,000 cells were counted
from three separate plates (n = 3) for each time and dose indicated.

Figure 2.4 Expression of apoptotic markers in TK6 cells following exposure to the
Hexane Fraction of AG. TK6 cells were exposed to indicated concentrations of the
Hexane Fraction of AG for 24 hr. A. Western blot analysis of p53, Phospho-p53-Serine15, p53 Up-regulator and Mediator of Apoptosis (PUMA) and β-actin. C-, indicates the
negative control, which were HCT116 p53-/- cells. C+, indicates the positive control,
which was a purified p53 peptide. Numbers under the bands indicate densitometry values
as a ratio relative to control (concentration 0 µg/ml) for each treatment. B. Densitometric
analysis of the expression of p53, Phospho-p53-Serine-15 and PUMA, adjusted for βactin.
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Figure 2.5 Expression of apoptotic markers in TK6 cells following exposure to the
Hexane Fraction of AG. TK6 cells were exposed to 200 µg/ml of the Hexane Fraction of
AG for indicated time points. Western blot was carried out for analysis of full length
PARP, cleaved PARP p53, Phospho-p53-Serine-15, Wip1, PUMA, and β-actin as
indicated. Numbers under the bands indicate densitometry values as a ratio relative to
control (time 0 hr) for each treatment.
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Figure 2.6 Experimental protocol for the DSS mouse model of Ulcerative Colitis. 11.9
mg/kg/day of whole AG extract, the Hexane Fraction of AG or Vehicle (1x PBS) was
given to the respective group of mice by oral gavage after 1.5 cycles of DSS and
continued daily until the end of the experiment (5.5 cycles). The mice from each group
were euthanized on days indicated.
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Figure 2.7 Effects of whole American ginseng (AG) extract and the hexane fraction of
American ginseng on the colon histology score in the DSS mouse model of colitis.
Results suggest that the hexane fraction of American ginseng is more potent in treating
colitis than the whole American ginseng extract. Values represent the mean ± SE.
Representative H&E-stained colons are shown for each group. Arrows point to areas of
inflammation and ulceration. Significant differences are indicated.

Figure 2.8 Effects of whole AG extract (AG) and the Hexane Fraction of AG on the
Disease Activity Index in the DSS mouse model of colitis. Mice received up to 5.5 cycles
(7 d DSS followed by 7 d water per cycle) of DSS with and without AG or the Hexane
Fraction of AG by oral gavage. ♦, indicates the DSS only group; ■, indicates the DSS +
whole AG extract group; ▼, indicates the DSS + the Hexane Fraction of AG group. *
and **, indicate significant difference from the DSS only group from day 21 to the end of
the experiment (p < 0.05).
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Figure 2.9 iNOS, COX-2, and p53, markers of inflammation and inflammatory stress, are
reduced in DSS + hexane fraction of American ginseng (AG)-treated mice. Tissues from
experiments carried out (3.5 cycles) were examined for iNOS, COX-2, and p53 by
immunohistochemistry, using the Antibody Amplifier (ProHisto, LLC) rocked on a
laboratory rocker to ensure even staining and reproducible results. A, representative
staining of indicated end points in serial sections from water (n = 11), DSS (n = 15), and
DSS + hexane fraction of American ginseng (n = 11) groups. Positive staining is brown
colored. ×100 magnification. B, quantification of indicated endpoints. All 3 markers were
elevated in the DSS-treated group and suppressed when the DSS-treated group was fed
the hexane fraction of American ginseng. P values are indicated.
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Figure 2.10 Effects of the hexane fraction of American ginseng (AG) on apoptosis in
cells of the epithelium (A and C) and the MLNs (B and D). A, IRS (TUNEL staining) in
epithelial cells of indicated groups. B, IRS (TUNEL staining) in MLNs of indicated
groups. C, quantification of staining in the epithelium. D, quantification of staining in the
MLNs.
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Figure 2.11 Experimental protocol for the AOM/DSS mouse model of colon cancer
associated with colitis. 11.9 mg/kg/day of whole AG extract, the Hexane Fraction of AG
or Vehicle (1x PBS) was given to the respective group of mice by oral gavage after a
single injection of AOM (10 mg/kg) and 1 week of 1% DSS. The mice from each group
were euthanized on days indicated.

Figure 2.12 ANA-1 Murine Macrophage cells exposed to the Hexane Fraction of AG
undergo apoptosis in vitro. ANA-1 cells were exposed to the Hexane Fraction of AG
(260 µg/ml) for indicated times. Fluorescent TUNEL assay was performed to determine
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apoptosis post-treatment and analyzed by flow-cytometry. Percentage of apoptotic cells
were depicted in each histogram. A minimum of 20,000 cells were counted for each
treatment.
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CHAPTER 3
A LIMITED ROLE OF P53 ON THE ABILITY OF A HEXANE FRACTION OF
AMERICAN GINSENG TO SUPPRESS MOUSE COLITIS.
∗

ABSTRACT: Ulcerative colitis (UC) is debilitating and carries a high colon cancer risk.
Apoptosis of inflammatory cells is a key mechanism regulating UC. We have recently
shown that American ginseng (AG), and to a greater extent, a Hexane fraction of AG
(HAG) can cause apoptosis and suppress mouse colitis through a p53-mediated
mechanism. Here, we tested the hypothesis that HAG suppresses colitis through a p53
mechanism. We found only a limited impact of p53 in the ability of HAG to induce
inflammatory cell apoptosis and suppress mouse colitis in vitro and in vivo. Finally, we
asked whether HAG could cause cell cycle arrest of HCT116 colon cancer cells in vitro.
Interestingly, HAG caused a G1 arrest of such cells independent of p53 status. Findings
are significant because HAG suppresses colitis and associated colon cancer, and mutation
in p53 is observed in most colitis-driven colon cancers. Therefore, HAG might be very
effective in targeting the inflammatory cells and cancer cells since it induces apoptosis of
inflammatory cells and cell cycle arrest in both p53-/- and WT p53 colon cancer cells.
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3.1

INTRODUCTION
Inflammatory Bowel Disease (IBD) is considered an autoimmune disease that causes

chronic inflammation in the gastro-intestinal tract. Ulcerative colitis (UC) is one of the
IBDs’ reflecting chronic relapsing inflammatory disorders of the intestine (1). Among the
cell types, epithelial cells, myeloid innate cells, effector-T cells, regulatory cells and Bcells have been implicated in IBD pathogenesis (2). Excessive effector T-cell cytokine
secretion or defective regulatory T cells leads to the disease propagation of IBD (2). The
intestinal barrier performs two important tasks to keep the balance between health and
disease. First, it must mediate effective absorption of fluids, nutrients and minerals from
the lumen across the epithelium and into the microcirculation and microvilli (3). Second,
the barrier must be impermeable to prevent the transfer of potentially pathogenic
microbes and infectious agents (3). Dysfunction in this intestinal barrier leads to the
dysfunction in the intestinal immune system, which has been implicated as the major
mechanism by which chronic inflammation occurs in colitis (4). Hence a common feature
of IBD pathogenesis is the dysregulated effector T cell response to commensal
microbiota. The intestinal mucosa is constantly exposed to several antigens, the mucosal
immune system have evolved several strategies to avoid an unnecessary and uncontrolled
inflammatory reaction. Once the antigen from the commensal microbiota has been
eradicated, T lymphocytes of the intestinal mucosa require a method to attenuate the local
immune response (4). One of the regulatory methods, down-regulation of activated T
lymphocytes via apoptosis, is a very potent and effective strategy, now considered as a
key controlling mechanism of IBD (5). Failure to regulate T-cell responses in the
intestinal or colonic mucosa leads to an inappropriate and sustained injurious
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immunologic reaction (6, 7). Because of their heightened activation and activity in IBD
pathogenesis, effector T cells are considered an excellent target for therapeutics.
Cells undergoing apoptosis are characterized by the shrinkage and condensation of
their cytoplasm, increased mitochondrial permeability, chromatin condensation into caps
at the edge of the nucleus, DNA fragmentation, and the appearance of plasma membrane
blebs, often referred to as “apoptotic bodies” (8). There are two signaling pathways for
the cell death by apoptosis: the intrinsic and extrinsic pathways (9, 10). Activation of the
extrinsic pathway occurs by ligand-induced cell surface receptor (e.g., tumor necrosis
factor receptor 1 [TNFR1], Fas, and death receptor 5) activation (11). The intrinsic
pathway is activated with growth factor deprivation, oncogene activation, or when DNA
damage is detected by cellular sensors such as ataxia telangiectasia mutated (ATM),
ataxia telangiectasia and Rad3-related (ATR), and tumor protein 53 (p53) (11).
Inflammation-induced reactive oxygen species and nitric oxide leads to p53 stabilization
and accumulation (12, 13). This activates p53 to eliminate the damaged cells by apoptosis
(12, 13). This is an intrinsic approach for the apoptosis of damaged cells, where activated
p53 plays an important role in mediating apoptosis in epithelial and inflammatory cells
during the process of colitis (4, 12, 14-17). The post-translational modification (often
phosphorylation at Serine 15) tends to elevate the level of wild-type (WT) p53 during
inflammation (12). p53 plays at least 2 separate roles in the responses to therapeutic
agents: it is an important component of cellular checkpoints (cell cycle arrest), and it can
mediate apoptosis (18). The role of p53 in the responses of tumor cells to therapy is
controversial. For example, loss of p53 function can cause resistance to 5‑fluorouracil
(5‑FU), but increased sensitivity to DNA damaging agent such as adriamycin (18). This
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provides a clear indication that some drugs may exert an apoptosis-inducing effect
through a p53-dependent while other drugs effect through a p53-independent pathway.
Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant
cells that will not die and continue to proliferate. Four cellular functions are
inappropriately regulated in the cancer cells: Cellular proliferation, differentiation,
chromosomal and genetic organization, and apoptosis (Reviewed in (19)). Abnormal cell
proliferation leading to accumulation of clonal cells is seen in cancer. As mentioned this
could be due to the defects with the cell cycle control. Upon sensing DNA damage, p53 is
activated, resulting in either G1 cell cycle arrest (20, 21) or apoptosis (22, 23). Cells
undergo a G1 cell cycle arrest to allow the DNA repair before replication and if the DNA
damage is beyond repair, the cells tend to undergo apoptosis. Cells can also undergo a G1
arrest due to targeting cyclins and cyclin-dependent kinases. p53 mutation is observed in
most cancers (24), which often tend to relax this G1-S cell cycle transition because p53
could not be activated. Hence, cancer cells lack the appropriate G1-S checkpoint
regulation and controlled apoptosis.
American ginseng (AG, Panax quinquefolius) is grown in the eastern temperate forest
areas of North America, from British Columbia, southern Quebec, Ontario, Minnesota,
and Wisconsin in the north, to Oklahoma, the Ozark Plateau, and Georgia in the south
(25). AG is an obligate shade perennial native of North America and its root is the
commonly used component. AG has been reported to have a wide range of
pharmacological effects, including effects on the central nervous system, blood-sugar
levels, cardiovascular system, endocrine system, immune system and cancer (4, 26, 27).
Recently we have shown AG extract suppresses colitis by the accumulation and
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activation of p53 to induce apoptosis of inflammatory cells (4). To further delineate the
active anti-inflammatory and pro-apoptotic components present in the AG, we subfractionated a different fraction of AG. A Hexane Fraction of AG (HAG) showed
increased anti-inflammatory and pro-apoptotic properties in the chemically induced
mouse model of colitis (28). The elevation of WT p53 levels during inflammation (12)
resulting in apoptosis of inflammatory and damaged cells (4, 29, 30) lead us to the notion
that the active anti-inflammatory components present in HAG might suppress colitis
through the p53 pathway. Here, we tested this hypothesis.
3.2

MATERIAL AND METHODS

3.2.1

BIOASSAY-GUIDED FRACTIONATION OF HEXANE FRACTION OF AG

The P. quinquefolius extract has been described previously in detail by our laboratory
(16). As well, we have recently described the generation of the HAG used in the present
study (28).
3.2.2

CHEMICALS AND REAGENTS

Dextran sulfate sodium (DSS) was purchased from MP Biomedicals (Solon, OH:
molecular weight, 36,000-50,000).
3.2.3

CELL CULTURE AND TREATMENTS

TK6 (p53+/+) and NH32 (p53−/−) cell lines were a kind gift from Curtis Harris
(National Cancer Institute), originally derived from Dr. William Thilly's and Howard
Liber's labs. TK6 cells are a lymphoblastoid cell line derived from the spleen more than
30 y ago (31). NH32 cells are an isogenic derivative of TK6 cells in which both alleles of
the p53 gene were knocked out (32). Jurkat T cells are an immortalized line of T
lymphocyte cells derived in the late 1970s from the peripheral blood of a 14-y-old male
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with T-cell leukemia (33). Jurkat T cells have a defective p53 pathway due to a mutation
in the COOH-terminal domain responsible for transactivation (34, 35). TK6, NH32 and
Jurkat T cells were maintained in exponentially growing suspension culture at 37°C in a
humidified 5% CO2 atmosphere in RPMI 1640 supplemented with 10% heat-inactivated
calf serum, 100 units/mL penicillin, 100 µg/mL streptomycin, and 2 mmol/L l-glutamine.
CD4+/CD25− cells from C57BL/6 mice were purified from the spleens using nylon
wool columns (Polysciences, Warrington, PA, USA) followed by depletion of B cells and
macrophages. CD4+/CD25− T cells were then isolated using a MACS mini separator and
CD4 and CD25 microbeads according to the manufacturer's instructions (Miltenyi Biotec,
Auburn, CA, USA) by depletion of CD4−CD25+ T cells (negative selection). The purity
of T cells was 88.6% (Figure 3.1) as determined by flow cytometry (Cytomics FC 500,
Beckman Coulter, Brea, CA, USA). Briefly, isolated CD4+/CD25− T cells were washed
with PBS and 2X105 cells were resuspended with 100 µl of PBS and incubated with antimouse CD4 antibody conjugated to Allophycocyanin (APC) (Clone: GK1.5; Isotype: rat
IgG2b, kappa) (0.125 µg/100 µl of cell suspension) (eBioscience, San Diego, CA, USA).
The anti-mouse CD25 antibody conjugated to R-Phycoerythrin (PE) (Clone:7D4;
Isotype: rat IgM) (Miltenyi Biotec, Auburn, CA, USA) was incubated during the isolation
of CD4+/CD25− effector T cells according to the manufacturer’s instructions (Miltenyi
Biotec, Auburn, CA, USA). The purity of CD4+ T cells were determined by obtaining a
dot plot of FL-4 (APC) Vs FL-2 (PE) and individual histogram plots of FL-4 and FL-2
versus the number of events (Supplementary Figure 1). Isogenic control was the nonantibody treated isolated effector T cells.
Isolated CD4+/CD25− effector T cells (1 × 106) were cultured in six-well plates
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overnight followed by experimentation as indicated.

All cells were maintained in

exponentially growing suspension culture at 37°C in a humidified, 5% CO2 atmosphere
in RPMI 1640 supplemented with 10% heat-inactivated calf serum, 100 units/ml
penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine.
HCT-116, human epithelial colon cancer cells line, proficient in p53, and isogenic
HCT-116 p53-/- cells, were maintained in exponentially growing adherent culture at
37°C in a humidified 5% CO2 atmosphere in RPMI 1640 supplemented with 10% heatinactivated calf serum, 100 units/mL penicillin, 100 µg/mL streptomycin, and 2 mmol/L
L-glutamine.
3.2.4

DSS MOUSE MODEL OF COLITIS

We followed our previous protocol for our DSS (MP Biomedicals, Solon, OH:
36,000-50,000 mw) mouse model of colitis (16). Briefly (Figure 3.2), 8-10 week old
C57BL/6 mice received either water ad	
   libitum or 1% DSS. All mice were on an
AIN93M diet as described previously (36). 11.9 mg/kg of HAG was dissolved in 100 µl
1x PBS per mouse and administered daily by oral gavage (per os, PO). 11.9 mg/kg daily,
which is the human equivalent dose of 58 mg daily (37). Of note, currently the use of
ginseng in human clinical trials can range anywhere from 200 mg to 9 g daily (38, 39).
The control group of mice was given 100 µl of 1x PBS by oral gavage. All procedures
performed were in accordance with the Guide for care and Use of laboratory animals
(National Research Council, Washington, DC, USA) and approved by the Animal
Resource Facility, University of South Carolina, Institutional Animal Care and Use
Committee. To determine whether the HAG can prevent the onset of colitis, mice were
fed 1% DSS for 2.5 cycles (7 days DSS, 7 days water making 1 cycle). The vehicle or the
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HAG was administered daily by oral gavage 7 days prior to the first DSS exposure and
continued throughout the course of the experiment. Mice were euthanized at 2.5 cycles
(Figure 1). For pathology, colon tissue samples were washed with phosphate-buffered
saline (PBS; Mediatech, Herndon, VA, USA), cut longitudinally, swiss-rolled, then
formalin fixed overnight, and paraffin embedded.
3.2.5

QUANTIFICATION OF INFLAMMATION TO EXAMINE EFFECTS ON COLITIS

Paraffin embedded tissues were serially sectioned, and one section from each mouse
was stained with H&E.

Sections were microscopically examined by two blinded

investigators (D.P and X.C) for histopathologic changes using a scoring system
previously validated, described and reported (4, 28, 40, 41). Histology score was
determined by multiplying the percent involvement for each of the three following
histologic features by the percent area of involvement (4): inflammation severity (0,
none; 1, minimal; 2, moderate; 3, severe), inflammation extent (0, none; 1, mucosa; 2,
mucosa and submucosa; 3, transmural), and extent of crypt damage (0, none; 1, one third
of crypt damaged; 2, two thirds of crypt damaged; 3, crypts lost, surface epithelium
intact; 4, crypts lost, surface epithelium lost). Percent area involvement was defined as:
0, 0%; 1, 1-25%; 2, 26-50%; 3, 51-75%; 4, 76-100%. Therefore, the minimal score is 0
and the maximal score is 40. Since, DSS induced colitis in mice leads to the damage in
colonic epithelial barrier and is characterized by extent and depth of inflammation thus a
grading or scoring system of inflammation with all these parameters provide an excellent
measure of histologic assessment of DSS induced colitis.
3.2.6

WESTERN BLOT ANALYSIS AND ANTIBODIES

Western blots were carried out as described previously (42). Antibodies used include:
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p53 (Mouse monoclonal, DO-1, diluted 1 in 500, cat# OP43T; Calbiochem, Gibbstown,
NJ, USA) and GAPDH (Rabbit monoclonal, diluted 1 in 1000, cat# 5174 P; Cell
Signaling Technology, Danvers, MA, USA). Horseradish peroxidase-conjugated antimouse and anti-rabbit secondary antibodies were purchased from Amersham Biosciences
(Piscataway, NJ, USA). Both secondary antibodies were diluted at 1:2000. All antibodies
were diluted in 5% milk/PBST (0.1% Tween 20 in 1× PBS). Western blot signal was
detected by Pierce ECL Western Blotting Substrate (Thermo Scientific, Rockford, IL,
USA) and developed onto Hyperfilm (GE Healthcare Life Sciences, Pittsburgh, PA,
USA). Briefly, after treating blot with the chemiluminescent substrate (Pierce ECL) for a
minute, the blot was exposed to the hyperfilm in the dark (Exposure time was optimized
based on the band signal obtained) and the film was developed in an automatic x-ray film
processor (Futura Classic E automatic x-ray film processor, Fisher Industry, Geneva, IL,
USA).
3.2.7

ANNEXIN V ASSAY

CD4+/CD25- effector T cells were seeded at 1 × 106 per well into six-well dishes for
24 h in triplicates (n=3). Fresh medium or fresh medium containing freshly dissolved
indicated concentrations of HAG (0 - 300 µg/mL) was added for 24 h, as indicated. Cells
were then harvested for Annexin V according to instructions provided by the kit
manufacturer (BD Biosciences, San Diego, CA, USA). Annexin V/propidium iodide (PI)
staining was examined using a Beckman Coulter Cytomics FC500 flow cytometer.
3.2.8

CELL CYCLE ANALYSIS

1 × 106 cells/wells of HCT-116 WT and HCT-116 p53-/- cells were incubated in
1.0% NBCS supplemented RPMI-1640 media for 24 hrs in 6 well culture plate. The
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media was changed and the cells were treated with Hexane fraction of AG (0-500 µg/ml).
The cells were harvested after 24 hrs of treatment and cell cycle assay was performed by
labeling the dsDNA of the cells with DAPI (4',6-Diamidino-2-phenylindole) (SigmaAldrich, MO, USA). Briefly, the harvested cells were fixed by gently vortexing and
adding 70% ethanol dropwise. The fixed cells were incubated at 4°C for at least 30
minutes. The cells were washed with PBS/1%BSA and stained with 1µg/ml of DAPI (in
PBS/ 0.1% Triton X-100) for 10 min. at room temperature. 20,000 cells/events were
directly analyzed by BD-LSR-II flow-cytometer (BD Biosciences, San Jose, CA, USA).
Based on the DNA content, the different phases of the cell cycle was determined by using
BD FACSDiva software (BD Biosciences, San Jose, CA, USA). Experiments were
repeated three times.
3.2.9

FLOW-CYTOMETRIC TUNEL ASSAY

TK6 (p53 WT), NH32 (isogenic p53-/-) and Jurkat T (dysfunctional p53) cells were
incubated in 0.1%NBCS supplemented RPMI-1640 media for 24hrs. The media was
changed and the cells were treated with Hexane fraction of AG (0-500 µg/ml) as
indicated in Figure 2. Cells were harvested after 24 hours of treatment and TUNEL assay
was performed as described by vendor (Roche Diagnostics, IN, USA) in triplicates (n=3).
Briefly, 1 × 106 cells were fixed using a 100µl of fixation solution (2%
paraformaldehyde) and permeabilized using a permeabilization solution (0.1% Triton X100 in 0.1% sodium citrate). Cells were washed and incubated with TUNEL reaction
mixture (Label Solution and Enzyme Solution) (Roche Diagnostics, IN, USA). Apoptosis
in the samples were analyzed by flow-cytometry (Beckman Coulter, CA, USA). The
fluorescence was evaluated using the excitation wavelength of 488nm and detected in the
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range of 515 -565 nm (green, FL-1 channel). The dot plot of FS Vs FL-1 and histogram
plot of (Number of Event) Vs (FL-1 Channel) were plotted to obtain a percentage
increase in the apoptosis of the Hexane fraction of AG treated cells. Positive control for
apoptosis is the fixed and permeabilized cells treated with DNase I recombinant (3U/ml
in 50mM Tris-HCL, pH7.5, 1mg/ml BSA) (Invitrogen, CA, USA) to induce DNA strand
breaks prior to labeling (following the vendors protocol). Negative control for apoptosis
is the non-treated, healthy cells. Isogenic Enzyme control is the fixed and permeabilized
cells with the labeling solution but without the terminal transferase enzyme.
3.2.10 STATISTICAL ANALYSIS
Statistical analysis was done using one-way ANOVA with Scheffe's post hoc test for
comparison of endpoint data between mouse groups. The results were analyzed using the
Stat- View II statistical program (Abacus Concepts, Inc., Piscataway, NJ, USA) and
Microsoft Excel (Microsoft, Bellevue, WA, USA) for Macintosh computers. The P value
chosen for significance in this study was 0.05.
3.3

RESULTS
In UC, intestinal immune responses are often characterized by activation of lamina

propria T lymphocytes (LPL) with potent effector functions (43). Among its regulatory
mechanisms, down-regulation of activated T lymphocytes via apoptosis is a very potent
and effective strategy, now considered as a key controlling mechanism of UC (5). To this
end, lymphoblastoid cell lines TK6 (WT p53), NH32 (isogenic to TK6, but p53-/-) and
Jurkat T cells (which have a dysfunctional p53 pathway) were tested for the apoptosis
inducing property of HAG.

Previously, we showed the whole AG extract induces

apoptosis of TK6, but not NH32 cells (4). Interestingly, here, we show HAG was able to
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induce apoptosis (TUNEL+) not only in TK6 cells but (albeit to a lesser extent) also in
NH32 cells (Figure 3.3). HAG induced a 3.9-fold increase in apoptosis of TK6 cells at
500 µg/ml of HAG when compared to the untreated cells. The isogenic p53-/- NH32 cells
underwent apoptosis up to 3-fold at 500 µg/ml of HAG when compared to the non-treated
cells (Figure 3.3). Of note, at 100 µg/ml, the HAG induced 2.6-fold apoptosis in the TK6
cells, but little apoptosis (2-fold) in the NH32 cells. Interestingly, the Jurkat T cell line
(with a defective p53 pathway) was somewhat resistant to HAG-induced apoptosis
(Figure 2C), which is consistent with what we have previously observed with the whole
AG extract (4).

Figure 3.3 provides confirmation of the p53 status of each of the cell

lines used in these experiments.
Overly aggressive CD4+/CD25- T cells are thought to contribute to colitis, and
defects in mucosal T-cell apoptosis are likely to be critical in the pathogenesis of colitis
(4, 6, 7). Recently we have shown HAG induces apoptosis of CD4+/CD25- T cells
derived from C57/BL6 WT mice during the suppression of colitis (28). In the present
manuscript, consistent with results from TK6 (p53+/+) and NH32 (p53-/-) cells, HAG
induced apoptosis of the CD4+/CD25- T cells isolated from both WT and p53-/C57/BL6 mice (Table 3.1). However, the induction of apoptosis was suppressed in the
absence of p53. There was 2.6-fold increase [From (5.1 ± 0.9%) to (13.2 ± 2.8%)] in
apoptosis (Mean ± S.E.) of effector T cells isolated from p53-/- C57/BL6 mice and a 4.6fold increase [From (4.5 ± 0.5%) to (20.7 ± 8.9%)] in the apoptosis was observed in
CD4+/CD25- T cells isolated from WT C57/BL6 mice upon treatment with increasing
concentration of HAG (0-300 µg/ml).
We have recently shown that HAG suppresses chemically (DSS-mouse model)
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induced colitis in the WT p53 C57/BL6 mice (28). Previously we have also shown that
AG whole extract suppresses chemically induced colitis only in the WT p53 C57/BL6
mice and not in the p53-/- C57/BL6 mice (4). This led us to the conclusion that the
suppression of colitis by AG extract is p53 dependent. We tested the same hypothesis for
the HAG. As shown in the Figure 3.4, the HAG was able to suppress the DSS-induced
colitis in both the p53-/- and WT p53 mice. However, consistent with our results on
apoptosis of inflammatory cells in vitro, the suppression was more prominent in WT mice
than in p53-/- mice. The H&E stained swiss rolled colon inflammation score of WT
C57/BL6 mice was reduced from 15 ± 0.86 to 4.4 ± 0.32 [Average ± S.E.] (a reduction of
71%) in the HAG treated mice (Figure 3.4). Similar results were obtained with the p53-/C57/BL6 mice, where the score dropped from 14.5 ± 2.12 to 7.8 ± 1.78 (a reduction of
46%) in the HAG treated mice. This result is consistent with the notion that the HAG
seems to act not only through a p53 pathway but also through a p53 independent pathway
while suppressing colitis.
Recently we have shown that HAG reduces colon cancer associated with colitis in
mice (28). The mitogenic stimuli triggered signal transduction pathways eventually
converge on the cell cycle checkpoint that controls the G0/G1 to S phase transition and
activate appropriate cyclin-dependent kinases (19). This anomaly increases proliferation
of the mutated cells to increase the cancer growth and progression. Thus, one way to
cause cancer to subside is to prevent this abnormal cancer cell growth by inducing cell
cycle arrest. We tested this hypothesis in vitro by using two different cell lines, HCT-116
p53 WT and HCT-116 p53-/- and treated these cells with increasing concentration of
HAG for 24hr. HAG was able to increase a G0/G1 cell cycle arrest in both the WT and
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p53-/- HCT-116 cells (Figure 3.5). HAG increased the G0/G1 cell cycle arrest of HCT116 p53 WT cells 1.7-fold (34% to 56.7%) at 100 µg/ml HAG treatment and the
percentage of cells in G0/G1 remained above 50% with the other concentrations (up to
500 µg/ml) (Figure 3.5). Similarly there was a 1.5-fold increase (34.1% to 51.2%) of
HCT-116 p53-/- cells in G0/G1 phase after treatment with 100 µg/ml of HAG (Figure
3.5). However, there were a slightly lower percentage of cells at this checkpoint with the
remaining concentrations. Figure 3.5 provides confirmation of the p53 status of HCT116 cells used in this experiment.
3.4

DISCUSSION
Our HAG is extracted from AG whole extract by non-polar solvent n-Hexane. Mostly

polyacetylenes (panaxynol, panaxydol and panaxydiol) and fatty acids present in the AG
whole extract were extracted in this fraction (28). Since HAG is more effective at
suppressing colitis than the whole AG extract (28) and based on our previous study,
where AG whole extract suppressed colitis through p53 mediated apoptosis of
inflammatory cells (4), we hypothesized that HAG also induces apoptosis of
inflammatory cells through a p53-mediated mechanism. We pursued our study with HAG
and its apoptotic properties with different inflammatory cells. Interestingly, we found out
that unlike the whole AG extract, HAG was able to induce modest apoptosis of p53-/CD4+/CD25- effector T cells and p53-/- lymphoblastoid cells in addition to their p53 WT
counter parts cells (Figure 3.3, Table 3.1). This indicates that HAG mechanistically acts
differently than the AG whole extract, where it shows a modest involvement of p53dependent apoptosis. This still raises the question, what is the most active component
present in the HAG? Recently we have identified the different components present in the
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HAG, Fatty Acids (FAs) comprising 43% w/w, polyacetylenes 26.52% w/w (7.39%
Panaxydiol, 8.92% Panaxydol, and 10.21% Panaxynol) and less than 0.1% w/w
ginsenosides (28). This indicates that specific FA ingredients or specific polyacetylenes
or both are responsible for the apoptotic property of HAG through both p53-dependent
and p53-independent mechanisms.
Interestingly, Wong et al. have shown that Asian ginseng extracted with ethanol
induces a G2-M arrest and apoptosis via modulation of MAPK and p53 pathway in LLC1 cells (Mouse Lewis lung carcinoma cells) (44). The AG whole extract is also extracted
with ethanol and the ginsenoside composition is for the most part, similar in Asian and
American ginseng. Separate studies from Kim et al. (45, 46) have shown that the
ginsenosides-Rs3 and -Rs4 selectively elevate protein levels of p53 and p21WAF1 and
down-regulate the activities of the cyclin-dependent kinases, resulting in cell cycle arrest
at the G1/S boundary and induces apoptosis of SK-HEP-1 cells (immortalized human
hepatoma cells) (45, 46). All these observations suggest that ginsenosides may be a key
player in modulating apoptosis and cell cycle through the p53 pathway and is consistent
with findings here, and our previous findings that our whole AG extract has 10.1%
ginsenoside (w/w) compared to the HAG which has 0.074% ginsenoside (w/w) content
(28).
Interestingly, ginsenoside Rd, which is present in AG whole extract (extracted with
aqueous ethanol) and absent in the HAG, has been shown to attenuate the inflammatory
response to TNBS (2,4,6-Trinotrobenzenesulfonic acid) induced relapsing colitis by
down-regulating multiple pro-inflammatory cytokines levels through modulation of JNK
(c-Jun N-terminal kinase) and p38 activation (47). Similarly another ginsenoside not
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present in HAG, Rb1 and its metabolite compound K after oral administration blocked
the TNBS-induced expressions of iNOS (inducible-Nitric oxide synthase), COX-2
(Cyclooxygenase-2) and the activation of NF-κβ (Nuclear transcription factor κβ) in mice
(48). Ginsenoside Rb1 and its metabolite compound inhibited the activation of key
inflammatory mediators IRAK-1 (Interleukin-1 receptor associated kinase-1), IKK-β
(Inhibitor of NF-κβ kinase), NF-κβ and MAPK (Mitogen-activated protein kinases) while
suppressing colitis (48). These studies suggest that different ginsenosides may help
attenuate inflammation, and our finding that n-Hexane doesn’t extract these ginsenosides
should not rule out that ginsenosides aren’t the active components of ginseng. Taken
together, these observations suggest that multiple components of AG, including
ginsenosides, FAs and polyacetylenes, are responsible for the activity of AG in the
suppression of colitis in animals. Further studies are necessary to delineate the most
active ingredient(s)/molecule(s).
Moon et al. have shown that during the G1/S cell cycle arrest, protein levels of
p21WAF1, p16INK4a, p53, pRb (retinoblastoma protein), and E2F-1 (Transcription
factor E2F1) were not changed after exposure to the polyacetylene, Panaxydol (isolated
from P. ginseng), in the human malignant melanoma cell line, SK-MEL-1 (49). Human
promyelocytic leukemia cells, HL60 cells, do not express the p53 protein due to a large
deletion in the gene (50). The polyacetylenes, panaxynol and panaxydol (isolated from
the lipophilic fractions of Panax notoginseng) have been shown to inhibit the
proliferation of HL60 cells in a time- and dose-dependent manner via an apoptotic
pathway (51). These studies indicate that polyacetylenes may act independently of p53
while inducing apoptosis of certain cell lines. HAG induced apoptosis indicated by
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cleaved PARP in TK6 cells, appears to change the protein levels of WT p53 and activated
form of p53 (phospho-Ser15) very little (28). After 24hr of HAG treatment (300 µg/ml),
we observed 2.6-fold increase in apoptosis of p53-/- CD4+/CD25- T cells and 4.6-fold
increase in apoptosis of p53+/+ CD4+/CD25- T cells when compared to their untreated
counterparts cells (Table 3.1). Figures 3.3, and our recent study (28) are consistent, and
indicate that p53 has a limited role in inducing HAG-mediated apoptosis of inflammatory
cells both in vitro and ex vivo. A clearly increased p53, phospho-p53 Ser-15 and cleaved
PARP protein levels along with the increased apoptosis was reported with the AG whole
extract; suggesting p53 plays a key role in apoptosis of inflammatory cells induced by the
whole AG extract (4). However, an increased cleaved-PARP protein expression and only
a slight change in the p53, phospho-p53 (Ser-15) and p53-Upregulated Mediator of
Apoptosis (PUMA) protein expression of TK6 cells after treatment with HAG (28) are
consistent with our current results: that HAG induces apoptosis but this induction of
apoptosis is likely mediated through both p53-dependent and p53-independent
mechanisms.
The other high volume component present in HAG is fatty acids, where 19% w/w is
linoleic acid, a polyunsaturated fatty acid (28). Kwon et al. have reported that linoleic
acid treatment resulted in a concentration-dependent growth inhibition of AGS cells
(human gastric adenocarcinoma cells) by inducing apoptosis in a p53-independent
manner with an elevated Fas and Fas ligand expression (52). This, then, is consistent with
our results regarding a limited role for p53 in the cells undergoing apoptosis after
treatment with HAG.
We further tested our compound in the in vivo animal study. As indicated (Figure
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3.2), both the p53-/- and p53 WT C57/BL6 mice were subjected to 2.5 cycles of 1% DSS
to induce colitis. In this preventive DSS model, 75ppm (11.9 mg/kg) of HAG or vehicle
(1x PBS) were administered to the mice daily (PO) and continued throughout the course
of the experiment. In our similar experiment AG whole extract was effective in
suppressing colitis only in the p53 WT C57/BL6 mice where whole AG extract prevented
colon epithelial cells from the DNA damage due to DSS and induced apoptosis of
lymphocytes in vivo (4). In this study, with the same protocol, the HAG was able to
suppress DSS-induced colonic inflammation to approximately one third (from 15 ± 0.86
to 4.4 ± 0.32). Interestingly, the HAG also showed modest suppression of inflammation
to about one-half (from 14.5±2.12 to 7.8±1.78) in the p53-/- C57/BL6 mice (Figure 3.4).
This provides evidence that the HAG is anti-inflammatory and p53 plays a limited role in
the HAG-mediated suppression of colitis.
Apoptosis is an ordered cellular process that occurs in various physiological and
pathological conditions. Two major problems are associated with apoptosis; too much
apoptosis is associated with various degenerative diseases and too little to no apoptosis is
associated with carcinogenesis (53). Hence one way to tackle the cancerous cells is to
induce apoptosis of such cells. Colon cancer is associated with long standing UC and
hence inflammation seems to drive the progression of cancer. Interestingly, both HCT116 p53+/+ and p53-/- colon cancer cells were quite resistant to apoptosis induced by
HAG (data not shown). However, there was a G1 cell cycle checkpoint with HAG
treatment (Figure 3.5). It is unlikely that the HAG causes DNA damage to cause this
checkpoint. It is more likely that one or more ingredients in HAG target modulators of
the cell cycle (e.g. cyclins or cyclin-dependent kinases). Experiments are ongoing to
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examine this possibility. Consistent with our findings, Kang et al. have shown that lipid
soluble ginseng extract (red Ginseng extracted with n-Hexane) induces a cell cycle arrest
at the G1 phase in NCI-H460 cells (Human lung cancer cells) (54). These separate
observations suggest that the HAG may halt the progression of cell cycle at G1 phase in
multiple cancer cell lines.
3.5

CONCLUSION
We have shown here that the HAG can induce apoptosis in lymphoblastoid cells,

CD4+/CD25- effector T cells and cause a G1 checkpoint in colon cancer cell lines. It also
suppressed chemically induced colitis in C57/BL6 mice. In all the above observations,
we simultaneously tested the pro-apoptotic and anti-inflammatory properties of HAG
with the WT p53 and its p53-/- counterpart cells and mice. It is evident that HAG can
perform its pro-apoptotic, anti-inflammatory, and cell cycle arrest activities even in the
absence of p53. However, the HAG has a more robust effect in the presence of p53.
These observations suggest that there is a role of p53 in the HAG mediated apoptosis of
inflammatory cells and suppression of colitis; but this role is limited. This entails that the
HAG affects other pathways independent of p53 in the suppression of colitis. The
reasoning for this can only be speculated. For example, is there one component in the
whole AG extract that is particularly powerful in inducing p53-mediated apoptosis that is
missing from the HAG? Does this component inhibit the ability of components only seen
in the HAG fraction to drive p53-independent apoptosis; and suppress p53-independent
colitis?

This is significant because the HAG suppresses colitis and associated colon

cancer (28). Because mutation in p53 is observed in most cancers, including colitisdriven colon cancer, the HAG may be particularly effective in targeting both p53+/+ and
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p53-/- inflammatory cells and cancer cells and hence particularly effective in inhibiting
the colitis-to-cancer sequence.
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Table 3.1 Apoptosis (Annexin V positive; propidium iodide negative) of CD4+/CD25effector T cells from the spleen of p53-/- mice and p53+/+ mice by the increasing
concentration of Hexane fraction of AG for 24 hrs.

Dose: Hexane fraction of
AG (24 hr)
0 µg/ml
100 µg/ml
200 µg/ml
300 µg/ml

Percentage of early apoptotic cells
C57/BL6 p53-/- Mice
C57/BL6 p53+/+ Mice
4.1%
4.9%
5.9%
9.8%
9.1%
15.7%
18.6%
38.5%

Table 3.2 Inflammation Score based on the inflammation severity, Extent, Crypt damage
and Percent involvement. (IRS score range: 0-40)
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Figures

Figure 3.1 Representative figure for the purity of CD4+/CD25− T cells isolated from the
spleen of the mice.

Figure 3.2 Experimental protocol for the DSS, prevention mouse model of colitis. 11.9
mg/kg/day of HAG or vehicle (1X PBS) was given to the respective group of mice by
oral gavage 7 days prior to the first DSS cycle and continued daily until the end of the
experiment (2.5 cycles). The mice (both C57/BL6 p53-/- and C57/BL6 p53+/+) were
euthanized on day 35.
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Figure 3.3 The Hexane fraction of AG (HAG) drives apoptosis (TUNEL+) of
lymphoblasts marginally better in p53+/+ cells compared with p53-/- cells. The TK6
human lymphoblastoid line, NH32 isogenic p53 knockout cells and Jurkat T cells
(dysfunctional p53 pathway) were cultured in RPMI-1640 + 10% NBCS. Cells were
exposed to HAG in RPMI-1640 + 0.1% NBCS for 24 hr at indicated doses and harvested
for TUNEL apoptotic assay. A. Represents Percentage of TK6 cells staining positive for
TUNEL, indicating apoptosis. B. Represents percentage of NH32 cells staining positive
for TUNEL. C. Represents percentage of Jurkat T cells staining positive for TUNEL. A
minimum of 20,000 events was counted by flowcytometry from each treatment. D.
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Confirmation of p53 protein status of the TK6, NH32 and Jurkat T cells. Cell lysates
were analyzed by western blot analysis. C+, indicates the positive control for p53, which
is an archived HCT-116 cell lysate with wild type p53. C-, indicates the negative control
for p53, which is an archived HCT-116 p53-/- cell lysate with p53 knockout. Results
indicate HAG induces apoptosis in lymphoblasts through a limited p53 activity.
Significant differences are indicated, where *P-value <0.05 and ** P-value <0.005, when
compared to the control (0 µg/mL) treatment.

Figure 3.4 Effect of the HAG on the colon histology score of the acute DSS colitis model.
Histological Inflammation score was determined from the H&E stained colon of each
group of mice treated with HAG after 2.5 cycles of DSS. Values represent mean ± S.E.
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Representative H&E stained colon (100X magnified) are shown for each group. Arrows
point to areas of inflammation and ulceration. Significant differences are indicated.

Figure 3.5 The HAG induces a G0/G1 checkpoint in colon cancer cells in both p53+/+
and p53-/- colon cancer cells. A. HCT-116 WT and p53-/- cells were exposed to HAG in
RPMI-1640 + 1% NBCS for 24 hr at indicated doses and harvested for cell cycle assay
with DAPI-stain. Representative percentage of cells in G0/G1, S and G2/M- phases are
indicated for each treatment. A minimum of 20,000 events was counted by
flowcytometry from each treatment. B. Confirmation of p53 protein status of the HCT116 cells. Cell lysates were analyzed by western blot analysis. C+, indicates the positive
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control for p53, which is an archived HCT-116 cell lysate with wild type p53. C-,
indicates the negative control for p53, which is an archived HCT-116 p53-/- cell lysate
with p53 knockout.
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CHAPTER 4
A HEXANE EXTRACT OF AMERICAN GINSENG SUPPRESSES COLON CANCER
CELL MIGRATION AND INVASION THROUGH THE INDUCTION OF MICRORNA29B.
ABSTRACT: Metastasis of colon cancer cells increases the risk of colon cancer mortality.
We have recently shown that American ginseng prevents colon cancer, and a Hexane
extract of American Ginseng (HAG) has particularly potent anti-inflammatory and anticancer properties. Dysregulated microRNA (miR) expression has been observed in
several disease conditions including colon cancer. Using global miR expression profiling,
we observed increased miR-29b in colon cancer cells following exposure to HAG. Since
miR-29b plays a role in regulating the migration of cancer cells, we hypothesized that
HAG induces miR-29b expression to target matrix metalloproteinase-2 (MMP-2) thereby
suppressing the migration and invasion of colon cancer cells. Results are consistent with
this hypothesis. Our study supports the understanding that targeting MMP-2 by miR-29b
is a mechanism by which HAG suppresses the migration and invasion of colon cancer
cells.
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4.1

INTRODUCTION
Colorectal Cancer (CRC) is the third most commonly diagnosed cancer in both

men and women and the third leading cause of cancer death. In the USA, the American
Cancer Society estimated 141,210 new cases of colorectal cancer and 49,380 deaths in
2011. Metastasis leads to 90% of cancer-related mortalities (1). In principle, during
metastasis of CRC, some cancer cells from the primary tumor mass invade surrounding
tissue, intravasate into the vasculature to travel through blood and lymphatic vessels,
arrest in distant capillaries, extravasate into parenchyma of distant tissue (primarily liver
and lungs) where they seed new colonies to form the macroscopic secondary tumors (2).
These metastatic cancer cells lose their ability to adhere to neighboring tumor cells and
develop migratory and invasive properties to disseminate to distant metastatic organs.
While doing so, the metastatic cells undergo changes in gene expression and function,
thereby gaining more mesenchymal- like features and this process is termed as Epithelial
to Mesenchymal Transition (EMT), a crucial event in malignancy. MicroRNAs (MiRs)
are small non-coding RNAs of approximately 22 nucleotides (nts) long that posttranscriptionally regulates the gene expression in plants and animals. In animals, miRs
target transcripts through imperfect base pairing of 2-7 nts of 5’-end of miR (so-called
‘seed’ sequence) to multiple sites in 3’-untranslated regions (UTRs) of target mRNA, and
this imperfect miR-mRNA hybrids with central bulges (nt 9-12) recruits miRNP
(microRNA Ribonucleoprotein complex) that enable translational inhibition or
exonucleolytic mRNA decay [Reviewed in (3)]. Many housekeeping genes have evolved
with shorter length of 3’-UTR to avoid miR regulation (4). About 50% of annotated
human miR genes are located in cancer associated genomic regions or fragile sites that
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are susceptible to amplification, deletion and translocation in variety of tumors including
colon tumors (5). Because of this some miRs could act either as tumor suppressor or
oncogenes (6-10). Expression profiling analysis has revealed characteristic miR
signatures that can predict the clinical outcomes of CRC (11, 12).
One of the classical hallmarks of cancer is the ability for tumor cells to invade and
metastasize (13). miRs are both positive and negative regulators of cancer metastasis (1416). One negative regulator of cancer metastasis is miR-29b [For example (17-21)]. miR29b belongs to the miR-29 family. The miR-29 family is comprised by three paralogs:
miR-29a, -29b and -29c. miR-29a and miR-29b1 are located on chromosome 7q32;miR29b2 and miR-29c are located on chromosome 1q23 (22). miR-29b1 and miR-29b2
sequences are identical but are distinguished b1 and b2 due to difference in locus. MMP2, an extracellular matrix (ECM) degrading enzyme that has a major implication in
metastasis and angiogenesis has been shown to be the direct target of miR-29b (19).
American ginseng (AG; Panax quinquefolius) is an obligate shade perennial
native of North America. From Bioassay guided fractionation of AG, we have recently
shown that a Hexane fraction of AG (HAG) is a potent anti-oxidant and anti-cancer agent
(23, 24). To date, only limited anti-cancer studies of lipophilic extracts of AG have been
carried out, and these studies are mostly focused on anti-proliferative and cytotoxic
effects (25-28). To further understand the anti-cancer mechanism of HAG (a lipophilic
extract), we studied the role of miR in cancer cell migration and invasion.
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4.2

MATERIAL AND METHODS

4.2.1

HEXANE FRACTION OF AG
The P. quinquefolius extract has been described previously in detail by our

laboratory (29). As well, we have recently described the generation of the HAG used in
the present study (23).
4.2.2

CELL CULTURES
HCT 116 wild-type (WT), LOVO and DLD-1 colon cancer cells were purchased

from American Type Culture Collection (ATCC; Manassas, VA). HCT 116 cells were
cultured in McCoy's medium (ATCC, Manassas, VA); LOVO cells were culture in F12K medium (ATCC, Manassas, VA); and DLD-1 cells were culture in RPMI-1640
medium. All media was supplemented with 10% Newborn Calf Serum (NBCS;
GIBCO/Life Technologies, Grand Island, NY), 2 mM glutamine (Biofluids, Rockville,
MD), penicillin (10 U/ml, Biofluids) and streptomycin (10 µg/ml, Biofluids).
4.2.3

GLOBAL MIR EXPRESSION
HCT 116 WT cells were seeded at 1×106 cells/plate in 6 well plates in triplicate.

After culture for 24 h, 260 µg/mL HAG was added into each well. Cells were harvested
at 0, 12, and 24 h separately in RNase free EP tubes. Total RNA was extracted using
TRIzol reagent (Ambion, Austin, TX). RNA concentration was determined by the
Nanodrop 2000 (NanoDrop, Wilmington, DE). 100 ng of RNA from HCT 116 WT cells
was used for the nCounter miRNA Expression Assay v1.2 (Nanostring Technologies,
Seattle, WA) containing 800 miRNA's following the manufacturer's instructions.
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4.2.4

MIR-29B EXPRESSION

Cells were seeded, exposed to vehicle (media only) or 260 µg/ml HAG, and
harvested at 24hr. For miR-29b detection, 10 ng of total RNA was used to reversetranscribe to cDNA using TaqMan miR Reverse Transcription kit (Applied Biosystems,
Foster City, CA) according to manufacturer's instructions and miR primers specific for
hsa-miR-29b for detection and the small nuclear protein RNU6B (U6) for normalization
(Applied Biosystems). qPCR measurement of miR-29b and U6 expression was
performed using TaqMan miR Assays (Applied Biosystems) with the 7300 PCR Assay
System (Applied Bioystems). The comparative threshold cycle (Ct) method was used to
evaluate the relative abundance of miR-29b compared with U6 expression (fold changes
relative to U6). All experimental treatments were carried out on three separate occasions;
each time with three replicates.
4.2.5

MIR TRANSFECTION

For MirVana-miR-29b inhibitor and mirVana-Negative control inhibitor
(Ambion, Austin, TX) transfection, 1.5 × 105 cells were grown in medium in 6 well
plates 1 day before transfection. Using INTERFERin siRNA Transfection Reagent
(Polyplus Transfections, Illkirch, France), the cells were transfected with 10 nmol/L of
MirVana-miR-29b inhibitor or MirVana-Negative control inhibitor. After 48 h of
transfection, the cells were harvested in RNase free EP tubes. Total RNA was extracted
using TRIzol regent. RNA concentration was determined by Nanodrop 2000. 10 ng of
total RNA was reverse-transcribed to cDNA using TaqMan MicroRNA Reverse
Transcription kit with microRNA primers specific for hsa-miR-29b and the small nuclear
protein RNU6B (U6) for normalization. qPCR measurement of miRNA-29b and U6
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expression was performed using TaqMan MicroRNA Assays with the 7300 PCR Assay
System. The relative fold change in miR-29b level was used to represent the relative
abundance of miRNA-16 compared with U6 expression. After 48 h of transfection with
MirVana-miR-29b Inhibitor, HAG (260 µg/mL) was added for 24 h and cells were
harvested for target gene (MMP-2) expression and for migration and invasion assay. All
experimental control samples were treated with an equal concentration of a non-targeting
inhibitor negative control sequence, for use as controls for non-sequence-specific effects
in miR experiments. Mock-transfected controls did not produce any significant effect on
any of the parameters analyzed.
4.2.6

MRNA ANALYSIS

Total RNA was extracted using Trizol reagent (Invitrogen, CA). One µg of total
RNA served as template for single strand cDNA synthesis in a reaction using oligo(dT)
primers and AMV reverse transcriptase (Promega Corp, WI) under conditions indicated
by the manufacturer. PCR of cDNA samples was performed with samples amplified for
30 cycles of denaturation at 94°C for 30 s, annealing at 50°C for 30 s, and extension at
72°C for 30 s with final extension at 72°C for 10 min. The sequences for Real Time PCR
primers used were: MMP-2 Forward 5′-ACA TCA AGG GCA TTC AGG AG-3’; MMP2 Reverse 5′-GCC TCG TAT ACC GCA TCA AT-3’ and GAPDH Forward 5′-GAG
TCA ACG GAT TTG GTC GT-3′, GAPDH Reverse 5′-TTG ATT TTG GAG GGA TCT
CG-3′ (Integrated DNA Technologies, Inc). Real-time PCR (qPCR) was performed using
the 7300 Real-Time PCR Assay System (Applied Biosystems, CA) with Power SYBR
green PCR master mix (Applied Biosystems, CA) and primers for MMP-2 and GAPDH
according to the vendor's protocol. The MMP-2 gene expression was normalized by
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GAPDH gene expression. The fold change in the gene expression is relative to the vector
treated [1x Phosphate Buffered Saline (PBS)] cells harvested at 24 h.
4.2.7

IN VITRO ASSAY FOR MIGRATION AND INVASION
The 24 well Costar transwell permeable support with 8-µm pore size

polycarbonate membrane (Corning Incorporated, NY), with 6.5 mm insert was used to
analyze the migration and invasion of tumor cells. For migration assay, the transwell
membrane was soaked with 15 µg/ml of Collagen Type I (BD Biosciences) for 30 min at
37°C in Serum free media. Collagen was removed by pipetting and collagen coated
membrane was place on a 24 well plate. Cells were serum starved for 12 h and 50,000
cells were resuspended in 200 µl of Serum Free Medium (SFM) and transferred on the
top chamber of the transwell. The bottom chamber was filled with 750 µl of SFM or
Complete growth medium (10% NCS supplemented, as a chemoattractant for cells) or
HAG (260 µg/ml in complete medium). The transwell plate was incubated at 37°C for 12
h. For cell invasion assay, the transwell membrane was coated with Matrigel Basement
Membrane Matrix overnight at 37°C in a serum free media. Cells were serum starved for
12 h and 1 X 105 cells/200 µl of SFM was placed on the top chamber of the transwell
membrane. The bottom chamber was filled with 750 µl of SFM or Complete growth
medium (10% NCS supplemented) or HAG (260 µg/ml in complete medium). The
transwell plate was incubated at 37°C for 12 h. After incubation, medium was removed
from the chamber, the transwell membrane was washed in 1X PBS and cells were fixed
by formaldehyde (3.7% in PBS) and permeabilized by 100% methanol and stained with
0.4% Crystal violet stain. The membrane was washed with 1X PBS and the non-migrated
and non-invasive cells on the top of the transwell membrane were scraped off with the
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sterile cotton swab. The transwell membrane was cut out from the transwell chamber and
fixed on microscopic slide with permount and viewed under the microscope (100x
magnification). 7 random sections were photographed from each slide and the migrated
and invasive cells on the bottom of the transwell membrane were automatically counted
by using Image J software (http://rsbweb.nih.gov/ij/).
4.2.8

STATISTICAL ANALYSIS
For global miR analysis, all data were imported into NSolver Analysis Software

v1.0 (Nanostring Technologies) and normalized to the geometric mean of the 100 miRs
with the highest expression values. Normalized data was imported into BRB-ArrayTools
v4.1.0 for analysis. Prior to analysis, data was filtered where any value less than 10 was
omitted and any miR missing in >50% of samples were excluded leaving 248 miR’s for
analysis. Class comparison test utilized Student's T-tests to compare miR’s of treated vs.
untreated cells. Trend tests used linear regression modeling on ordered categorical
variables of 0 h, 12 h and 24 h. The Benjamini-Hochberg procedure was used to calculate
false discovery rates. When more than two groups were compared, we determined
statistical differences using a one-way analysis of variance, followed by a Scheffe's
multiple comparison test. If two groups were compared, we used a Student's T-test. The P
value chosen for significance in this study was 0.05.
4.3

RESULTS

4.3.1

HAG INDUCES MIR-29B IN COLON CANCER CELLS
American Ginseng and HAG have both exerted preventive effect on the

chemically induced colon cancer model (23, 30). To initiate our study, since miRs have
been shown to have both pro-tumor and anti-tumor properties, we looked at the effect of
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HAG on global miR expression in colon cancer cells. There was a significant positive
correlation in 2 miRs, and significant negative correlation in 6 miRs after exposure of
HCT 116 cells to HAG (260 µg/ml) for 0 h, 12 h, and 24 h (Table 4.1.1). Based on the
understanding that miR-29 family has been down regulated in multiple malignancies (20,
22, 31, 32), that several studies have shown that up regulation of miR-29 to have antitumor effects (21, 33), and that increased expression of miR-29b was shown with two
different statistical methods (Table 4.1.1 and 4.1.2), we focused on this miR. To confirm
miR-29b up-regulation by HAG, we repeated the experiment and examined miR-29b
upregulation by qRT-PCR. Consistent with the global miRNA analysis results, Figure
4.1 shows that there was increased miR-29b expression (7.3-fold) with exposure of HCT
116 cells to HAG. There was also an increase in miR-29b expression with exposure of
two other colon cancer cell lines (DLD-1, 3.1-fold; and LOVO, 1.5-fold) (Figure 4.1).
4.3.2

HAG SUPPRESSES MMP-2 EXPRESSION IN COLON CANCER CELLS
Potential target genes of miR-29b were first predicted using online databases,

including TargetScan, PicTar, and miRanda. MMP-2 was predicted to be the potential
target of miR-29b by all these databases (Figure 4.2). Because MMP-2 is overexpressed
in tumor tissues (34-36), and has a direct implication in metastasis and angiogenesis of
cancer cells (37, 38), we first examined the effects of HAG on MMP-2 expression.
Treatment of HCT-116 cells with HAG for 24 h resulted in the reduction of MMP-2 gene
expression by approximately half HAG treatment [(1 ± 0.14 to 0.57 ± 0.05), pvalue=0.078] (Figure 4.2). HAG treatment for 24 h, significantly reduced the expression
of MMP-2 gene in DLD-1 cells [(1 ± 0.03 to 0.03 ± 0.01), p-value <0.005] (Figure 4.2).
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Similarly treatment of LOVO cells with HAG for 24h resulted in the reduction of MMP-2
expression [(1 ± 0.06 to 0.74 ± 0.017), p-value <0.05] (Figure 4.2).
To verify if the HAG mediated suppression of MMP-2 gene is dependent on miR29b, we silenced miR-29b (Figure 4.3) using a miR-29b inhibitor (see methods 4.2.5).
HAG does not suppress MMP-2 gene expression when miR-29b is silenced (Figure 4.2).
In fact, there is a 2.4 fold increase in expression of MMP-2 in miR-29b silenced HCT116
cells when exposed to HAG, 24h (Figure 4.2). Similarly, there was no change in MMP-2
gene expression in miR-29b silenced DLD-1 cells when exposed to HAG, 24h (Figure
4.2). In mir-29b silenced LOVO cells, HAG was unable to suppress the MMP-2 gene
expression (Figure 4.2). All together, these results are consistent with the hypothesis that
the suppression of MMP-2 by HAG is dependent on miR-29.
4.3.3

HAG SUPPRESSES MIGRATION OF COLON CANCER CELLS
MiR-29b targets key players to repress invasion and metastasis (18-21). Since

HAG up-regulates miR-29b expression and down-regulates the ECM degrading enzyme
MMP-2 gene expression, we further investigated the functional effect of HAG on cancer
cell migration and invasion. In HCT116 cells, HAG suppressed the migration of cancer
cells by almost 7-fold (Figure 4.4). In the miR-29b silenced HCT-116 cells, HAG didn’t
suppress migration. Consistent with MMP-2 results (Figure 4.2), in the absence of miR29b activity, HAG elevated the number of cells migrating to the lower chamber of
transwell membrane by almost 2.5 fold when compared to positive control (Figure 4.4).
Similarly, HAG suppressed the migration of DLD-1 cells only in the presence of miR29b, where it reduced the number of migrating cells by almost 5 fold compared to the
positive control (Figure 4.5). HAG did not exert anti-migratory activity when miR-29b
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was silenced in DLD-1 cells (Figure 4.5). Overall, results here show miR-29b is at the
crossroads in the ability of HAG to exert anti-migratory activities.
4.3.4

HAG SUPPRESSES INVASION OF COLON CANCER CELLS
The effect of HAG on the number of cells invading a matrigel matrix that mimics

the basement membrane was also examined. HAG reduced the number of HCT116 cells
invading the matrigel matrix by almost 4 fold (Figure 4.6). In the miR-29b silenced
HCT116 cells, although not as striking as the anti-migratory results, the ability of HAG to
reduce invasion was mitigated. Figure 4.6 show HAG suppressed invasion by only half of
that when miR-29b was present in colon cancer cells.
4.4

DISCUSSION
Here we have demonstrated that HAG suppresses migration and invasion of colon

cancer cell. This anti-metastatic property of HAG is mediated by the up-regulation of
microRNA-29b, which directly targets and down-regulates a key player in metastasis,
MMP-2.
Global miR analysis of HAG - treated HCT116 cells resulted in the elevated
expression of miR-29b that matched both the trend and fold-change statistical analysis
(Tables 4.1.1 and 4.1.2). There were 8 miRNAs (hsa-miR-938, hsa-miR-203, hsa-miR1975, hsa-miR-29b, hsa-miR-600, hsa-miR-1244, hsa-miR-548o and hsa-miR-590-5p)
that were statistically (p < 0.05) up or down-regulated. A positive correlation coefficient
indicates increased levels of miR with increased exposure to HAG (0 h to 12 h to 24 h)
with only 2 miRs (hsa-miR-29b and hsa-miR-590-5p) falling in this category. Of these 2
miRs, miR-29b had the highest correlation coefficient value of 0.621. As well, since
miR-29b was also statistically significantly up-regulated by HAG in the fold change
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analysis (Table 4.1.2), and that this miR has been shown by others to play a tumor
suppressor role (22, 31, 39-41), we focused on miR-29b for this particular study. The role
of miR-29b as a tumor suppressor has been well elucidated in several malignancies
including, AML (22, 39), lung (31), CLL (40, 41) and cholangiocarcinoma (42). Downregulation of the miR-29 family has been reported in several human cancers including
lung (43), prostate (44), invasive breast cancer (45). Recently, Kuo et’al have reported a
lower expression level of miR-29a/c in a colorectal cancer early recurrence group
compared with that of a non-early recurrence group indicating miR-29a/c as a potential
biomarker for early recurrence of CRC (46). Our results have better elucidated the
possible mechanisms of this finding.
The miR-29 family consists of three members: miR-29a, miR-29b, and miR-29c
(miR29a/b/c) that display high sequence similarity and share a common seed sequence
for target recognition (Figure 4.2). Others have reported an inverse relationship regarding
the expression of miR-29b and MMP-2 (19, 21, 47, 48). As well, because miR databases
(TargetScan, PicTar, and miRanda) indicate MMP-2 as a direct target of miR-29b, we
examined the functional significance of this. MMP-2, also known as gelatinase A or type
IV collagenase, is an ECM degrading enzyme, and is widely expressed in most tissues
and cells (49). As well, MMP-2 is overexpressed in tumor tissues (34-36) and activation
of MMP-2 results in ECM degradation, which facilitates the invasion and metastasis of
tumor cells (50).

Our real-time RT-PCR data showed that HAG reduces the MMP-2

expression by half fold in HCT116 cells and to about 30-fold reduction in DLD-1 cells
(Figure 4.2). When miR-29b activity is silenced by transfecting colon cancer cells with
miRVana miR-29b Inhibitor (Figure 4.3), HAG has no effect on reduction of MMP-2
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expression (Figure 4.2). Interestingly there was a 2.4-fold and 1.8-fold increase in MMP2 gene expression in miR-29b silenced HCT116 and LOVO cells, respectively after HAG
treatment. Due to the loss of miR-29b, HAG might have triggered MMP-2 expression to
go up. In the absence of functional miR-29b, HAG might exert a negative effect in colon
cancer cells. At this point, the reason can only be speculated and further investigation is
required to come to a proper conclusion about this opposite activity of HAG in the miR29b silenced colon cancer cells. This suggests that miR-29b is critical for HAG to
suppress the MMP-2 expression in cancer cells.
Matrix metalloproteinases have been regarded as key molecules assisting tumor
cells during metastasis (51-54). The MMPs are a family of zinc-containing
endopeptidases best known for their roles in physiological and pathological remodeling
of the ECM during angiogenesis, wound healing, embryogenesis, tumor metastasis, and
various cardiovascular and inflammatory diseases (55, 56). It has been shown that miR29b is involved in the negative regulation of metastasis in several cancer types (17, 19,
57). Combining these findings, where miR-29b is negative regulator of metastasis and
targets key player of metastasis MMP-2, and HAG induces miR-29b and suppresses
MMP-2 expression (Tables 4.1.1 and 4.1.2, Figures 4.1 and 4.2), we asked the question if
HAG functionally suppresses metastasis of colon cancer cells. We demonstrated that
HAG functionally suppresses metastasis of colon cancer cells by performing migration
and invasion assay of colon cancer cells (Figures 4.4, 4.5 and 4.6). In the absence of miR29b activity, HAG was not efficient in suppressing the migration and invasion of colon
cancer cells. Although, yet to be shown in vivo, all together, our in vitro data indicate that
HAG performs its anti-metastatic activity by regulating miR-29b.
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Major components present in the Hexane extract (lipophilic extract) of AG are
polyacetylenes (Panaxydiol, panaxydol and panxynol), which comprises about 50% of
the total extract, as well as fatty acids, with almost no ginsenosides (23). We have
recently shown HAG possesses anti-inflammatory and anti-cancer properties (23).
Several other studies on anti-inflammatory and anti-cancer property of American ginseng
have focused on the ginsenoside or the saponin content of ginseng (58-61), which is
obtained from an aqueous ethanol extract (polar solvent) of ginseng. Of particular interest
regarding our study, several studies have reported the anti-angiogenic and anti-metastatic
properties of ginsenosides (62-65). Ginsenoside 20(R) and 20(S)-Rg3 possess an ability
to inhibit lung metastasis of tumor cells such as B16-BL6 melanoma and colon 26M3.1
by inhibition of adhesion and invasion of tumor cells and also by anti-angiogenesis
activity (62). Ginsenoside Rb2 inhibits invasion via MMP-2 suppression resulting in the
inhibition of secondary spreading of uterine endometrial cancer (63). Rd has been shown
to inhibit migration of liver cancer cell lines HepG2 by reducing expression of MMP-1,
MMP-2 and MMP-7 (64). In contrast, ginsenoside Rg1 has been reported to promote and
enhance angiogenesis and migration (66-68). Relatively very few studies on cancer and
inflammation are focused on the non-polar or lipophilic extract of AG. Consistent with
our present study, however, Park et al have shown that glucocorticoid receptor-induced
suppression of MMP-9 by panaxadiol and panaxatriol appears to reduce invasion of
highly metastatic human fibrosarcoma cell line, HT1080 (69).
In conclusion, given the increasing understanding that ginseng and/or its’
components have potent anti-cancer and anti-metastatic activities, it is important to better
understand the mechanisms. Here, we have demonstrated that miR-29b and MMP-2 are
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key players in the ability of HAG to suppress colon cancer cell migration and invasion.
Although the in vivo translation remains to be shown, we have shown that HAG
suppresses colon cancer in mice (23), and these current experiments shed light into the
mechanism by which HAG works. Our mechanistic findings open up the possibility that
HAG alone, or in concert with and/or miRNA-29b mimics, may have efficacy in the
chemoprevention and/or treatment of colon cancer.
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Table 4.1: MicroRNA expression changes with exposure to HAG (260µg/ml)
1. Trend Change Analysis
1
2
3
4
5
6
7
8

Correlation coefficient
-0.899
-0.739
-0.719
0.621
-0.621
-0.688
-0.695
0.592

Parametric p-value
0.0008802
0.0081706
0.0241946
0.0348001
0.0348001
0.0350915
0.0441186
0.0457531

FDR*
0.218
0.958
0.958
0.958
0.958
0.958
0.958
0.958

Unique id
hsa-miR-938
hsa-miR-203
hsa-miR-1975
hsa-miR-29b
hsa-miR-600
hsa-miR-1244
hsa-miR-548o
hsa-miR-590-5p

2. Fold Change Analysis (Untreated Vs Treated)

1
2
3
4
5
6
7
8
9
10
11

Parametric
p-value

FDR*

0.0043164
0.0071632
0.0089105
0.0245673
0.0317838
0.0434628
0.0446853
0.0448605
0.0449166
0.0457623
0.0470418

0.737
0.737
0.737
0.945
0.945
0.945
0.945
0.945
0.945
0.945
0.945

Geom
Geom mean mean
of
of intensities intensities
in treated
in
untreated
72.78
44.07
45.92
30.11
40.62
54.78
66.4
35.04
22.76
36.21
182.05
216.73
14.08
20.47
14.52
21.68
16.15
28.51
11.65
17.72
67.08
48.86

*, Indicates False Discovery Rate
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Foldchange

Unique id

1.65
1.53
0.74
1.9
0.63
0.84
0.69
0.67
0.57
0.66
1.37

hsa-miR-1308
hsa-miR-151-3p
hsa-miR-203
hsa-miR-590-5p
hsa-miR-1975
hsa-miR-222
hsa-miR-34c-3p
hsa-miR-142-3p
hsa-miR-548o
hsa-miR-938
hsa-miR-29b

	
  

Figures

Figure 4.1 miRNA-29b expression increases in colon cancer cells after exposure to
Hexane fraction of American Ginseng (HAG). HCT 116, DLD-1, and LOVO cells were
exposed to 260 µg/mL HAG for 24 h (n = 3 per time point). Relative endogenous miR29b expression levels were detected by qRT-PCR using Taqman primers and probes to
detect mature miR-29b and the small nuclear RNA RNU6B (U6), an internal control.
Relative miR-29b expression levels were normalized to the average value of the nontreated samples (0 h). *, indicates significant difference (pvalue<0.005) from the 0 h
control.
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Figure 4.2 Hexane fraction of American Ginseng (HAG) suppresses MMP-2 gene
expression. (a) miR-29 family (miR-29a/b/c) and its putative binding sequence in the 3’UTR of MMP-2 gene. The seed sequence of miR-29 family is shown in the box. (b)
HCT116 WT cells were exposed to 260 µg/mL HAG for 24 h. (c) HCT116 cells
transfected with 10 nM of mirVANA miR-29b, 48 h and exposed to 260 µg/mL HAG for
24 h. (d) DLD-1 cells were exposed to 260 µg/mL HAG for 24 h. (e) DLD-1 cells
transfected with 50 nM of mirVANA miR-29b, 48 h and exposed to 260 µg/mL HAG for
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24 h. (f) LOVO cells were exposed to 260 µg/mL HAG for 24 h. (g) LOVO cells
transfected with 50 nM of mirVANA miR-29b, 48 h and exposed to 260 µg/mL HAG for
24 h. Relative MMP-2 expression level was detected by qRT-PCR. MMP-2 mRNA for
each sample was normalized by GAPDH expression. Fold change in the MMP-2 mRNA
level was relative of non-treated cells harvested at 0 h (n=3 per time point). Results
indicate the Hexane Fraction of AG suppresses MMP-2 mRNA level compared to the
non-treated cells. *, Indicates significant difference, P value<0.05 from 0h control.

Figure 4.3 Suppression of endogenous microRNA-29b using mirVANA miR-29b
Inhibitors. Relative fold change in miR-29b expression normalized by endogenous
control U6 snRNA after 48h of miR-29b inhibitors or Control negative oligonucleotides.
a. Relative miR-29b expression in HCT116 cells after transfection with either miR-29b
inhibitor or control negative oligonucleotides (10nM concentrations) for 48h. b. Relative
miR-29b expression in DLD-1 and LOVO cells after transfection with miR-29b inhibitor
(50nM concentration) for 48h. *, indicates significant difference (pvalue<0.05) from the
wild type control. #, indicates significant difference (pvalue<0.005) from the wild type
control.
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Figure 4.4 Hexane fraction of American Ginseng (HAG) represses HCT116 colon cancer
cell migration in vitro. Collagen type-I (15 µg/mL) coated transwell chamber were
applied with 5 X 104 HCT116 cells (a/b) for 12 h. The lower chamber contains SFM/
Serum (10%) or HAG (260 µg/mL in complete medium). (a) 5 X 104 HCT116 WT cells
were applied to the upper chamber of the transwell membrane. (b) 5 X 104 HCT116
(transfected with mirvana miR-29b, 10nM, 48h) cells were applied to the upper chamber
of transwell membrane. After 12 h incubation at 37°C, the cells migrated to the inside
(lower membrane) of transwell membrane was counted using ImageJ software (7 random
microscopic fields (100X) were evaluated for cell counting). (c) Depicts the
representative picture of HCT116 WT cell migration from each treatment. (d) Depicts the
representative picture of HCT116 (transfected with mirvana miR-29b, 10 nM, 48 h) cell
migration from each treatment. The background in the picture shows the 8 µm pore in the
transwell membrane. *, indicates significant difference (pvalue<0.005) when compared to
SFM. #, indicates significant difference (pvalue<0.005) when compared to 10% Serum.
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Figure 4.5 Hexane fraction of American Ginseng (HAG) represses DLD-1 colon cancer
cell migration in vitro. Collagen type-I (15 µg/mL) coated transwell chamber were
applied with 5 X 104 HCT116 cells (a/b) for 12 h. The lower chamber contains SFM/
Serum (10%) or HAG (260 µg/mL in complete medium). (a) 5 X 104 DLD-1 WT cells
were applied to the upper chamber of the transwell membrane. (b) 5X104 DLD-1
(transfected with mirvana miR-29b, 10 nM, 48h) cells were applied to the upper chamber
of transwell membrane. After 12 h incubation at 37°C, the cells migrated to the inside
(lower membrane) of transwell membrane was counted using ImageJ software (7 random
microscopic fields (100X) were evaluated for cell counting). (c) Depicts the
representative picture of DLD-1 WT cell migration from each treatment. (d) Depicts the
representative picture of DLD-1 (transfected with mirvana miR-29b, 10nM, 48h) cell
migration from each treatment. The background in the picture shows the 8 µm pore in the
transwell membrane. *, indicates significant difference (pvalue<0.005) when compared to
SFM.
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Figure 4.6 Hexane fraction of American Ginseng (HAG) represses HCT116 colon cancer
cell invasion in vitro. Matrigel matrix coated transwell chamber were applied with 1X105
HCT116 cells (a/b) for 12 h. The lower chamber contains SFM/ Serum (10%) or HAG
(260 µg/mL in complete medium). (a) 1 X 105 HCT116 WT cells were applied to the
upper chamber of the transwell membrane. (b) 1 X 105 HCT116 (transfected with
mirvana miR-29b, 10 nM, 48h) cells were applied to the upper chamber of transwell
membrane. After 12 h incubation at 37°C, the cells that invaded the matrigel membrane
(lower membrane) of transwell membrane was counted using ImageJ software (7 random
microscopic field (100X) were evaluated for cell counting). (c) Depicts the representative
picture of HCT116 WT cell invasion from each treatment. (d) Depicts the representative
picture of HCT116 (transfected with mirvana miR-29b, 10nM, 48h) cell invasion from
each treatment. The background in the picture shows the 8 µm pore in the transwell
membrane. *, indicates significant difference (pvalue<0.005) when compared to SFM. #,
indicates significant difference (pvalue<0.005) when compared to SFM.
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CHAPTER 5
BIOACTIVE COMPONENTS OF HEXANE FRACTION OF AMERICAN GINSENG,
CONCLUSION AND FUTURE DIRECTIONS
5.1

BIO-ACTIVE COMPONENTS OF HEXANE FRACTION OF AMERICAN GINSENG

5.1.1

OVERVIEW
Bioassay guided fractionation is one of the most commonly used strategies for the

isolation of bioactive lead component and new drugs (1, 2). The isolation of a pure
chemical agent of natural origin by employing a step-by-step separation of extracted
components based on the differences in their physicochemical properties, and
simultaneously assessing the biological activity followed by a next round of separation
and assaying is the main principle of bioassay-guided chemical fractionation (3). The
probability of finding a bioactive species (a “hit”) can be expressed as:
hits = samples × biodiversity of samples × assays (1). It is obvious that the greater the
number of samples assayed in the greatest number of possible assays enhances the
probability of finding useful compounds. “Biodiversity of samples” is a qualitative factor
relating to the number of unique structural classes of compounds sampled (1). There are
several approaches to drug discovery utilizing higher plants: random selection followed
by chemical screening or followed by one or more biological assays; follow-up of
biological activity reports (eg. Ecology based); follow-up of ethno-medical (traditional
medicine) use of plants (1). The ethno-medical approach includes plants used in
organized traditional medical systems; herbalism, folklore and shamanism; the use of
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databases (4). Briefly, for our project we chose the ethnomedical approach of bioassayguided fractionation of AG root extract to isolate and identify bioactive compounds
against colitis and colon cancer. After fractionating the crude extract, usually by
chromatography techniques such as column chromatography and HPLC, the fractions
generated are tested by in vitro assay (3). For our studies, we further tested the fraction
beyond the in vitro assay to in vivo animal studies. We initiate our studies with AG root
extract (aqueous ethanol solvent) and assessed its biological activity against colitis and
colon cancer (5-7). Once the bioactivity of AG extract was confirmed with the biological
assay, we fractionated the AG root extract by bioassay method into 5 different fractions
(Solvents Used: Ethanol, Butanol, Hexane, Dichloromethane and Ethylacetate). Each
individual fractions were assessed for its biological activity, by performing an iNOS
suppression in activated macrophages (Refer to Chapter 2 (8), Material and Methods
2.2.6) and pro-apoptotic activity against inflammatory cells (T-lymphoblastoid cell) and
CD4+/CD25- effector T cells (Refer to Chapter 2 (8), Material and Methods 2.2.6). By
accessing these anti-inflammatory and pro-apoptotic activities, the Hexane fraction was
found to most potent fraction of AG (Chapter 2, 3 and 4 (8, 9)) against colitis and colon
cancer. The next round of separation and assaying for accessing the biological activity of
bioactive components present in Hexane Fraction of AG was performed. The details are
listed in materials and result and discussion section (Chapter 5) below.
5.1.2
5.1.2.1.

MATERIALS
AMERICAN GINSENG WHOLE EXTRACT [Modified From (6)]
American ginseng extract was purchased from the National Research Council

(NRC) of Canada, Institute for National Measurement Standards. The ginseng obtained

151

	
  

by NRC and processed by Canadian Phytopharmaceuticals Corporation (Richmond,
British Columbia, Canada) was grown on the Harper Ranch, Kamloops, British
Columbia, Canada, and obtained from the Harper 113 planting. The Harper 113 planting
was made in 1999, emerged as seedlings in 2000 and was harvested as 4-year olds in the
fall of 2003. Following grinding to pass 80 mesh, 35 kg of the root material was extracted
with aqueous ethanol (75% ethanol and 25% water) in a recirculating filter extraction
system for 4 h at a temperature of 60°C under vacuum. The ratio of solvent to root was
8:1 (vol/wt). After extraction, the filtrate was partially dried in vacuo to yield a
concentrated extract; 2.8 kg of maltodextrin (40% of final weight) was then blended as a
support and the resultant slurry was spray dried to yield 7 kg of free flowing powder.
Analysis by Canadian Phytopharmaceuticals Corporation by High-performance liquid
chromatography–ultraviolet against pure standards determined the total ginsenoside
content and confirmed by High-performance liquid chromatography–mass spectrometry
at the NRC of Canada. Proximate analysis of American ginseng for carbohydrate and
protein content was conducted at the University of Guelph report. The majority of the
polysaccharide component is reported by the Ontario Ministry of Agriculture and Food to
be starch. The NRC Canada values were determined using external standards that were
obtained from Chromadex (Irvine, CA). Critically, liquid chromatography-mass
spectrometry confirmed no detectable ginsenoside Rf characteristic of Asian ginseng and
the presence of ginsenoside F11.
5.1.2.2.

BIOASSAY-GUIDED FRACTIONATION OF AG EXTRACT

(Refer to Material Section 2.2.1)
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5.1.2.3.

ANALYSIS OF THE HEXANE FRACTION OF AG

(Refer to Material Section 2.2.3)
5.1.2.4.

FATTY-ACID

ANALYSIS

BY

GAS-CHROMATOGRAPHY-MASS

SPECTROMETRY AND FLAME IONIZATION DETECTOR
(Refer to Material Section 2.2.4)
5.1.2.5.

PREPARATIVE HPLC FRACTIONATION OF HEXANE FRACTION OF AG
A large (1 Kg) scale extraction of the AG extract has been undertaken to produce

sufficient crude Hexane fraction of AG for the purification of individual active
components in quantity as they are identified. This will provide highly purified and
characterized bioactive components as reference standards. To subfractionate this HAG
preparative, reverse phase HPLC method was applied to obtain 5 sub-fractions, based on
elution time (4min ea.), using an acetonitrile/water gradient on a C-18 column. The
fractions were collected over 6 repeat runs (6 x 50 mg injected) and evaporated to
dryness using a vacuum centrifuge. A comparative analysis by analytical scale LC-UV of
both the whole and each sub-fractions were performed.
5.1.2.6.

LIQUID CHROMATOGRAPHY – UV ANALYSIS

(Refer to Material Section 2.2.5)
5.1.2.7.

LARGE SCALE PURIFICATION OF PUTATIVE BIOACTIVES
1 kg of AG spray dried extract was processed as 10 x 100g lots where each 100g

was dissolved in 1 L of water in a separatory funnel and extracted with 4 x 400 mL of
hexane. The organic layers were concentrated by vacuum centrifuge to yield ~10g of a
free flowing oil. The extract was crudely separated using C-18 flash chromatography,
developed stepwise with 6L of 55% ACN, 9L of 75% and 2L of 100% ACN with all
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eluents collected in 500 mL volumes and each fraction analyzed by LC-UV. The PA’s
eluted at 75% ACN over 18 fractions and those with equivalent profiles were combined
and all fractions were evaporated to dryness. Each of the major PAs will be purified by
multi-pass, preparative HPLC to achieve high purity (>99%) and an exact purity assigned
by quantitative 1H-NMR and confirmation of structure by 1D and 2D 1H and 13C NMR.
Each of the five sub-fractions and the 300 mg of intact AG-Fraction V (HAG) were then
re-dissolved in 3 ml of solvent (e.g., DMSO). This gives a 100 mg/ml solution of the AGFraction V (HAG) and five fractions of the same volume. Therefore, the chemical
composition (identity and concentration) in each fraction is equivalent to that present in
the intact material. That is, fractions are not equivalent by weight, but by the
concentration of each chemical constituent in a given fraction with their concentrations in
the whole material. The AG-Fraction V (HAG) comprises ~ 1% by weight of the of the
whole AG extract; the 300 mg of AG-Fraction V (HAG) is therefore equivalent to 30 g
of the AG extract. An appropriate dilution for a given assay target may then be made to
give a dose equivalence to the AG extract or the AG-Fraction V (HAG).
5.1.2.8.

CELL CULTURE AND INOS SUPPRESSION EXPERIMENT
ANA-1 murine macrophage cells were received as a kind gift from Michael Espey

(National Cancer Institute, Bethesda, MD) and maintained in Dulbecco's modified
Eagle's media (Hyclone, Logan, UT) supplemented with 10% New Born Calf serum
(NBCS) (Biofluids, Rockville, MD), 2 mM glutamine (Biofluids), penicillin (10 U/ml)
and streptomycin (10 µg/ml, Biofluids) in growing suspension culture at 37°C in a
humidified 5% CO2 atmosphere. Experiments with the subfractions of HAG (F1 to F5)
were carried out by pre-incubating cells with indicated concentrations of Subfractions
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(F1-F5) for 12h. All subfractions (F1-F5) were dissolved in DMEM medium (0.1%
NBCS). Following a wash, cells were activated by exposure to 100 U/ml interferon
(IFN)-γ (R&D Systems, Minneapolis, MN) for indicated time.
Following the treatments, cells were harvested and immunoblotted with
antibodies against iNOS and loading control GAPDH (For more details on Western blot,
Refer to Chapter 2, Materials 2.2.13).
5.1.3
5.1.3.1.

RESULT AND DISCUSSION
AMERICAN GINSENG COMPONENTS (6)
The final powder form of P.quinquefolius (American ginseng) extract supplied by

Canadian Phytopharmaceutical Corporation contains total Ginsenoside content to be
11.1% with 2% w/w additional ginsenosides (Table 5.1). Proximate analysis of American
ginseng conducted at the University of Guelph report a mean carbohydrate content of
73.4% and protein of 11.3% (Table 5.1). Majority of polysaccharide component reported
by the Ontario Ministry of Agriculture and Food was found to be starch. Critically, liquid
chromatography-mass

spectrometry

confirmed

no

detectable

ginsenoside

Rf

characteristic of Asian ginseng and the presence of ginsenoside F11.
5.1.3.2.

PRELIMINARY CHEMICAL ANALYSIS OF HEXANE FRACTION OF AG

(Modified from Chapter 2, Result Section 2.3.8, (8))
Given the potency of the Hexane Fraction of AG, we initiated experiments to better
understand the components of this fraction. The amounts of fatty acids determined from
the analysis of the Hexane Fraction of AG are given in Table 2.6, and account for greater
than 40% w/w of the total extract. Strikingly, linoleic acid (18:2n6) was the major fatty
acid, accounting for approximately 50% of the total fatty acids detected, followed by
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palmitic (16:0) and palmitoleic (16:1) acids.

LC-MS analysis did not detect either

protopanaxdiol or protopanaxtriol; however, low levels of ginsenosides Re, F11, Rb1 and
Rd were found, but amounted to less than 0.1% w/w of the Hexane Fraction of AG.
Descriptive LC-UV Diode Array Detector analysis of the Hexane Fraction of AG
detected total polyacetylene content to be 26.52% w/w. Polyacetylenes in HAG is
comprised of Panaxydiol (7.39% w/w), Panaxydol (8.92% w/w) and Panaxynol (10.21%
w/w). Confirmation of identity and precise quantification of these compounds awaits
individual isolation and structural elucidation.
5.1.3.3.

IDENTIFICATION AND EXTRACTION OF SUBFRACTIONS OF HEXANE

FRACTION OF AG
Preparative HPLC- mediated isolation of subfraction of HAG resulted in 5
different subfractions (F1-F5) (Figure 5.1). The peaks identified in Figure 5.1 are 1.
Panaxydiol, 2. Panaxydol, 3. Panaxynol, 4. Linolenic acid, and 5. Linoleic acid. Based on
UV spectra, subfraction F1 comprises of less than 10% of HAG, showed no peaks in
HPLC and has only 2 minor polyacetylenes. 30% of HAG is subfraction F2, showed two
peaks (1 and 2), which are identified as two major polyacetylenes: Panaxydiol and
Panaxydol. Subfraction F3 (24% of whole HAG) contains 1 major polyacetylene [Peak 3,
Panaxydol and Peak 4, Linolenic acid (18:3n3)]. Subfraction F4 (27% of whole HAG)
showed only one peak corresponding to Linoleic acid (18:2n6) and no polyacetylenes.
Subfraction F5 is 10% of HAG with no identifiable peaks in HPLC, contains only minor
FAs, including saturates but no polyacetylenes. From these observations, it is clear that
HAG subfractions comprise about 50% polyacetylenes and remaining are FAs. 10mg/ml
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of each subfraction (F1-F5) was prepared by dissolving the fraction in DMSO; as the
stock, for assessing its bioactive property.
5.1.3.4.

Anti-inflammatory property of sub-fraction of Hexane fraction of AG
Of the 5 subfractions of HAG, subfractions F2 and F3, substantially reduced the

iNOS expression in the activated mouse macrophage cell line (Figure 5.3). Compared to
the crude HAG extract, which showed its anti-inflammatory activity at 260 µg/mL,
subfractions F2 and F3 was potent in suppressing iNOS expression at much lower
concentration of 10 µg/mL. This clearly indicates the advantage of bioassay-guided
fractionation and successful extraction of bioactive components of American Ginseng.
From our perspective of identifying anti-inflammatory and anti-cancer bio-active
compounds, F2 and F3 with major polyacetylenes, Panaxynol, Panaxydol and Panaxydiol
could very well be an important players in suppressing mouse colitis and colon cancer
that was observed with HAG.
5.2

CONCLUSION AND SUMMARY
In summary, we have identified through various endpoints that the Hexane

Fraction of AG is at least one component of AG extract responsible for the suppression of
DSS-induced colitis, and apoptosis of inflammatory cells is a mechanism by which it
acts; and suppression of AOM/DSS-induced colon cancer (Chapter 2). These findings
represent a significant advancement in the field, since it has previously been thought that
ginsenosides, extremely minor elements of this fraction (HAG), are key antiinflammatory and anti-cancer agents in AG (10). It is currently unclear exactly what
component within the HAG suppresses colitis and colon cancer associated with colitis.
However, many of the fatty acids detected in our HAG, can induce apoptosis in various
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cell types (11-17), and conjugated linoleic acid and oleic acid has been shown to suppress
colitis in other studies (18-21). This is consistent with the hypothesis that at least one of
these ingredients may be responsible for the activity of AG root extract against colitis and
associated colon cancer.
The elevation of WT p53 levels during inflammation (22) resulting in apoptosis of
inflammatory and damaged cells (5, 23, 24) led us to the notion that the active antiinflammatory components present in HAG might suppress colitis through the p53
pathway. We have shown here that the HAG can induce apoptosis not only in the p53
WT cells such as lymphoblastoid cells, CD4+/CD25- effector T cells; cause a G1
checkpoint in colon cancer cell lines and suppress chemically induced colitis in C57/BL6
p53 WT mice, but also in p53-/- counterpart cells and mice. HAG is an important antiinflammatory and pro-apoptotic fraction of AG that is effective even in the absence of
p53.

However, the HAG has a more robust effect in the presence of p53. These

observations suggest that there is a role of p53 in the HAG mediated apoptosis of
inflammatory cells and suppression of colitis; but this role is limited (Chapter 3). This
entails that the HAG affects other pathways independent of p53 in the suppression of
colitis.
Given the increasing understanding that ginseng and/or its’ components have
potent anti-cancer and anti-metastatic activities, it is important to better understand the
mechanisms. Hence Chapter 4 deals with the anti-cancer mechanism of HAG in detail. In
Chapter 4, we demonstrated that miR-29b and MMP-2 are key players in the ability of
HAG to suppress colon cancer cell migration and invasion.

Although the in vivo

translation remains to be shown, we have shown that HAG suppresses colon cancer in
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mice (8), and these current experiments shed light into the mechanism by which HAG
works. Our mechanistic findings open up the possibility that HAG alone, or in concert
with and/or miRNA-29b mimics, may have efficacy in the chemoprevention and/or
treatment of colon cancer.
Chapter 5, briefly focuses on the next step of bioassay-guided fractionation of AG
and identification and isolation of bioactive compounds against colitis and colon cancer.
Using analytical techniques (preparative and reverse phase HPLC), we isolated 5
subfractions of HAG (F1 to F5) and tested its anti-inflammatory property in vitro by
assessing iNOS suppressing ability on activated mouse macrophage. Subfractions F2 and
F3 are the only fraction that contain major polyacetylenes, were most effective in
suppressing iNOS induction in ANA-1 mouse macrophage, indicating polyacetylenes
could be a key player in suppressing colitis and associated colon cancer.
5.3

FUTURE DIRECTIONS
We successfully performed bioassay-guided fractionation of AG and delineated

the bioactive compounds present in the AG root extract that could be a potent antioxidant and anti-cancer agent. This was tested using various in vitro, ex-vivo and in vivo
animal models. This project holds a very promising future, where from the major
polyacetylenes identified, the most potent anti-inflammatory polyacetylene could be
identified and isolated. By further studying the signaling pathways of polyacetylene
mediated anti-inflammatory and anti-cancer effects, one could pin point major target
molecules. A pre-clinical mice study could be performed with this potent polyacetylene
to understand its pharmacokinetics (absorption, distribution, metabolism and excretion).
Our results support the possibility of testing individual components of AG in treating
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IBD in humans to develop an anti-inflammatory and anti-cancer lead drug compound
from American Ginseng.
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Table 5.1 Analysis of components found in the American Ginseng whole extract
[Modified from (6)].
Components
A. Ginsenosides (Total)
Rg1
Re
Rb1
Rc
Rb2
Rd
Rf (Ginsenoside found in Asian Ginseng)
B. Additional Ginsenosides (Total)
F11
Ro
Isomers of Rd
Traces of malonyl ginsenosides
C. Carbohydrates (Starch)
D. Proteins
E. Moisture Content

Composition Percent (w/w)
11.1%
0.3%
2.37%
4.42%
1.59%
0.07%
2.35%
No traces
2%
Not Determined
Not Determined
Not Determined
Not Determined
73.4%
11.3%
2.2%

Maltodextrin (40%) from hydrolyzed corn starch added to above fraction of AG as a
filler.
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Figure 5.1 Preparative HPLC subfractionation of Hexane fraction of AG (Whole Fraction
V). Subfraction F1 to F5 represents the collected fractions, 4 min each. Condition;
Column C-18 19 x 300 mm, 50mg injection, gradient 55-90% acetonitrile/water in 15
min, hold 5 min, re-equilibration for 10 min. Note, Vo: void volume not collected.
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Figure 5.2 LC-UV/DAD analysis of Hexane fraction of AG (Whole AG-fraction V) and
each subfraction. Column C-18 2.1 x 100mm, 1µL injection of a 5mg/mL (whole or
equivalent fraction), gradient 55%-90% acetonitrile/water in 15 min; hold 5 min, reequilibration 10 min. Note the scale magnification for fractions 1 and 5.
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Figure 5.3 Effect of the whole Hexane fraction of AG and different fractions of HAG on
IFN-γ-induced iNOS expression. ANA-1 mouse macrophages were incubated for 12h
with HAG or the indicated subfractions (10µg/mL) washed, then exposed to IFN-γ (100
U/mL) for 0, 2 and 4 h. C+, indicates positive control which are ANA-1 cells induced by
IFN-γ incubated with media.
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